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ABSTRACT 
 
Stimulation of a patient’s immune system to fight cancer is the underlying mechanism of 
immunotherapy. Cancer immunotherapy manipulates the dendritic cells (DCs) to identify the non-
self present in the immunosuppressive microenvironment. This vaccination strategy based on 
nanoparticulate drug delivery system has the potential to treat cancer through packaging of 
therapeutic cargoes and delivering them to target immune cells (DCs). FDA approved poly-(D, L-
lactic-co-glycolide) is approved for use in human due to its widely accepted properties such as low 
immunogenicity, minimal toxicity, biocompatibility and biodegradability. The goal of this project is 
to develop an understanding of a comprehensive relationship between nanoparticle (NP) structure 
and activity; and address the important requirements of NP structure and chemistry to selectively 
target specific markers. Plain NPs were prepared by emulsification solvent evaporation method with 
number of preparation variables. Double emulsification solvent evaporation method was used to 
prepare ovalbumin (OVA) and/or adjuvant loaded NPs. The DC targeting ligand (anti-CD205 
monoclonal antibody) was attached to the NPs through two methods: covalent binding in presence 
of spacer molecule and physical adsorption method. Infra-red (IR) spectroscopy was performed to 
ensure the structural modification of NPs. Formulations were evaluated in respect to particle size, 
polydispersity index, zeta potential, surface display, cytotoxicity assay, OVA release studies, 
structural integrity of OVA in formulations, DC uptake study, DC maturation study, T cell 
proliferation study, estimation of total IgG and cytokine secretion profile. Results indicated that 
different formulation groups of NPs with different viscosity grades had desirable physicochemical 
properties. In case of the ligand (anti-CD205 antibody) conjugated NP’s spectrum, there was 
presence of amide-I vibrations resulted from C=O stretching vibration near 1610 cm-1 and N-H 
stretching of high intensity between 3310 to 3250 cm-1. These characteristic IR peak reflects the 
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antibody conjugation with the NPs. DC uptake study shows when ligand was adsorbed onto the 
surface, these NPs were better uptaken compared to covalently attached formulations. No 
significant correlation was observed in uptake due to change of polymer viscosity and type. Highest 
expression of markers CD40, CD86 and MHCII molecules were observed with adjuvant 
(monophosphoryl lipid A)-antigen loaded targeted NPs. Though, high viscosity grade polymers 
(ester or COOH terminated) had higher OVA loading, they expressed lower percentage of markers 
compared to low viscosity formulations. These could be attributed to the release mechanism of the 
respective PLGA NP formulation.  In addition, sufficient secretion of T helper cell 1 (Th1) and Th2 
cytokines was observed. This confirmed the maturation of DCs as well as activation of the T cells. 
The T cell proliferation study confirmed the proliferation of cells in-vitro for both wild type balb/c 
and TCR transgenic (OT1) mice. Results from OT1 mice confirmed the OVA-specific immune 
response. Secretion of higher level of OVA-specific IgG by the formulations confirms the antigen 
specific immune response. Therefore, a comprehensive evaluation of effect of formulation 
parameters (polymer viscosity, polymer end group, conjugation methods) was performed to 
modulate the antigen specific immune response. These findings would be insightful when designing 
a vaccine formulation for a specific type of cancer. 
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General overview 
 
In this ‘manuscript style’ of thesis, the entire project work is presented in Chapters 2 to 5, each of which 
has its own hypothesis and objectives leading to achieve a common goal of the thesis.  
In the beginning, an introduction and a general literature review pertaining to the subject of the thesis 
leading to overall hypothesis and objectives of the thesis in its entirety are given.  
Subsequently, each chapter containing relevant literature review, introduction, materials and methods, 
results and discussion is presented. The style of all these chapters has been uniformly maintained 
irrespective of the journals considered for publication. At the end, a general discussion of the thesis in its 
entirety is given. 
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CHAPTER 1 
 
1 Literature review 
1.1 Overview of immune system 
The immune system consists of intricate structures designated to protect the body against attack by non-
self intruder.(1) The immune system protects against pathogens and ensures tolerance for self-antigens.(2) 
The innate components act rapidly, but in a non-specific manner. And the adaptive components act 
specifically, but need time for clonal expansion and subsequent differentiation to effector cells. Adaptive 
immune response is relatively late since both the B cells and T cells undergo some progression before 
migrating to the site of infection.(3) Thus, two types of immunity are obtained, namely innate and 
acquired/adaptive immunity.(4) 
1.2 Immune system components 
1.2.1 Innate defense components  
The components of innate defense are epithelial barriers, leukocytes, circulating proteins (complement, 
collectins) and cytokines (interferons, chemokines, interleukins).(5) Innate defense composes mainly of 
phagocytic cells such as macrophages, B cells and interdigiting dendritic cells.(6),(7) Granulocytic cells 
such as eosinophils, basophils, mast cells also protect host from parasitic infection. In addition, natural 
killer (NK) cells work by antibody-dependent cell mediated cytotoxicity (ADCC), killer activating signal 
(when target cell do not express MHCI molecules) and killer inhibiting signal (when self-cell express 
MHCI molecules).(7) 
1.2.2 Acquired immune components  
It is composed of humoral and cellular immunity.  
Humoral immunity: This type of immunity involves B cells produced ‘antibodies’ in response to certain 
antigen. The functions of antibodies include: neutralisation of antigens, prevention of infectivity, 
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phagocytosis, utilizing products of complement activation and antibody dependent cell mediated 
cytotoxicity (ADCC).(8), (9) 
Cellular immunity: It is mainly performed by B and T cells. Here, discussions will specifically focus on 
CD4 and CD8 T cells. Immune response occurs through several steps, starting from antigen recognition 
by naive cells’ to differentiation into activated T cells. Antigen specific T cells are able to recognize non-
self epitopes of foreign antigens on their surface. T cells recognize antigen presented on MHC molecule 
with the help of T cell receptor (TCR). The human MHC locus encodes three human leukocyte antigen 
(HLA) class-1 and three HLA class-2 molecules. These HLA molecules are highly polymorphic in nature. 
Thus, different T cells from individuals are able to recognize a specific epitope.(8), (10) 
1.2.2.1 CD4 T cells 
CD4 T cells are subdivided into T helper 1 (Th1) and T helper 2 (Th2) subsets. Both the subsets are 
responsible for producing different types of cytokines.(11) The memory T cell proliferation depends on 
the production of IL-2. Cells capable of producing both IFNγ and IL-2 are considered as the precursor of 
CD4 T cell memory.(12) There are some mutually inhibitory functions of the cytokines. It is found that, 
IL-10 can inhibit cytokine synthesized by Thl cells. On contrary, the proliferation of Th2 cells is inhibited 
by IFNγ. Thus, a bias towards either Thl or Th2 responses are observed during many infections. In 
addition, Th0 cells are capable of secreting mixed types of cytokines such as IL-4, IL-5, IFNγ and IL-
10.(13) 
Th17 is another type of CD4 cell that requires TGF-β and IL-6 cytokines for induction. Thus, the 
involvement of Th1 cells in auto-immune diseases was excluded.(14)  
Regulatory T cells (Tregs) are important to maintain self-tolerance and immune response. They have 
beneficial role in treating auto-immune diseases. TGF-β induces RORγt expression in both Th17 and Treg 
cells, whereas Foxp3 is only found in Treg cells. Both IL-2 and TGF-β are required for Treg 
differentiation, survival and action.(12) CD4 T cells recognize pathogen by MHCII molecules. Thus, the 
functions of CD4 T cells are restricted.(5), (15) 
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1.2.2.2 CD8 T cells 
CD8 T cells recognize infected and altered cells upon epitope expression on MHCI molecules. These 
MHC1 molecules are present in all types of cells. The naïve T cells take about 72 hours to recruit after 
infection.(16) CD8 positive CTLs are group of T cells that release cytotoxic granules upon recognition of 
the infected cells and thereby directly kills that cell. They kill pathogen by lethality (perforin and nuclear 
fragmentation) and IFNγ secretion. Activation of antigen presenting cells (APC) can then prime cytotoxic 
CD8 T cells directly.(17) The interaction of DC costimulatory molecules with the ligands present on CD4 
T cells increases the efficacy of these APCs to generate effector and memory CD8 T cells.(18)  
1.3 Mechanism of innate immune recognition 
Multicellular organisms have the capacity to recognize patterns unique to microorganisms. These 
molecular structures are known as pathogen associated molecular patterns (PAMPs). The host organism 
has receptors that can easily recognize these molecular patterns. C-type lectins, leucine rich proteins, 
scavenger receptors are some of the members of pathogen recognition receptors (PRRs). Therefore, the 
PRRs are capable of initiating immune responses.(19) 
Microorganisms upon entering the body come across the immune cells. The PAMPs on organisms being 
recognized results in secretion of biologically active cytokines and chemokines. This inflammation 
process can also be triggered by the activation of the microorganisms own system. Neutrophils are the 
first sentinels recruited at the site of inflammation. The later events of this inflammation involve 
lymphocytes that have been activated by an antigen.(20) 
1.4 Interface between innate and adaptive immunity 
DCs are the unique immune cells capable of linking innate and adaptive immunity. DCs can promote 
adaptive immune response or control overactive immune response. Immature DCs upon pathogen 
encounter undergo the process of maturation. This pathogen recognition occurs by the toll-like receptors 
(TLRs) present abundantly on the surface of DCs. This process leads to synthesis and release of 
cytokines. This secretion of interleukins creates the interface between the two types of immunity. 
5 
 
Therefore, the cross-talk exists; the innate system alerts the adaptive system for dangers and the adaptive 
system triggers the innate response.(21), (22) 
1.5 Mechanism of immune response produced by CD4 and CD8 T cells 
Upon antigen attack, T cells are activated via signal through TCR. The receptor for costimulatory 
molecules (CD40, CD80) also needs to be activated to avoid the clonal anergy process. Unless, 
unresponsive state is created, rendering the T cells to produce its own growth hormone (IL-2). Therefore, 
signals through both the receptors are necessary to produce effector molecules and consequential T cell 
multiplication. CD4 or CD8 molecules are also present in the TCR complex. CD4 binds MHC class II 
molecules, whereas CD8 binds MHC class I molecules to show responses to antigen.(23) 
The ability to produce an immune response upon reinfection depends on the presence of large number of 
antigen specific memory T cells. Primary CD8 immune response to acute infections does not depend on 
CD4 T cell help. In this case, recognition of microbial products through TLR directly activates APCs 
bypassing CD4 help. But, CD8 response to non-inflammatory immunogens requires CD4 T cell help. 
This involves activation of both APCs and CD40 molecules.(24) 
1.6 Regulation of T cell activity 
T cell activity is dependent on costimulatory signals provided by TCR. The specificity of T cell response 
depends on the interaction between ‘MHC: peptide complex’ and ‘TCR’.(25) This interaction is known as 
immunological synapse (IS). The stability of IS depends on:(26) 
 
• The duration of interaction between APC and T cell. For example, when DCs are mature the 
durability of IS is long-lasting and leads to immunity. When the DCs are immature they lead to 
shorter durability, leading to tolerance development.  
• The receptors present in IS region helps to maintain stability and organization of IS region.  
• Pre-activation of T cells is required to obtain complementary response from DC to form stable IS.  
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Surface proteins present on DCs and T cells in an IS are represented in Figure 1.1.(26) This synapse is 
required for MHC molecules to present antigen to T cell. This induces T cell to produce T cell effector 
function. Thus, expression of costimulatory molecules through this co-stimulation as well as secretion of 
cytokines that regulate T cell activity can be obtained.(27) 
 
Figure 1.1: Immunological synapse formed between APC and T cell (27) 
1.7 Organs/tissues of immune system 
Bone marrow, thymus, lymph node, spleen are specialized organs where lymphocytes interact with non-
lymphoid cells either for their maturation or initiation of adaptive immune response. Lymphatic tissues 
have numerous lymphocytes.(7) Thus, the immune system provides protection from any type of 
pathogens or neoplastic changes. Utilizing the immune system for cancer is attracting scientists for new 
treatment development.(28) 
1.8 Immune system and cancer 
The immune system identifies the tumor cells through immunosurveillance before their progression. In 
spite of continuous observation of the immune system, tumor cells escape the immune defense, 
instigating the scientists to discover various mechanisms to treat cancer. Thus, Paul Ehrlich’s concept of 
immunosurveillance came to a refined hypothesis elaborated by Brunet as ‘immunoediting’. Elimination, 
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equilibrium and escape are the three Es’ of immunoediting to balance between immune system and 
developing tumor. In addition, elimination phase occurs during early tumor growth and destroy the cells 
before further tumor occurs. In the escape phase, tumor cells become resistant to the effect of adaptive 
immunity. The immunoediting theory suggests that the immune system can eradicate suboptimal tumors, 
but when equilibrium is reached tumor burden starts to increase and enters escape phase.(29), (30) 
1.8.1 Tumor development, recognition by immune system, tumor microenvironment  
1.8.1.1 Tumor development 
The major challenge for the immune system is to eliminate cells undergoing neotransformation. The 
development of malignant cells is a multi-step process. The immune system applies some tumor-
suppressor mechanisms to prevent the capability of abnormal cell proliferation.(29), (31) But, progression 
of tumors escape such controls due to mutation of the genes. This occurs due to breakdown of one or 
several components of the genomic integrity. Cancer cells are self-sufficient and evade all the control 
mechanism of the immune system allowing continuous growth of cells.(32) 
1.8.1.2 Tumor recognition by the immune system 
A mutated or new protein can express their fragments on their surface as a target for immune cell, 
especially CD8 positive T cells. Several methods have been utilized to identify the tumor antigens 
recognised by T cells. There are about 11,000 mutations found in tumors. These mutations undergo 
immunogenic selection in the early stage of cancer and might not be present at advanced stage of 
disease.(33) 
Previously mentioned, NK cells kill target lacking MHCI molecules, an underlying fact for many cancer 
cells. Recently it has been found that, receptors like natural cytotoxicity receptor (NCR) of NKs can lyse 
tumor cells.  However, though these activating NCRs are present still there is limited tumor regression. 
The underlying reason is the immunosuppressive environment operating within the tumor manifesting 
tumor progression.(34) 
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1.8.1.3 The tumor microenvironment 
The tumor is considered as organ having complex biology. The tumor epithelial cells form a unique 
compartment named parenchyma. And the mesenchymal cell forms the tumor stroma. The stromal cell 
changes in abundance, histology, phenotypic characterization. A solid tumor is a collection of distinctive 
cells such as cancer stem cell, cancer cell, cancer associated fibroblast, pericytes, immune inflammatory 
cells, endothelial cells and invasive cancer cells.(32) 
There are several immune cells present in tumor mediating immunity such as T cells, DCs, B cells, 
macrophages, NKs, polymorphonuclear leukocytes. CD4+CD25high FoxP3 + cells, subset of CD4 T cells, 
are also expanded in that environment. These cells are Tregs capable of suppressing proliferation of 
effector T cells through secretion of IL-10 and TGF-β cytokines. Cytotoxic T lymphocyte antigen 4 
(CTLA-4), an immune-inhibitory molecule, is expressed by CD8 and CD4 T cells and FoxP3 Tregs. 
Programmed death (PD-1) receptor is also expressed on Tregs, monocytes and T cells. Macrophages 
present in tumor secret inhibitory cytokines such as IL-10, prostaglandin, reactive oxygen species.(35) 
Myeloid suppressor cells (CD34+CD33+CD13+CD15) are bone marrow-derived immature DCs that 
accumulate in tumor, suppress immune cells by production of enzyme arginase 1, superoxide and nitric 
oxide. Tumors themselves produce IL-10, vascular endothelial growth factor (VEGF), GM-CSF, TNF-α, 
IL-1, IL-6 that blocks DC maturation. Thus, the tumor not only manages to escape the immune cells but 
also creates a microenvironment to promote progression.(36) The immunosuppression is battled by 
various treatments such as via cytokines, checkpoint inhibitor against adoptive cell transfers and 
therapeutic cancer vaccines.(37)  
1.9 Immune escape 
There are several reasons responsible for immune escape of tumors. Some of the reasons could be due to 
reduced immunogenicity, resistance to immune mediated cytotoxicity, destabilization of immune 
response, escape through both immunosuppression and alteration of tumor microenvironment.(38),(39) 
Thus, the older concept that immune system has integrated ability to recognize only non-self is not 
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enough for immune response. The immunosuppressive tumor microenvironment has initiated newer 
concepts to balance between immune-stimulating and tumor inhibitory mechanisms. Strategies are being 
developed to harness the power of immunity against cancer. Therapeutic tools are necessary to halt the 
tumor progression through effective identification of non-self-antigens. This research work targets to 
provide a tool to stimulate the immune system to antigenic message and manipulate tolerance and 
productive immunity.(40) 
1.10 Dendritic cells: The best-known antigen presenting cells 
DCs are the key antigen presenting cells that transfer information to the cells of adaptive immune 
response.(41) DCs are heterogeneous in origin, morphology, phenotype and function. DCs play a crucial 
role in inducing immune response against all types of antigens.(42) They are unique among all antigen 
presenting cells. Table 1.1 mentions the speciality of different APCs. 
Table 1.1: Speciality of different APCs (43) 
Properties Dendritic cells Macrophages B cells 
Antigen uptake 
activity 
• Phagocytosis, 
macropinocytosis, 
receptor-mediated 
endocytosis 
• Phagocytosis, 
receptor-mediated 
endocytosis 
 
• Receptor-mediated 
endocytosis via 
immunoglobulin 
 
MHCII 
expression 
• Constitutive, high 
level of expression, 
inducible 
• Low level expression, 
inducible 
• Constitutive 
expression, inducible 
Antigen 
presenting 
activity 
• Activation of naive 
T cells 
• Activation 
of naive B cells by 
recruiting CD4+ T cells 
• Recruitment of helper 
T cells for antibody 
production 
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1.11 DC activation process 
Upon pathogen encounter DCs engage their PRRs to alert the immune system that a pathogen has 
breached the immune barrier. In response, the chemokine receptors allow them to migrate from peripheral 
site of infection to secondary lymphoid organs. Thus, biochemical signals within the tissue 
microenvironment educates immature DCs to down regulate tissue homing and upregulate chemokine 
receptor which in turn promotes DCs to lymph node. During this migration, they undergo the process of 
‘maturation’. Mature DCs initiate DC receptors to pick up the danger signal to present the antigens. The 
danger signal increases the surface density of MHCII, gathers costimulatory molecules and release 
cytokines for further immune response. They are the only cells that can prime naive T cells.(43), (44) 
Activation or tolerization of DCs are determined by the antigen microenvironment. When the foreign or 
self-antigen are not dangerous the tolerance is expected as the DCs will not mature and no signal will be 
delivered further.(45) 
1.12 DC subtypes  
DCs are classified in different ways. (46), (47), (48) Figure 1.2 represents the classification of DCs.(49)
 
Figure 1.2: Classification of DCs (49) 
Dendritic cells
Conventional
(derived from 
common DC 
progenitor and pre-
DCs)
Migratory
(In intestine, liver, lungs, 
skin: langerhans and 
dermal DCs , kidney)
Lymphoid 
(CD8- and CD8 + 
DCs)
Non-conventional
Plasmacytoid
Monocyte derived 
(In intestine, liver, 
lungs, skin , kidney)
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1.13 Functions of DC 
DCs play a major role in initiating tolerance, memory and T cell differentiation. In the vicinity of DC and 
T cells, the following signals are required to initiate immune response.(45) DCs are 1,000 times more 
potent than other APCs in activating resting T cells.(50) 
Signal 1: Response of CD4 and CD8 T cells to antigen displayed on MHCI and MHCII molecules 
Signal 2: Expression of accessory molecules is required for division and differentiation of T cells 
Signal 3: Secretion of cytokines 
These three stimulations are necessary for T cell activation.(51)  
1.14 DC Receptors 
Antigens have special structured proteins or carbohydrates known as pathogen associated molecular 
pattern (PAMPs). Uptake of these antigens occurs by phagocytosis, pinocytosis, macropinocytosis and/or 
receptor mediated uptake. The process of phagocytosis is triggered by recognition of foreign particles 
through the recruitment of receptors. Among these, macroendocytosis or receptor mediated uptake are the 
most efficient ones. Scavenger receptors, PRRs, Fc receptors (CD64 and CD32), complement receptors 
and viral receptors are the DC surface receptors. The important PRRs on DCs are TLRs, mannose 
receptors and C-type lectin receptors.(52) 
Presently, 15 mammalian TLRs have been discovered. Among them, 10 of the TLRs are present in 
humans.(53) Some TLRs subset agonists have been employed in clinical trials, whereas some are already 
in market.(54) The mannose receptor is a C-type lectin that can perform phagocytosis, antigen 
presentation and processing.(55) Compared to TLRs and mannose receptors, CD205 C-type lectin 
receptor is the most recent one to be explored.(56) 
1.15 CD205, a C-type lectin receptor 
CD205 receptor is expressed by lymphoid, interstitial, epidermal Langerhans DCs and thymic epithelial 
cells.(52) This receptor is overexpressed when DCs are mature. CD205 receptor binds primarily with 
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carbohydrates.(57) This receptor contains an N-terminal domain, a fibronectin domain and multiple 
carbohydrate recognition domains (CRDs). The number of these CRDs are ten for this receptor.(58) This 
receptor is an excellent antigen-targeting receptor for monoclonal antibodies to efficiently bind target 
DCs in-vivo.(59) It has been found that, targeting CD205 with anti-CD205 monoclonal antibody 
enhanced antigen presentation by DCs to T cells (CD4+ and CD8+).(60) Besides, the receptors can both 
present and cross-present antigens on MHC molecules. This receptor delivers antigens to late endosomes, 
which then display fragments of antigens on MHCII molecules.(61), (62)  
Thus, it is critical to design a delivery system capable to reach and target CD205 receptors in-vivo.(63). 
This potentiates the structural modification of NPs with a complementary ligand to play a significant role 
in NP delivery to the target site.(64) 
1.16 Cancer Immunotherapy 
Immunotherapy uses the immune system for boosting the cancer patient’s immune response. This will 
improve its ability to recognize tumor. The aim of immunotherapy is to modulate immune response.(65) 
Presently, there are several treatment options for cancer; but combination approach is the best selected 
method for cancer patients.(66) For example, radiotherapy might be successful when chemotherapy is 
coupled with it. Chemotherapy can be more beneficial when coupled with immunotherapy. Nowadays, 
targeted therapy with monoclonal antibody is a significant treatment option to interact with immune 
system.(67) Tumor blood vessels are different from normal blood vessels due to their proliferating nature. 
Increasing the dose of drug may not eliminate the tumor load due to genetic plasticity of tumor cells. This 
can be the reason for development of resistance against chemotherapeutic drug. Nevertheless, combined 
chemo-immunotherapy can be advantageous for cancer treatment.(68), (69) Combination therapy 
enhances vaccine efficacy by several mechanisms. Chemotherapeutic agents act by ‘immunogenic tumor 
cell death’. Prostvac vaccine with chemotherapeutic Docetaxel for patients with prostate cancer is an 
example of combination therapy.(70) 
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1.17 Types of cancer immunotherapy 
The uptake of tumor cells and presentation of their antigens to T cells is a complex criterion. DCs need 
help to effectively present the antigens to T cells. The process of cancer immunotherapy can be divided in 
different ways. Generally, it can be divided as specific and non-specific immunotherapy (Figure 1.3).(71) 
A.  Non-specific immunotherapy 
Non-specific immunotherapy modulates the immune system generally, without targeting tumor associated 
antigens (TAAs). It can be further subdivided as:  
• Active immunotherapy: This induces the generation of immune effector mechanisms. It 
educates the immune system to recognize tumor cells and induces immune memory.(71)  
• Passive immunotherapy: It is obtained by supplying readymade immune effectors so that the 
immune system can consume the effector molecules. This type of immunotherapy is obtained by 
general stimulants of the immune system the  ‘immunomodulators’ through various mechanisms 
such as induction of stimulatory cytokines, activation of  T cells and APCs. (71),  (72) 
B. Specific immunotherapy 
Specific immunotherapy targets one or several TAAs. It can be further subdivided into two groups: 
• Passive immunotherapy: This is performed by supplying tumor specific monoclonal antibodies. 
For example, treating breast cancer overexpressing HER-2 antigen.(73), (74) Though the 
antibodies are either humanized or chimeric, side effects occur due to residual immunogenicity 
causing serum sickness or hypersensitivity reactions.(75) Similarly, T cells can be adoptively 
transferred to cancer patients through passive transfer of tumor-reactive T cells into the host that 
results in the destruction of established tumors.(76) 
• Active immunotherapy (therapeutic vaccine) 
The goal of therapeutic vaccine is to generate an active immune response against an existing 
cancer. The vaccine can lead to clonal expansion of cytotoxic T cells that recognize cancer cells 
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and induce cell death. However, the optimal vaccine should provide both humoral and cellular 
immunity.(77) Among all the approaches, DC based vaccination strategy has showed 
encouraging results.(78) However, linear dose-response might not be observed in immunotherapy 
due to other factors. It depends on number of factors such as route of administration, dose, dosage 
regimen, adjuvant and immunological status. Moreover, the heterogeneous nature of antigen 
should be explored, especially in the later stage of the disease. Targeting multiple antigenic 
epitope should be considered for an effective anti-cancer therapy.(79) 
Nevertheless, identification of the important parameters for clinical effectiveness of a vaccine warrants 
research. In case of prostate cancer, it has been found that mature monocyte DCs are superior to their 
immature state. In addition, DCs should be able to produce IL-12p70 cytokine. The expansion of newer 
vaccines is influenced towards Th1 immune response with potential of CTL activity.(80)    
Figure 1.3: Schematic representation of immunotherapeutic approaches(71) 
DC based therapeutic vaccines can be subdivided as:(81) 
• Ex-vivo modification of DCs 
• In-vivo manipulation of DCs 
 
Cancer 
immunotherapy
Non-
Specific
Active
Passive(Using 
immunomodulatory 
agents)
Specific
Active (therapeutic 
vaccination)
: DC targeting in-vivo
: DC  modified ex-vivo
Passive (ready 
made 
immunoglobulins)
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• Ex-vivo modifications of DCs  
In this case, DCs are loaded with antigen; the maturation of DCs are confirmed and then the newly 
generated complete DC vaccine is injected to the patient. The injected vaccine triggers the immune 
system which in turn recognizes the cancer cells efficiently and to attack them back. Each vaccine 
manufactured is unique, customized for individual patient, which is very expensive.(71) However, the 
obtained immune response and the clinical response were different, which could be partially due to the 
immunosuppressive environment present in the later stage of the disease.(82)  
Sipuleucel-T(Dendreon Corp.)  is the first US Food and Drug administration (FDA) approved DC vaccine 
against prostate cancer. Prostvac is another ex-vivo DC vaccine which is pox virus based vaccine targeting 
prostate specific antigen to treat men with metastatic castration resistant prostate cancer. Choice of 
antigen is an vital factor for this type of vaccine. Non-mutated self-antigens are preferred over muted ones 
as it has broader application on the vaccine. However, mutated antigens could provide personalized 
treatment to avoid this shortcoming.(83) 
• In-vivo modifications of DC 
The disadvantages of ex-vivo DC vaccine seek an alternative to obtain immediate T cell activation. This 
could be achieved by administration of tumor antigen-adjuvant-ligand conjugated vaccine system. In the 
absence of adjuvant, antigen-specific tolerance is developed. This type of vaccine is “cell-free vaccine” 
that targets the endogenous DCs. The in-vivo polarization of DCs delivers the antigens selectively to 
DCs.(82) This in-vivo vaccination strategy is simple, inexpensive and labor saving compared to ex-vivo 
DC vaccines.(64)  
The in-vivo vaccination protocols are aimed to initiate CD8+ T cell differentiation regulated by CD4 T 
cells. As a result proliferation of tumor antigen specific T cells will occur with long term memory CD8+ 
T cells.(84) This is the driving strategy of our work to introduce an antibody-NP adjuvant to target DC 
receptor for effective DC based in-vivo immunotherapy.  
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1.18 Mechanism of in-vivo delivered DC vaccine 
In-vivo delivered DC vaccines are manipulated in ex-vivo laboratory setup. This in-vivo generated vaccine 
represents an economic option as it requires less labor than ex-vivo generated DCs. Tumor expressed well 
characterized antigens could be delivered so that they are presented on MHC molecules. Strategies that 
show both CD4 and CD8 effect can provide protective anti-tumor effect. Also, endogenous DCs can be 
targeted via specific targeting molecules.(85, 86) These cancer vaccines should be capable of epitope 
distribution, preferentially by eliminating tumor cells that expresses a specific epitope. Therefore, we will 
get antigen-specific response where the number and the quality of tumor-specific cytotoxic T cells will 
increase.(87) This produces antigen specific CTLs which will kill the tumor cells.(88) 
1.18.1 Components of therapeutic cancer vaccine 
The components of cancer vaccine include tumor-specific antigens, carrier or delivery systems and 
adjuvants. A vaccine should have effective shelf-life, proper delivery device and packaging. Nevertheless, 
an ideal vaccine is always beyond the choice of adjuvant and immune potentiator.(89) 
1.18.2 Selection of tumor antigen 
Cancer vaccine contains antigens of varied composition, identity and source. For example, recombinant 
proteins, synthetic peptides, carbohydrates, extracted tumor derived proteins, monoclonal antibodies can 
be used as antigen.(90) Antigens should be expressed on tumor cells only because mutated proteins 
cannot be expressed by MHC molecules. The mutated region is sometimes masked by modification. So, 
proteins expressed on tumor cells are less possibly expressed by normal cells and good tumor target.(91) 
Previously it was found that there are two types of antigen classes such as: tumor-specific antigens, which 
are present only on tumor cells and not on any other cell and tumor-associated antigens, which are present 
on some tumor cells and some normal cells. However, there are several types of antigens discovered till 
date.(92) 
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In immunotherapy, the APCs are modulated so that they can stimulate T cells in an effective manner. 
Manipulation of this response can be significantly achieved by delivering antigen using a NP system.(93) 
Studies showed when anti-CD205 Ab ligand is conjugated with ovalbumin, the receptor mediated antigen 
presentation via MHCI and MHCII increased 1000 and 300 times, respectively. This CD205 receptor 
targeted antigen conjugate provided immunity upon obtaining maturation stimulation for DCs. Therefore, 
non-targeted antigens are less effective to activate immune response.(94) 
1.18.3 Adjuvants and their role in vaccine formulation 
Adjuvant is a vital component of ideal vaccine system. Adjuvants should be effective to produce antigen 
specific immune response, immunological memory, safety profile and stability profile. Modern vaccines 
are unable to obtain optimum immune response. This justifies the necessity of adjuvants that can produce 
both cell-based and humoral immune response.(95) Moreover, the need for antigen and the frequency of 
vaccination decreases when adjuvant is present in the formulation. All the advantages of adjuvants can 
help immuno-compromised patients.(96) Among all the adjuvants, toll-like receptor (TLRs) agonists have 
gained attention as it can be displayed on DCs. A ligand can bind with TLRs to help DC maturation, 
antigen processing and presentation. Different clinical trials are running with use of TLR ligands.(97) 
When peptide is used as an antigen in NP delivery system, they form complex with MHCI molecules in 
endoplasmic reticulum and transported to cell surface receptor to be recognized by T cells.(98) However, 
clinical response with peptide alone has shown low success. This justifies the co-delivery of adjuvant and 
antigen through NPs.(99) 
1.19 NPs as delivery system: importance of particle size, shape, charge and surface chemistry 
Several delivery systems are used as platforms to be used as vaccine delivery carrier. Liposomes, 
emulsions, immunostimulatory complexes, polymeric NPs are now widely used. Polyester based particles 
started in late 70s. In 1976, polyacrylamide nanostructures were first used to obtain immune response. 
Among the polyesters, PLGA is well known for their numerous properties. Detailed discussion will be in 
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the next section.(100) The term ‘NP’ is used for diverse range of nanosized particle that includes particle 
upto 1 µm.(101) 
There are several aspects of research on NPs to be kept in mind when formulating a delivery system such 
as drug loading capacity, site specific targeting, and biological fate of the drug and carrier, toxicity and 
storage stability. For instance, liposomes might face chemical and physical stability problems solid-lipid 
NPs might have low drug payload and stability problems, incomplete removal of residual organic solvents 
and polymer cytotoxicity occurs with some polymer based NPs, protein based particles might face long 
term storage, aggregation problem in aqueous solution, cationic micelles have toxicity issues, carbon 
nanotubes are non-biodegradable, dendrimers have toxicity issues; and metallic NPs are unable to load 
drugs.(102) Biodegradable, biocompatible polymers like PLGA has been approved for use in human 
beings. These can load high amount of antigen to slowly release from the formulation. In this way the 
polymer protects the antigen from degradation.(103)  
Advances in understanding the properties of NPs such as size, shape and surface properties for biological 
interactions, are creating new opportunities for their therapeutic applications. Particle size is an important 
factor for effective NP design. However, 10-100 nm is the best fitted particles for cancer therapy. But 
internalization of particles is extended up to 5 µm depending upon the type of formulation. Different 
studies have found that lower particle size (~100 nm) is internalized quickly than 5 µm size 
particles.(104) 
Surface charge also effects particle internalization. Positively charged particles can exhibit perinuclear 
localization and shorter stay in circulation. Particles with lower surface charge have longer blood 
circulation time.(104), (105) Both surface property and particle size determines the composition of 
protein corona attracted towards NPs. Presence of this corona influences particle clearance my 
mononuclear phagocytic system (MPS). Surface functionalization is the possible mechanism to avoid 
corona proteins and immunoglobins.(106)  
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Surface modification of particles can be done by attaching targeting ligands such as transferrin, 
antibodies, small peptides, aptamer, and folic acid. Particles with ligand can be internalized by 
phagocytosis, pinocytosis or other mechanisms. Surface manipulation will increase the circulation time of 
particles and secondly allow selective interaction with cancer cells.(104) Particle shape also plays key 
role in cellular internalization.(107)  
1.19.1 PLGA NPs in drug delivery: Structure and composition 
PLGA NPs, the well known in its class, approved by United States FDA to be used for various diseases. It 
is currently under intense development for applications in cancer imaging, vaccines, targeted therapy and 
tissue engineering.(108) 
 
Figure 1.4: Poly lactide co-glycolide (PLGA) structure (109) 
PLGA is a synthesized by ring-opening copolymerization of two different monomers, glycolic acid and 
lactic acid (Figure 1.4). During polymerization, monomeric units (of glycolic or lactic acid) are linked 
together in PLGA by ester linkages yielding a linear, amorphous aliphatic polyester product. The most 
widely used glycolic and lactic ratio of 50:50 with variety of end groups and viscosities. PLGA is 
preferred over its monomers as it can be dissolved by wide range of solvents.(109) PLGA NPs can be 
prepared by various methods. The popular methods are emulsification, solvent evaporation method, 
nanoprecipitation, polymerization, coacervation, ionic gelation and salting out.(110) Depending on the 
mode of preparation, NPs might possess different properties and characteristics for optimum delivery of 
therapeutic agent. Among all the processes, W/O/W or single O/W emulsification-solvent evaporation 
method are used.  PLGA NPs typically range from 10 to 1000 nm in diameter, with the therapeutic agent 
either entrapped into or adsorbed or chemically coupled onto the polymer matrix.(111) It undergoes 
hydrolysis in the body to produce biodegradable metabolite monomers, lactic acid and glycolic acid 
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(Figure 1.5). Therefore, the whole process leaves non-toxic residues after metabolism. This biological 
degradation occurs at very slow rate, without affecting normal cell function.(112)  
 
Figure 1.5: Hydrolysis of PLGA polymer (112) 
1.19.2 PLGA NPs as a vaccine delivery system for immunotherapy 
Particulate delivery system is considered as recent development in field of immunotherapy.(113) An 
antigen, an adjuvant and a delivery system is required to formulate NP based ideal cancer vaccine. This 
cargo system is able to deliver antigen to the APC to manipulate their response.(114) Surface modified 
NPs will render a hydrophilic layer that is capable to escape reticulo-endothelial system to reach receptors 
on target APCs (DCs).(115) Table 1.2 summarizes some examples of PLGA based vaccine delivery 
system. 
Table 1.2: PLGA based vaccine delivery systems and their biological effects 
Nanoparticl
e system 
Antigen Adjuvant Results Refer
ence# 
PLGA NP OVA TLR9 
agonist/ 
CpG  
•  Increased secretion of IFNγ, indicating Th1 
based response 
• No significant difference between OVA-
CpG and PLGA-OVA-CpG groups for anti-
tumor and cytotoxic T cell response. But, the 
(116) 
21 
 
tumor was below 50mm2 after day 17 
PLGA 
micro-
particles 
OVA CpG  • PLGA helped to increase IgG and IFNγ 
secretion. A Th1 biased humoral response 
was obtained 
• No clear benefit of CpG and OVA in 
microparticles were found 
(117) 
PLGA NP OVA and 
MUC1  
 
MPLA • The vaccine system increased antigen 
specific Th1 polarized response 
• MUC1-pLGA-MPLA combination showed 
MUC1 specific T cell response and 
breakdown of self-MUC1 tolerance  
(118) 
PLGA MUC1 and 
tetanus toxoid 
(TT) 
CpG and 
MPLA 
• The T cell proliferation observed in the 
presence of PLGA-MUC1-MPLA was 
higher than MUC1 and empty NPs 
• Same data trend was found for TT-PLGA-
CpG system. T cell proliferation was 
significantly higher than soluble OVA 
pulsed DCs 
(119) 
PLGA 
micro-
spheres 
OVA CpG  • Triggered clonal expansion of primary and 
secondary antigen specific CD4 and CD8 
cells 
• Out of 5 mouse 4 showed complete tumor 
regression, one showed retarded tumor 
growth   
(120) 
PLGA NP OVA poly(I:C) or • Enhanced MHC I restricted antigen (121) 
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CpG  presentation but not the MHC II restricted, 
presentation of exogenous antigen 
• NP with OVA-CpG induced effective 
proliferation of CD4 and CD8 T cells 
PLGA NP OVA MPLA or 
TLR7 
• 10 µg of antigen plus PLGA (MPLA+TLR7) 
yielded a much greater response than that 
induced by 50 µg of antigen alone. Thus, 5-
fold less dose was required 
• The antigen-adjuvant combination created 
memory B cells as well as plasma cell 
response 
(122) 
PLGA NP Melanoma 
antigen 
recognized by 
T-cells-1 
(MART), 
gp100, OVA, 
SIINFEKL 
and mouse six 
transmembran
e epithelial 
antigens of the 
prostate (m 
STEAP) 
Incomplete 
Freund’s 
adjuvant 
(IFA) 
• PLGA NPs encapsulating a three-peptide 
(MART-1, gp100:154–162 and gp100: 209–
217) generated significantly more robust 
cytotoxic activity than those encapsulating a 
two-peptide (MART-1 and gp100:154–162) 
• The peptide dose encapsulated in PLGA NPs 
was 63 times less than that emulsified in 
incomplete Freund’s adjuvant 
• Tumor size in the mice immunized with 
PLGA-mSTEAP NPs was smaller than 
tumors in the mice immunized with 
mSTEAP+ IFA 
(123) 
PLGA NP Melanoma MPLA • Mouse treated with PLGA-TRP2-MPLA had (114) 
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antigen, 
tyrosinase-
related protein 
2 
60-65-fold high CD8+T cell count 
• Controlled tumor growth (85%) was 
observed when treated with the NP system 
• Increased all cytokines such as IFNγ, TNFα, 
IL-2, IL-12, IL-6 and decreased production 
of VEGF 
PLGA NP Tetanus toxoid 
(TT) 
CpG  • Induction of both Th 1 and Th2 immune 
responses with potent Th1 response 
(124) 
PLGA NP or 
microparticl
e 
Murine 
cytomegalovir
us epitope 
pp89 
EP67 • Sufficient secretion of IFNγ, TNFα and IL-2 
• Varying the diameter of particles affected 
the CD8 memory T cell response 
(125) 
 
There are several studies performed with PLGA-antigen combination without using adjuvant. Due to their 
limitations in adequate immune response incorporation of an adjuvant in formulations in necessary. (126), 
(127), (128) 
1.19.3 Drawbacks of NP based vaccine delivery systems 
NP based vaccine shows failure to achieve efficacy in clinical trials due to improper relation between 
maximum tolerated dose and tumor response rate, drug exposure and its efficacy/toxicity and prolong 
time to achieve immunotherapeutic response.(129) When delivering therapeutic agent through active 
targeting strategy, the target recognition needs to be highly specific with the scope of accommodating the 
ligand with greater binding capacity.(130) Difficulties arise when the reproducibility of the manufacturing 
parameters could not be ensured. In addition, the physicochemical properties of NPs needs to be 
correlated with their biodistribution and targeting property.(131)  
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This scenario can be changed by choice of formulation to prepare vaccine, being critical in patient 
selection, being aware of patients’ previous medical history, applying novel technologies to standardize 
treatment and selection of strong adjuvant in the vaccine.(132)  For instance, PLGA based vaccines 
require the use of organic solvents, sonication and high speed agitation. Proteins/epitopes are susceptible 
to these experimental conditions. However, strict formulation parameters should be maintained along with 
use of protein stabilizers (sugars, polysaccharides) for commercial scale-up preparation.(133) Toxicity 
issues and accumulation of NPs within cells can hinder effective vaccine delivery. To overcome this 
biodegradable polymeric NPs can be used.(134) To achieve success from therapeutic vaccination, 
treatment in the last stage of tumor should be avoided. In addition, survival rate will be improved when 
delivered with suitable combination of antigen-adjuvant in formulation.(135)  
1.19.4 Surface functionalization of PLGA NPs 
To spare the destroying of normal cells over cancer cells requires highly efficient anti-cancer therapeutics 
to efficiently deliver the drug load to the tumor site. The most commonly used method is employing 
molecules or ligands that specifically recognize and interact with cancer cells. These molecules include 
antibodies, growth factors, cytokines, protein or other agents.(136) 
NPs should be surface functionalized for the following reasons: (137), (138) 
• Non-modified NPs are easily recognized by phagocytic system rich organs and tissues like blood, 
liver, spleen, lung and bone-marrow. 
• Hydrophobic surface of NPs can easily adsorb plasma proteins to the surface. Increasing 
hydrophilicity of NP surface is a commonly used strategy to avoid this problem.  
• Surface functionalization can prolong the circulation time of NPs in-vivo until they reach the 
target site. 
• In case of cancer targeting, abnormal tumor structure can hinder localization of NPs to the tumor 
by enhanced permeability and retention. This can inhibit effective drug delivery. 
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The theory behind it is to deliver ligand-targeted therapeutics that bind with antigen or receptors that are 
either uniquely expressed or overexpressed on target cells compared to normal tissues. This allows the 
specific and targeted delivery of drugs to cancer cells.(139),(140) 
1.19.4.1 Functionalization of NP surface with antibody 
Antibodies should be linked to the NPs properly, as wrong binding to NPs without specificity may impair 
the activity of antibody.(141) Antibodies can be linked to NPs by two ways: 
1. Covalent attachment of antibodies to NPs 
There are several approaches through which monoclonal or polyclonal antibodies are covalently linked to 
the prepared NPs using cross-linkers.  
i) Via carbodiimide chemistry:  Carboxylic group of NPs and amine group of the antibody combines to 
form amide bond.(142) 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) couples’ carboxylic acid 
groups of PLGA with the amino group of antibodies. N-hydroxysuccinimide (NHS) is often included in 
EDC coupling protocols.(143)  
ii) Via maleimide: The maleimide group reacts with thiol groups resulting in cross linking that is more 
selective and precise. Combining thiol groups with amine groups of biomolecules through a maleimide 
can be achieved when there is no free thiols present in the antibody.(144)  
2. Adsorption of antibodies to NPs 
Besides covalent attachment, antibodies could also be adsorbed to the NP surface. Ligands are coated on 
NP surface by non-covalent attachment. Hydrophobic PLGA polymers and hydrophobic part of the 
antibody molecule facilitated this hydrophobic interaction. MAb-decorated NPs could enter the target 
cells exclusively, while the unmodified NPs were non-selective.(141)  
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1.19.4.2 The use of spacer molecules for attaching the targeting ligands 
Thamake et al (145) reported non-covalent incorporation of a homobifunctional spacer. The spacer, bis-
sulfosuccinimidyl suberate (BS3) was incorporated onto PLGA NPs for effective attachment of antibody 
to NP surface. BS3 enables formation of amide linkage between the carboxylic group of BS3 and the 
amine group from the ligand following the hydrolysis and exposure of the carboxylic group of the spacer. 
The covalent bond between the antibody and BS3 enhances the NPs cellular uptake. (125) 
Heterobifunctional crosslinkers have different chemical groups at both ends. For example, an amine-
reactive N-hydroxysuccinimide ester (NHS ester) at one end and a sulfhydryl-reactive group on the other 
end. Doxorubicin containing amine group (-NH2) could be covalently bound with spacer forming thio-
ether bond to mAb. The length of different spacer groups were selected in order not to create steric 
hindrance between Doxorubicin and the mAb.(146) 
1.20 Methods used in this specific research 
I. Covalent conjugation of antibodies to the NPs surface  
Two methods of covalent conjugation were utilized in this research to attach antibody and NP. One was 
through carbodiimide chemistry; other was using a spacer to attach antibody and NP. For adsorption, 
antibody was attached with the NPs following controlled procedure.  
A. Conjugation method 1: Carbodiimide chemistry 
B. Conjugation method 2: Using spacer for covalent conjugation 
II. Physical adsorption of antibodies to the NPs surface (non-covalent) 
An alternative means to conjugate ligands to NPs is the use of non-covalent techniques. This simple 
method, the ligand is added to the mixture of NPs during the attachment of the antibody to the NP.(145) 
 
27 
 
1.21 References 
1. Spitzer MH, Gherardini PF, Fragiadakis GK, Bhattacharya N, Yuan RT, Hotson AN, et al. 
IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. Science. 
2015 Jul 10;349(6244):1259425. PubMed PMID: 26160952. Pubmed Central PMCID: 4537647. 
2. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer 
development. Nature reviews Cancer. 2006 Jan;6(1):24-37. PubMed PMID: 16397525. 
3. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annual review of immunology. 
2002;20:197-216. PubMed PMID: 11861602. 
4. Paul WE. Bridging innate and adaptive immunity. Cell. 2011 Dec 09;147(6):1212-5. PubMed 
PMID: 22153065. 
5. Chaplin DD. Overview of the immune response. The Journal of allergy and clinical immunology. 
2010 Feb;125(2 Suppl 2):S3-23. PubMed PMID: 20176265. Pubmed Central PMCID: 2923430. 
6. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. 
Science. 2010 Jan 15;327(5963):291-5. PubMed PMID: 20075244. Pubmed Central PMCID: 3645875. 
7. Delves PJ, Roitt IM. The immune system. Second of two parts. The New England journal of 
medicine. 2000 Jul 13;343(2):108-17. PubMed PMID: 10891520. 
8. Parkin J, Cohen B. An overview of the immune system. Lancet. 2001 Jun 2;357(9270):1777-89. 
PubMed PMID: 11403834. 
9. Goldman AS, Prabhakar BS. Immunology Overview. In: Baron S, editor. Medical Microbiology. 
4th ed. Galveston (TX).1996. 
10. Rosa DS, Ribeiro SP, Cunha-Neto E. CD4+ T cell epitope discovery and rational vaccine design. 
Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):121-30. PubMed PMID: 20155490. 
11. Kemeny DM, Noble A, Holmes BJ, Diaz-Sanchez D. Immune regulation: a new role for the 
CD8+ T cell. Immunol Today. 1994 Mar;15(3):107-10. PubMed PMID: 8172642. 
28 
 
12. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008 Sep 1;112(5):1557-69. 
PubMed PMID: 18725574. Pubmed Central PMCID: 2518872. 
13. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol 
Today. 1996 Mar;17(3):138-46. PubMed PMID: 8820272. 
14. Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity. 
Immunological reviews. 2010 Mar;234(1):317-34. PubMed PMID: 20193028. 
15. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T 
lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998 Jun 4;393(6684):480-3. PubMed 
PMID: 9624005. 
16. Gasteiger G, Ataide M, Kastenmuller W. Lymph node - an organ for T-cell activation and 
pathogen defense. Immunological reviews. 2016 May;271(1):200-20. PubMed PMID: 27088916. 
17. Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naive 
to memory and everything in between. Advances in physiology education. 2013 Dec;37(4):273-83. 
PubMed PMID: 24292902. Pubmed Central PMCID: 4089090. 
18. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and 
function of CD40/CD40L engagement in the immune system. Immunological reviews. 2009 
May;229(1):152-72. PubMed PMID: 19426221. Pubmed Central PMCID: 3826168. 
19. Medzhitov R, Janeway CA, Jr. Innate immunity: impact on the adaptive immune response. Curr 
Opin Immunol. 1997 Feb;9(1):4-9. PubMed PMID: 9039775. 
20. Janeway CJ, Travers P, M. W. Principles of innate and adaptive immunity. 5th ed. 
Immunobiology:The Immune System in Health and Disease.: New York: Garland Science; 2001. 
21. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M. Dendritic cells the tumor 
microenvironment and the challenges for an effective antitumor vaccination. Journal of biomedicine & 
biotechnology. 2012;2012:425476. PubMed PMID: 22505809. Pubmed Central PMCID: 3312387. 
22. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nature 
immunology. 2004 Oct;5(10):971-4. PubMed PMID: 15454919. 
29 
 
23. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990 Jun 
15;248(4961):1349-56. PubMed PMID: 2113314. 
24. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell 
memory. Science. 2003 Apr 11;300(5617):337-9. PubMed PMID: WOS:000182135400059. English. 
25. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-
stimulation by the human CTLA-4/B7-2 complex. Nature. 2001 Mar 29;410(6828):604-8. PubMed 
PMID: 11279501. 
26. Rodriguez-Fernandez JL, Riol-Blanco L, Delgado-Martin C. What is an immunological synapse? 
Microbes Infect. 2010 Jun;12(6):438-45. PubMed PMID: 20227515. 
27. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. 
Nat Rev Immunol. 2003 Dec;3(12):939-51. PubMed PMID: 14647476. 
28. Block KI, Boyd DB, Gonzalez N, Vojdani A. Point-counterpoint: the immune system in cancer. 
Integr Cancer Ther. 2002 Sep;1(3):294-316. PubMed PMID: 14667287. 
29. Suckow MA. Cancer vaccines: harnessing the potential of anti-tumor immunity. Vet J. 2013 
Oct;198(1):28-33. PubMed PMID: 23850019. 
30. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from 
immunosurveillance to tumor escape. Nature immunology. 2002 Nov;3(11):991-8. PubMed PMID: 
12407406. 
31. Diaz-Cano SJ. Tumor heterogeneity: mechanisms and bases for a reliable application of 
molecular marker design. International journal of molecular sciences. 2012;13(2):1951-2011. PubMed 
PMID: 22408433. Pubmed Central PMCID: 3292002. 
32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 
4;144(5):646-74. PubMed PMID: 21376230. 
33. Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H. Generation of tumor-specific T-cell 
therapies. Blood Rev. 2006 Mar;20(2):61-9. PubMed PMID: 15978709. 
30 
 
34. Soloski MJ. Recognition of tumor cells by the innate immune system. Curr Opin Immunol. 2001 
Apr;13(2):154-62. PubMed PMID: 11228407. 
35. Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest. 2007 
May;117(5):1130-6. PubMed PMID: 17476342. Pubmed Central PMCID: 1857237. 
36. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 
2008 Oct 6;27(45):5904-12. PubMed PMID: 18836471. Pubmed Central PMCID: 3689267. 
37. Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. 
International immunology. 2016 Mar 22. PubMed PMID: 27006304. 
38. Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, et al. The immune system--
is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol). 2008 
Mar;20(2):101-12. PubMed PMID: 18037277. 
39. Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-
cell-inflamed tumor microenvironment. International immunology. 2016 Mar 17. PubMed PMID: 
26989092. 
40. Zigler M, Shir A, Levitzki A. Targeted cancer immunotherapy. Current opinion in pharmacology. 
2013 Aug;13(4):504-10. PubMed PMID: 23648271. 
41. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of 
dendritic cells. Annual review of immunology. 2000;18:767-811. PubMed PMID: 10837075. 
42. Kim R, Emi M, Tanabe K, Arihiro K. Potential functional role of plasmacytoid dendritic cells in 
cancer immunity. Immunology. 2007 Jun;121(2):149-57. PubMed PMID: 17371541. Pubmed Central 
PMCID: 2265944. 
43. Diebold SS. Activation of dendritic cells by toll-like receptors and C-type lectins. Handb Exp 
Pharmacol. 2009 (188):3-30. PubMed PMID: 19031019. 
44. Alvarez D, Vollmann EH, von Andrian UH. Mechanisms and consequences of dendritic cell 
migration. Immunity. 2008 Sep 19;29(3):325-42. PubMed PMID: 18799141. Pubmed Central PMCID: 
2818978. 
31 
 
45. Lipscomb MF, Masten BJ. Dendritic cells: immune regulators in health and disease. Physiol Rev. 
2002 Jan;82(1):97-130. PubMed PMID: 11773610. 
46. Breckpot K BA, Aerts JL, Thielemans K. Dendritic cells: Subtypes, life cycle, activation, 
biological functions and their exploitation in cancer immunotherapy. Nova Science Publishers Inc. 
2010:1-42  
47. Fehres CM, Garcia-Vallejo JJ, Unger WW, van Kooyk Y. Skin-resident antigen-presenting cells: 
instruction manual for vaccine development. Frontiers in immunology. 2013;4:157. PubMed PMID: 
23801994. Pubmed Central PMCID: 3687254. 
48. Klechevsky E, Banchereau J. Human dendritic cells subsets as targets and vectors for therapy. 
Ann N Y Acad Sci. 2013 May;1284:24-30. PubMed PMID: 23651190. 
49. Kushwah R, Hu J. Complexity of dendritic cell subsets and their function in the host immune 
system. Immunology. 2011 Aug;133(4):409-19. PubMed PMID: 21627652. Pubmed Central PMCID: 
3143352. 
50. Pozzi LM, Maciaszek JW, Rock KL. Both Dendritic Cells and Macrophages Can Stimulate Naive 
CD8 T Cells In Vivo to Proliferate, Develop Effector Function, and Differentiate into Memory Cells. The 
Journal of Immunology. 2005;175::2071-81. 
51. Corthay A. A three-cell model for activation of naive T helper cells. Scandinavian journal of 
immunology. 2006 Aug;64(2):93-6. PubMed PMID: 16867153. 
52. Clark GJ, Angel N, Kato M, Lopez JA, MacDonald K, Vuckovic S, et al. The role of dendritic 
cells in the innate immune system. Microbes Infect. 2000 Mar;2(3):257-72. PubMed PMID: 10758402. 
53. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, et al. Toll-like receptor 
expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer 
immunotherapy. Cancer immunology, immunotherapy : CII. 2010 Oct;59(10):1573-82. PubMed PMID: 
20204387. 
54. Liu K. Dendritic cell, toll-like receptor, and the immune system. J Cancer Mol 2006 13 December 
2006;2(6):213-5. 
32 
 
55. Gazi U, Martinez-Pomares L. Influence of the mannose receptor in host immune responses. 
Immunobiology. 2009 Jul;214(7):554-61. PubMed PMID: 19162368. 
56. Ebner S, Ehammer Z, Holzmann S, Schwingshackl P, Forstner M, Stoitzner P, et al. Expression 
of C-type lectin receptors by subsets of dendritic cells in human skin. International immunology. 2004 
Jun;16(6):877-87. PubMed PMID: 15113774. 
57. Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic 
cell receptors for vaccine development. J Drug Deliv. 2013;2013:869718. PubMed PMID: 24228179. 
Pubmed Central PMCID: 3817681. 
58. Llorca O. Extended and bent conformations of the mannose receptor family. Cell Mol Life Sci. 
2008 May;65(9):1302-10. PubMed PMID: 18193159. 
59. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo 
targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. 
The Journal of experimental medicine. 2004 Mar 15;199(6):815-24. PubMed PMID: 15024047. Pubmed 
Central PMCID: 2212731. 
60. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune 
responses. Nat Rev Immunol. 2009 Jul;9(7):465-79. PubMed PMID: 19521399. 
61. Shrimpton RE, Butler M, Morel AS, Eren E, Hue SS, Ritter MA. CD205 (DEC-205): a 
recognition receptor for apoptotic and necrotic self. Mol Immunol. 2009 Mar;46(6):1229-39. PubMed 
PMID: 19135256. Pubmed Central PMCID: 2680960. 
62. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F, et al. Targeting the nuclear 
antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell 
responses. Blood. 2008 Aug 15;112(4):1231-9. PubMed PMID: 18519810. Pubmed Central PMCID: 
2515117. 
63. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, et al. Targeting of the non-mutated 
tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects 
33 
 
against breast cancer in mice. Breast cancer research : BCR. 2012;14(2):R39. PubMed PMID: 22397502. 
Pubmed Central PMCID: 3446373. 
64. Xu H, Cao X. Dendritic cell vaccines in cancer immunotherapy: from biology to translational 
medicine. Frontiers of medicine. 2011 Dec;5(4):323-32. PubMed PMID: 22198743. 
65. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in 
cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Sep;23 
Suppl 8:viii6-9. PubMed PMID: 22918931. Pubmed Central PMCID: 4085883. 
66. Characiejus D, Hodzic J, Jacobs JJ. "First do no harm" and the importance of prediction in 
oncology. EPMA J. 2010 Sep;1(3):369-75. PubMed PMID: 21151487. Pubmed Central PMCID: 
2987560. 
67. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of 
cancer? BMC medicine. 2016 May 05;14:73. PubMed PMID: 27151159. Pubmed Central PMCID: 
4858828. 
68. Roy A, Singh MS, Upadhyay P, Bhaskar S. Combined chemo-immunotherapy as a prospective 
strategy to combat cancer: a nanoparticle based approach. Molecular pharmaceutics. 2010 Oct 
4;7(5):1778-88. PubMed PMID: 20822093. 
69. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in 
nanotechnology for cancer treatment. Urologic oncology. 2008 Jan-Feb;26(1):74-85. PubMed PMID: 
18190835. 
70. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 
2012 Apr 18;104(8):599-613. PubMed PMID: 22395641. Pubmed Central PMCID: 3328421. 
71. Strioga MM, Felzmann T, Powell DJ, Jr., Ostapenko V, Dobrovolskiene NT, Matuskova M, et al. 
Therapeutic dendritic cell-based cancer vaccines: the state of the art. Crit Rev Immunol. 2013;33(6):489-
547. PubMed PMID: 24266347. 
72. Thotathil Z, Jameson MB. Early experience with novel immunomodulators for cancer treatment. 
Expert Opin Investig Drugs. 2007 Sep;16(9):1391-403. PubMed PMID: 17714025. 
34 
 
73. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011 Dec 
22;480(7378):480-9. PubMed PMID: 22193102. 
74. Singer J, Jensen-Jarolim E. IgE-based immunotherapy of cancer: challenges and chances. 
Allergy. 2013 Oct 14. PubMed PMID: 24117861. 
75. Jensen-Jarolim E, Singer J. Cancer vaccines inducing antibody production: more pros than cons. 
Expert review of vaccines. 2011 Sep;10(9):1281-9. PubMed PMID: 21919618. 
76. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical 
path to effective cancer immunotherapy. Nature reviews Cancer. 2008 Apr;8(4):299-308. PubMed PMID: 
18354418. Pubmed Central PMCID: 2553205. 
77. Serda RE. Particle platforms for cancer immunotherapy. Int J Nanomedicine. 2013;8:1683-96. 
PubMed PMID: 23761969. Pubmed Central PMCID: 3674015. 
78. Hanlon DJ, Aldo PB, Devine L, Alvero AB, Engberg AK, Edelson R, et al. Enhanced stimulation 
of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor 
antigen. Am J Reprod Immunol. 2011 Jun;65(6):597-609. PubMed PMID: 21241402. Pubmed Central 
PMCID: 3082607. 
79. Ahmed MS, Bae YS. Dendritic cell-based therapeutic cancer vaccines: past, present and future. 
Clin Exp Vaccine Res. 2014 Jul;3(2):113-6. PubMed PMID: 25003083. Pubmed Central PMCID: 
4083062. 
80. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for 
cancer therapy. Lancet Oncol. 2014 Jun;15(7):e257-67. PubMed PMID: 24872109. 
81. Parmiani G, Cimminiello C, Maccalli C. Increasing immunogenicity of cancer vaccines to 
improve their clinical outcome. Expert review of vaccines. 2013 Oct;12(10):1111-3. PubMed PMID: 
24124873. 
82. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013 Jul 
25;39(1):38-48. PubMed PMID: 23890062. Pubmed Central PMCID: 3788678. 
35 
 
83. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nature reviews Cancer. 
2012 Apr;12(4):265-77. PubMed PMID: 22437871. Pubmed Central PMCID: 3433802. 
84. Demento S, Steenblock ER, Fahmy TM. Biomimetic approaches to modulating the T cell 
immune response with nano- and micro- particles. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:1161-
6. PubMed PMID: 19963488. 
85. Gallois A, Bhardwaj N. Dendritic cell-targeted approaches to modulate immune dysfunction in 
the tumor microenvironment. Frontiers in immunology. 2013;4:436. PubMed PMID: 24339825. Pubmed 
Central PMCID: 3857536. 
86. Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, et al. Optimizing dendritic cell-
based approaches for cancer immunotherapy. The Yale journal of biology and medicine. 2014 
Dec;87(4):491-518. PubMed PMID: 25506283. Pubmed Central PMCID: 4257036. 
87. Baxevanis CN, Papamichail M, Perez SA. Therapeutic cancer vaccines: a long and winding road 
to success. Expert review of vaccines. 2014 Jan;13(1):131-44. PubMed PMID: 24224539. 
88. Franks HA, Wang Q, Patel PM. New anticancer immunotherapies. Anticancer Res. 2012 
Jul;32(7):2439-53. PubMed PMID: 22753700. 
89. Amorij JP, Kersten GF, Saluja V, Tonnis WF, Hinrichs WL, Slutter B, et al. Towards tailored 
vaccine delivery: needs, challenges and perspectives. Journal of controlled release : official journal of the 
Controlled Release Society. 2012 Jul 20;161(2):363-76. PubMed PMID: 22245687. 
90. de Souza AP, Bonorino C. The immune system: endogenous anticancer mechanism. Frontiers in 
bioscience. 2012 Jun 01;4:2354-64. PubMed PMID: 22652642. 
91. Sheng WY, Huang L. Cancer immunotherapy and nanomedicine. Pharmaceutical research. 2011 
Feb;28(2):200-14. PubMed PMID: 20821040. 
92. Barnas JL, Simpson-Abelson MR, Yokota SJ, Kelleher RJ, Bankert RB. T cells and stromal 
fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer 
microenvironment : official journal of the International Cancer Microenvironment Society. 2010 Mar 
31;3(1):29-47. PubMed PMID: 21209773. Pubmed Central PMCID: 2990491. 
36 
 
93. Stephan MT, Stephan SB, Bak P, Chen J, Irvine DJ. Synapse-directed delivery of 
immunomodulators using T-cell-conjugated nanoparticles. Biomaterials. 2012 Aug;33(23):5776-87. 
PubMed PMID: 22594972. Pubmed Central PMCID: 3395588. 
94. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient 
targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen 
presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. 
The Journal of experimental medicine. 2002 Dec 16;196(12):1627-38. PubMed PMID: 12486105. 
Pubmed Central PMCID: 2196060. 
95. Heegaard PM, Dedieu L, Johnson N, Le Potier MF, Mockey M, Mutinelli F, et al. Adjuvants and 
delivery systems in veterinary vaccinology: current state and future developments. Arch Virol. 2011 
Feb;156(2):183-202. PubMed PMID: 21170730. 
96. Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis. 2000 Jun;30 Suppl 
3:S266-70. PubMed PMID: 10875797. 
97. Mantia-Smaldone GM, Chu CS. A review of dendritic cell therapy for cancer: progress and 
challenges. BioDrugs. 2013 Oct;27(5):453-68. PubMed PMID: 23592406. 
98. Weidanz JA, Hawkins O, Verma B, Hildebrand WH. TCR-like biomolecules target peptide/MHC 
Class I complexes on the surface of infected and cancerous cells. International reviews of immunology. 
2011 Oct-Dec;30(5-6):328-40. PubMed PMID: 22053972. Pubmed Central PMCID: 3405915. 
99. Boraschi D, Italiani P. From Antigen Delivery System to Adjuvanticy: The Board Application of 
Nanoparticles in Vaccinology. Vaccines. 2015 Nov 05;3(4):930-9. PubMed PMID: 26556378. Pubmed 
Central PMCID: 4693225. 
100. Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine delivery carriers: insights and future 
perspectives. International journal of pharmaceutics. 2013 Jan 2;440(1):27-38. PubMed PMID: 
22561794. 
101. Thorley AJ, Tetley TD. New perspectives in nanomedicine. Pharmacol Ther. 2013 
Nov;140(2):176-85. PubMed PMID: 23811125. 
37 
 
102. Mishra D, Hubenak JR, Mathur AB. Nanoparticle systems as tools to improve drug delivery and 
therapeutic efficacy. Journal of biomedical materials research Part A. 2013 Dec;101(12):3646-60. 
PubMed PMID: 23878102. 
103. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Advanced drug 
delivery reviews. 2008 May 22;60(8):915-28. PubMed PMID: 18325628. 
104. Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines through particle 
design. Small. 2011 Jul 18;7(14):1919-31. PubMed PMID: 21695781. Pubmed Central PMCID: 3136586. 
105. Koua L, Suna J, Y. Z, Hea Z. The endocytosis and intracellular fate of nanomedicines: 
Implication for rational design Asian Journal of Pharmaceutical Sciences. 2013;8(1):1-10. 
106. Pearson RM, Juettner VV, Hong S. Biomolecular corona on nanoparticles: a survey of recent 
literature and its implications in targeted drug delivery. Frontiers in chemistry. 2014;2:108. PubMed 
PMID: 25506050. Pubmed Central PMCID: 4245918. 
107. Moon JJ, Huang B, Irvine DJ. Engineering nano- and microparticles to tune immunity. Advanced 
materials. 2012 Jul 24;24(28):3724-46. PubMed PMID: 22641380. Pubmed Central PMCID: 3786137. 
108. Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research 
and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009 May;9(4):325-41. 
PubMed PMID: 19435455. Pubmed Central PMCID: 2701163. 
109. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. Journal of drug targeting. 2008 
Feb;16(2):108-23. PubMed PMID: 18274932. 
110. Grabnar PA, Kristl J. The manufacturing techniques of drug-loaded polymeric nanoparticles from 
preformed polymers. J Microencapsul. 2011;28(4):323-35. PubMed PMID: 21545323. 
111. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for 
delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. Journal 
of controlled release : official journal of the Controlled Release Society. 2008 Feb 11;125(3):193-209. 
PubMed PMID: 18083265. 
38 
 
112. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug 
Delivery Carrier. Polymers. 2011 Sep 01;3(3):1377-97. PubMed PMID: 22577513. Pubmed Central 
PMCID: 3347861. 
113. De Souza Reboucas J, Esparza I, Ferrer M, Sanz ML, Irache JM, Gamazo C. Nanoparticulate 
adjuvants and delivery systems for allergen immunotherapy. Journal of biomedicine & biotechnology. 
2012;2012:474605. PubMed PMID: 22496608. Pubmed Central PMCID: 3303624. 
114. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, et al. Co-delivery of cancer-
associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-
mediated anti-tumor immunity. Vaccine. 2008 Sep 15;26(39):5046-57. PubMed PMID: 18680779. 
115. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an 
overview of biomedical applications. Journal of controlled release : official journal of the Controlled 
Release Society. 2012 Jul 20;161(2):505-22. PubMed PMID: 22353619. 
116. Nikitczuk KP, Schloss RS, Yarmush ML, Lattime EC. PLGA-polymer encapsulating tumor 
antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific 
IFN-gamma response and enhances survival. J Cancer Ther. 2013 Jan 1;4(1):280-90. PubMed PMID: 
23741626. Pubmed Central PMCID: 3670804. 
117. San Roman B, Irache JM, Gomez S, Tsapis N, Gamazo C, Espuelas MS. Co-encapsulation of an 
antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. European journal of 
pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische 
Verfahrenstechnik eV. 2008 Sep;70(1):98-108. PubMed PMID: 18501572. 
118. Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. "Pathogen-mimicking" nanoparticles 
for vaccine delivery to dendritic cells. Journal of immunotherapy. 2007 May-Jun;30(4):378-95. PubMed 
PMID: 17457213. 
119. Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J. Biodegradable nanoparticle mediated 
antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. 
Journal of drug targeting. 2003;11(8-10):495-507. PubMed PMID: 15203918. 
39 
 
120. Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants 
efficiently drive protective T cell immunity. Eur J Immunol. 2007 Aug;37(8):2063-74. PubMed PMID: 
17628858. 
121. Lee YR, Lee YH, Im SA, Yang IH, Ahn GW, Kim K, et al. Biodegradable nanoparticles 
containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the 
antigen. Arch Pharm Res. 2010 Nov;33(11):1859-66. PubMed PMID: 21116790. 
122. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming 
the magnitude and persistence of antibody responses with innate immunity. Nature. 2011 Feb 
24;470(7335):543-7. PubMed PMID: 21350488. Pubmed Central PMCID: 3057367. 
123. Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, Ozkan C, et al. PLGA nanoparticle-mediated 
delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine. 
2012;7:1475-87. PubMed PMID: 22619507. Pubmed Central PMCID: 3356185. 
124. Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG 
oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. Journal of controlled release : 
official journal of the Controlled Release Society. 2002 Dec 13;85(1-3):247-62. PubMed PMID: 
12480329. 
125. Karuturi BVK, Tallapaka SB, Yeapuri P, Curran SM, Sanderson SD, Vetro JA. Encapsulation of 
an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy 
of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated 
Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner. Molecular pharmaceutics. 2017 
May 01;14(5):1469-81. PubMed PMID: 28319404. 
126. Silva AL, Rosalia RA, Sazak A, Carstens MG, Ossendorp F, Oostendorp J, et al. Optimization of 
encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient 
CD8(+) T cell activation. European journal of pharmaceutics and biopharmaceutics : official journal of 
Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2013 Apr;83(3):338-45. PubMed PMID: 
23201055. 
40 
 
127. Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, et al. TLR ligands and antigen 
need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic 
T lymphocyte responses. Vaccine. 2008 Mar 20;26(13):1626-37. PubMed PMID: 18295941. 
128. Ebrahimian M, Hashemi M, Maleki M, Abnous K, Hashemitabar G, Ramezani M, et al. Induction 
of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG 
ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice. International journal of 
pharmaceutics. 2016 Dec 30;515(1-2):708-20. PubMed PMID: 27989827. 
129. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy--revisited. Nature reviews Drug 
discovery. 2011 Aug;10(8):591-600. PubMed PMID: 21804596. 
130. Lin YS, Lee MY, Yang CH, Huang KS. Active targeted drug delivery for microbes using nano-
carriers. Current topics in medicinal chemistry. 2015;15(15):1525-31. PubMed PMID: 25877093. 
Pubmed Central PMCID: 4997950. 
131. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al. Nanoparticle vaccines. 2014;32 
(3):327–37. PubMed PMID: 24295808. 
132. Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the 
initial optimism of phase II studies. Vaccine. 2011 Nov 3;29(47):8501-5. PubMed PMID: 21933695. 
133. Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer 
vaccines. Pharmaceutical research. 2011 Feb;28(2):215-36. PubMed PMID: 20721603. Pubmed Central 
PMCID: 3559243. 
134. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Frontiers in cellular 
and infection microbiology. 2013;3:13. PubMed PMID: 23532930. Pubmed Central PMCID: 3607064. 
135. D'Elios MM, Del Prete G, Amedei A. New frontiers in cell-based immunotherapy of cancer. 
Expert opinion on therapeutic patents. 2009 May;19(5):623-41. PubMed PMID: 19441938. 
136. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated 
nanoparticles for drug delivery. Mol Cancer Ther. 2006 Aug;5(8):1909-17. PubMed PMID: 16928810. 
41 
 
137. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of 
passive and active targeting in the era of modern cancer biology. Advanced drug delivery reviews. 2014 
Feb;66:2-25. PubMed PMID: 24270007. Pubmed Central PMCID: 4219254. 
138. Gunaseelan S, Gunaseelan K, Deshmukh M, Zhang X, Sinko PJ. Surface modifications of 
nanocarriers for effective intracellular delivery of anti-HIV drugs. Advanced drug delivery reviews. 2010 
Mar 18;62(4-5):518-31. PubMed PMID: 19941919. Pubmed Central PMCID: 2841563. 
139. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nature reviews Cancer. 2012 Mar 
22;12(4):278-87. PubMed PMID: 22437872. 
140. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in 
cancer therapy: innovative trends and prospects. Cancer science. 2011 Jul;102(7):1247-52. PubMed 
PMID: 21447010. 
141. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA 
nanoparticles surface modified with monoclonal antibody. Journal of controlled release : official journal 
of the Controlled Release Society. 2007 Jul 16;120(1-2):18-26. PubMed PMID: 17509712. 
142. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in 
cancer therapeutics. Advanced drug delivery reviews. 2008 Dec 14;60(15):1615-26. PubMed PMID: 
18840489. 
143. Ikeda J, Sun YL, An KN, Amadio PC, Zhao C. Application of carbodiimide derivatized synovial 
fluid to enhance extrasynovial tendon gliding ability. The Journal of hand surgery. 2011 Mar;36(3):456-
63. PubMed PMID: 21371626. Pubmed Central PMCID: 3625936. 
144. Zhang F, Lees E, Amin F, Rivera Gil P, Yang F, Mulvaney P, et al. Polymer-coated 
nanoparticles: a universal tool for biolabelling experiments. Small. 2011 Nov 18;7(22):3113-27. PubMed 
PMID: 21928301. 
145. Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK. Surface functionalization of 
PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in 
cancer therapy. Nanotechnology. 2011 Jan 21;22(3):035101. PubMed PMID: 21149963. 
42 
 
146. Lau A, Berube G, Ford CH. Conjugation of doxorubicin to monoclonal anti-carcinoembryonic 
antigen antibody via novel thiol-directed cross-linking reagents. Bioorganic & medicinal chemistry. 1995 
Oct;3(10):1299-304. PubMed PMID: 8564395. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
CHAPTER 2 
2. Purpose and hypothesis of the project 
2.1 Main goal 
The main goal of this project was to develop an understanding of a detailed relationship between NP 
structure and activity; and address the key questions regarding the fundamental requirements of 
nanoparticle structure and chemistry to selectively target specific markers on cells/tissues. To achieve 
this, various formulations of NPs was developed and optimized. The developed system will be established 
as a model delivery system for immunotherapeutic purpose.    
2.2 Hypothesis 
The hypothesis of this study can be divided as: 
✓ Hypothesis 1: Poly-lactide co-glycolic acid (PLGA) NP formulation can be structurally modified 
with anti-CD205 antibody ligand. 
✓ Hypothesis 2: PLGA NPs can selectively target dendritic cells (DCs) by enhancing the 
recognition and DC uptake. 
✓ Hypothesis 3: PLGA NPs can provide effective immunotherapeutic response in DC and mice 
model. 
2.3 Objectives 
The purpose of this study was to develop a structurally modified PLGA NP formulation. Here, four 
groups of PLGA (two types of end group: COOH and ester and each offering two viscosities) were 
assessed and utilized to develop the suitable formulation for in-vivo model. Surface modification of 
PLGA NPs with antibody against CD205 receptor will accomplish our goal to targeting DCs by 
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enhancing the recognition and DC uptake. The encapsulation of Ovalbumin (model antigen) and adjuvant 
(MPLA) in the formulations will stimulate the immune system both in-vitro and in-vivo. Therefore, the 
targeted PLGA NPs loaded with antigen-adjuvant can be used as a model therapeutic system for 
immunotherapeutic purpose in future. The objectives can be divided as follows: 
1. Development of suitable emulsification solvent evaporation technique for preparation of PLGA NPs 
and selection of solvent and cryoprotectant to stabilize the formulations 
2. Development of structurally modified NP delivery system with anti CD205 antibody through: a) 
physical adsorption of antibody onto ester- and COOH-terminated PLGA NPs, b) covalent 
attachment of antibody to ester- and COOH-terminated PLGA NPs 
3. Characterization of antibody modified PLGA NPs in terms of their size, polydispersity index, zeta 
potential, safety profile, antibody quantification and surface characteristics in comparison with 
unmodified PLGA NP 
4. Selection of a suitable fluorescent dye to assess the uptake of NPs in the DCs. And further 
development and characterization of coumarin-6 loaded NPs 
5. Assessment of the targeting efficiency of coumarin-6 loaded PLGA NPs modified with anti CD205 
antibody by DC uptake studies and compare it with unmodified PLGA NPs to establish a 
relationship between the structure and targeting 
6. Development of OVA and/or MPLA loaded PLGA NPs and characterize in terms of particle size, 
zeta potential, polydispersity index, safety profile, OVA quantification, release of antigen OVA and 
assessment of structural integrity of OVA 
7. Evaluation of OVA and/or MPLA loaded NPs (plain and antibody modified) on enhancing DC 
stimulatory immune response in-vitro through DC maturation study and cytokine estimation. A dose-
response relationship will be estimated for in-vivo experiments   
8. Evaluation of OVA and/or MPLA loaded modified PLGA NPs (plain and antibody modified) on 
enhancing DC stimulatory immune responses in wild-type (balb/c) and transgenic (OT1) mice model 
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through proliferation study, IgG secretion and cytokine release and stabilizing the dose-response 
relationship 
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3. 1 Brief introduction to chapter 3 
Chapter 3 is based on two different approaches of nanoparticle preparation using emulsification solvent 
evaporation technique, choice of suitable solvent, cryopreservation of formulations, surface modification 
of NPs, cytotoxicity profile and surface display of antibody.  
Two types of PLGA polymers with different inherent viscosities (i.v.) are being studied: 
a. PLGA with carboxyl end group (uncapped) and inherent viscosities of 0.18 and 0.55-0.75 dl/g  
b. PLGA with ester end group (capped) and inherent viscosities of 0.15-0.25 and 0.55-0.75 dl/g 
NP preparation and antibody attachment scheme are represented in figure 3.1 and 3.2. The parameters 
evaluated for both NP preparation and antibody attachment are represented in table 3.1 and 3.2. 
 
Figure 3.1: Schematic diagram for emulsification solvent evaporation technique 
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Figure 3.2: Schematic diagram for Ab-attachment process 
Table 3.1: Experimental parameters and their levels for NP preparation 
Formulation parameters Specific parameter  Method 1 Method 2 
1. Polymer 0.15-0.25 iv PLGA 
(ester-terminated) 
100 mg 65 mg 
0.55-0.75 iv PLGA 
(ester-terminated) 
100 mg 65 mg 
0.18 iv PLGA  
(COOH-terminated) 
100 mg 65 mg 
0.55-0.75 iv PLGA 
(COOH-terminated) 
100 mg 65 mg 
2. Cross-linker BS3 --------- 1.5 mg (COOH and 
ester PLGA) 
3. Organic solvent Chloroform 400 µl -------- 
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Ethyl acetate --------- 1 ml 
4. Stabilizer PVA 5 % 2.2 % 
5. Sonication time   1-4 minutes 2-3 minutes 
6. Stirring time  2-3 hours 2-3 hours 
7. Centrifugation speed and 
time (twice) 
 30,000 rpm for 30 
mins, 25,000 rpm 
for 25 mins 
30,000 rpm for 30 
mins, 25,000 rpm 
for 25 mins 
8. Freeze-drying  ≥48 hours ≥48 hours 
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Table 3.2: Experimental parameters and their levels for antibody attachment 
Specific parameters Method 1 Method 2 
 Adsorption Covalent 
attachment 
Adsorption Covalent 
attachment 
1. Nanoparticles (NP) type  
0.15-0.25 iv PLGA ester NP √ ----- √ ----- 
0.55-0.75 iv PLGA ester NP √ ----- √ ----- 
0.18 iv PLGA COOH NP √ √ √ √ 
0.55-0.75 iv PLGA COOH NP √ √ √ √ 
2. Cross-linker 
EDC (2mg) ----- √ ----- ----- 
NHS (2mg) ----- √ ----- ----- 
4. Sonication time: 30 seconds-1 
min 
√ √ √ √ 
5. Stirring time (4 hours) √ √ √ √ 
6. Centrifugation speed: 14, 000 
rpm and time: 25-30 minutes 
√ √ √ √ 
7. Freeze-drying (≥48 hours) √ √ √ √ 
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3.2 Abstract 
The purpose of this study was to assess the effect of various formulation parameters on anti-CD205 
antibody decorated poly (D, L-lactide co-glycolide) (PLGA) nanoparticles (NPs) in terms of their ability 
to target dendritic cells (DCs). In brief, emulsification solvent evaporation technique was adapted to 
design NP formulations using two different viscosity grades (low and high) of both ester and carboxylic 
acid terminated PLGA. Incorporation of ligand was achieved following physical adsorption or chemical 
conjugation processes. The physicochemical characterizations of formulations were executed to assess the 
effects of different solvents (chloroform and ethyl acetate), stabilizer percentage, polymer types, polymer 
viscosities, ligand-NP bonding types, cross-linkers, and cryoprotectants (sucrose and trehalose). 
Modification of any of these parameters shows significant improvement of physicochemical properties of 
NPs. Ethyl acetate was the solvent of choice for the formulations to ensure better emulsion formation. 
Infrared spectroscopy confirmed the presence of anti-CD205 antibody in the NP formulation. Finally, 
cytotoxicity assay confirmed the safety profile of the NPs for DCs. Thus, ligand modified structurally 
concealed PLGA NPs is a promising delivery tool for targeting DCs in vivo. 
 
 
 
 
 
 
 
 
 
Keywords: nanoparticle, anti-CD205, PLGA, dendritic cells 
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3.3 Introduction 
Dendritic cells (DCs) are known as the potent antigen presenting cells to induce adaptive immune 
responses. Manipulating DCs by targeted antigen delivery through various endocytic and secretory 
pathways is a consequence of delivering site-specific therapeutic delivery system. C-type lectin receptor 
CD205 (molecular weight of 205 kDa), exclusively expressed on DCs; is a widely studied DC target 
molecule for induction of immune response. Anti-CD205 monoclonal antibody (mAb) linked delivery 
system can efficiently deliver its cargo to the processing compartments of DCs in vivo.(1) CD205 
receptor possesses a fast internalization speed, where over 80% of surface CD205 are internalized within 
90 minutes.(2), (3) The proportion of targeted molecules endocytosed by this receptor in both immature 
and mature DCs is exceptionally higher compared to other surface receptors. In addition to 
internalization, antigen presentation on major histocompatibility complex (MHC)-1 and MHC-2, CD205 
receptors elicited superior presentation compared to CD11c receptor. Thus, targeting this receptor would 
be promising in both steady-state and inflammatory conditions.(2), (4) Therefore, CD205 specific 
antibodies can induce efficient antigen processing and presentation, notably eliciting both T helper1 
CD4+ T cell and CD8+ T cell responses. Engagement of anti-CD205 mAb to target CD205 receptors 
shows high consensus to deliver vaccine utilizing an appropriate delivery system. (5) 
Over the past decade, nanoparticles (NPs) have gained increasing attention in the field of drug delivery. 
Particularly, polyester based NPs offer the advantage of effective delivery of drug to the target site, 
ensuring therapeutic benefit with minimum side effects. Industry has recently focused on the US Food 
and Drug Administration (FDA) approved poly (D, L-lactide co-glycolide) (PLGA) based NPs because of 
their biodegradability, biocompatibility, low toxicity, controlled release, and surface-modification 
properties.(6), (7) Hence, functionalization of PLGA NPs with ligands such as anti-CD205 antibody 
presents an opportunity for an innovative antibody-targeted vaccine delivery system. This coupling aims 
to provide increased payload of drug/antigen, thereby increasing response and reducing the number of 
doses required. The ligand itself might function in a non-activating manner, which is important for 
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immunotherapeutic diseases. (8) PLGA polymers are commercially available with different terminal 
groups, namely, free carboxylic acid (COOH) end groups (uncapped) or esterified terminal groups 
(capped). The end groups of PLGA can influence drug encapsulation efficiency, degradation, stability, 
and conjugation of ligands. For example, COOH terminated NPs can result in a slightly acidic 
environment, that may cause degradation of encapsulated antigen during formulation process or inside 
endosomal compartment. (9) 
The present study focuses on the formulation optimization with anti-CD205 ligand using both capped and 
uncapped PLGA; each type offered with low and high viscosity grades (Figure 1).(10) Discussions are 
based on the comparison and evaluation of how different process parameters affect these two subtypes of 
ester and COOH ended PLGA NPs for in vitro experiment setups. To serve this purpose, standardization 
of various parameters was executed to obtain NPs with suitable particle size, surface charge, 
polydispersity index (PDI), surface display, toxicity profile, and structural modification. Therefore, a 
structure-activity relationship is concluded after analyzing the results. As a consequence, the ultimate goal 
is to develop a delivery system with suitable formulation strategy that could simulate the in vitro 
responses in an animal model. Altogether, our results support the potential use of PLGA NPs as 
therapeutic delivery system to design a cancer vaccine. 
3.4 Materials and methods 
3.4.1 Materials 
Ester terminated PLGA (inherent viscosity 0.15–0.25 dL/g and 0.55–0.75 dL/g) and COOH terminated 
PLGA (inherent viscosity 0.18 dL/g and 0.55–0.75 dL/g) were purchased from LACTEL Absorbable 
Polymers, Birmingham, AL, USA. Polyvinyl alcohol (PVA), bis(sulfo-succinimidyl) suberate (BS3), 
alpha minimum essential medium, fetal bovine serum, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay kit, and bicinchoninic acid (BCA) assay kit were purchased 
from Sigma-Aldrich Co., St Louis, MO, USA. Other reagents used were N-hydroxysuccinimide esters 
(sulfo-NHS) and 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) from Thermo 
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Fisher Scientific, Waltham, MA, USA. Biotin anti-mouse CD205 antibody was purchased from 
Biolegend (San Diego, CA, USA). JAWSII DC line was obtained from American Type Culture 
Collection (ATCC), Manassas, VA, USA. GM-CSF was purchased from Thermo Fisher Scientific. 
Solvents like chloroform and ethyl acetate were of analytical grade. 
3.4.2 Preparation of NPs by emulsification solvent evaporation method 
Method 1 
PLGA NPs were prepared by the double emulsification solvent evaporation technique as previously 
reported.(11) Briefly, PLGA was dissolved in chloroform (25% weight/volume [w/v]). Aqueous phase 
comprised of 5% w/v PVA was added to the oil phase in a drop wise manner and sonicated by probe-
sonicator. The resulting primary emulsion was transferred into water to form the secondary emulsion and 
stirred to evaporate the chloroform. NPs were then collected by centrifugation, washed with distilled 
water to remove the residual PVA, and resuspended in distilled water. Cryoprotectant was used in the 
formulations to minimize freeze-drying stress after washing.(12) 
Method 2 
The NPs were prepared following single oil in water emulsification solvent evaporation technique.(13) In 
brief, PLGA was dissolved in ethyl acetate (6.5% w/v) and transferred into 2.2% of PVA to form the 
emulsion. The procedure was then followed as mentioned in Method 1 with some minor modifications. 
To prepare pre-activated NPs for the covalent attachment of ligand, presence of BS3 in the aqueous phase 
is mandatory. The prepared NPs were lyophilized with cryoprotectants to avoid aggregation. Parameters 
mentioned in Table 3.3 were considered in the preparation and evaluated for both methods 1 and 2. 
Discussion will be based on the effect of these parameters on the physicochemical properties of NPs. 
3.4.3 Antibody coupling to the particle surface 
Antibody coupling was carried out through two approaches, physical adsorption and covalent 
conjugation. 
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Physical adsorption of antibody to NPs’ surface 
Biotinylated anti-CD205 mAb was added at a certain concentration to previously lyophilized PLGA NPs 
in phosphate buffered saline (PBS) and stirred for 4 hours in ice. After that, excess PBS was centrifuged 
and washed out. The NPs were freeze-dried upon re-suspension followed by storage at −20°C. At each 
washing step, the obtained supernatants were stored to determine the amount of un-conjugated antibody 
by BCA assay. This is an indirect method to measure the actual amount of antibody attached to the NPs. 
The control groups for BCA assay were the supernatants obtained from antibody-free NPs of each 
formulation through the similar conditions maintained in antibody-NP conjugation process.(14) 
Covalent attachment of antibody with NPs 
Two different approaches were followed for covalent attachment where, one was using carbodiimide 
chemistry with EDC and sulfo-NHS (for method 1); and the other one with the use of BS3 (for method 2). 
For the first method, EDC/sulfo-NHS solution was added to antibody solution. The resulting suspension 
was stirred for 4 hours in ice, after which, centrifugation was done twice to remove excess reagents and 
soluble isourea by-product. Therefore, the amide bonds were formed between the primary amine groups 
of antibodies with the free carboxylic end groups of PLGA NPs.14For the second method, BS3 pre-
activated freeze-dried NPs were resuspended in PBS for the covalent attachment of antibody.(13) Upon 
addition of antibody, the activated NPs underwent the process of conjugation followed by washing twice 
with PBS of pH 7.2. The covalent amide linkage was formed by replacing lysine groups of the antibody 
with free carboxylic group of BS3 upon releasing sulfo-NHS groups. The obtained NPs were further 
freeze-dried followed by storage at −20°C. The reaction schemes for both approaches are shown in Figure 
3.3. 
3.4.4 Determination of particle size, zeta potential (ZP), and PDI 
Dynamic light scattering technique was used to measure the particle size, ZP, and PDI using Malvern 
ZetaSizer, Nano ZS (Malvern Instruments, Malvern, UK).(15) ZP was measured on the basis of 
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electrophoretic mobility in an electric field.(16) The measurements were performed for both unmodified 
and modified NPs before and after freeze-drying. Recovery percentage or yield of the preparation 
technique was calculated from the amount of NPs obtained divided by the total amount of initial PLGA 
polymer used to prepare NPs (the amount of PVA is negligible). 
3.4.5 Morphology by scanning electron microscopy (SEM) 
Morphology of the NP surface was analyzed by SEM. In brief, PLGA NPs were dispersed in distilled 
water (0.2% w/v). Appropriate portion of nano-suspension was placed on the carbon tape of the metal 
stub and allowed to air-dry. The samples were then placed in a sputter coater (S150B; BOC Edwards, 
Sussex, UK) for 1 minute to produce a gold coating with ~20 nm thickness; and viewed under a scanning 
electron microscope at voltage of 20–25 kV (Carl Zeiss Evo 60; Carl Zeiss Meditec AG, Jena, 
Germany).(17) 
3.4.6 Structural characterization by Fourier transform infrared spectroscopy (FTIR) 
FTIR analysis of NPs was recorded on a Bruker IFS 66v/S infrared spectrophotometer (Bruker Optics 
Inc, Billerica, MA, USA) in the mid-infrared range at the Canadian Light Source (CLS), University of 
Saskatchewan, Saskatoon, SK, Canada. All samples were mixed with spectroscopic grade potassium 
bromide and mulled to prepare pellets. The spectra were taken for potassium bromide pellets in the range 
of 4,000–400 cm−1 in absorbance mode.(13), (18) Data analysis was performed with Bruker Opus 
software. Baseline correction was performed on all raw absorbance spectra. 
 
3.4.7 Determination of amount of antibody attached to the NPs 
A BCA protein assay was performed to measure the amount of antibody attached per mg of NPs. The 
antibody was analyzed both directly (on the NP surface) and indirectly (in the supernatant). Briefly, a 
sample of modified NP was taken and resuspended in water to assess the antibody attached to the surface. 
Unmodified NPs were used as controls. In indirect method, the collected supernatants during washing 
steps were stored for BCA assay to quantify the amount of unbound antibody. Ninety-six well plate was 
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used and the instructions from the BCA assay kit were followed for the quantification. The standard curve 
was generated by plotting the absorbance versus various concentrations of the standard solution, bovine 
serum albumin. The standard curve was found to be linear over the range of 0–32 μg/mL. The absorbance 
was measured at a wavelength of 562 nm in a microplate reader.(19) 
3.4.8 DC (JAWS II) culture 
The DC line obtained from American Type Culture Collection was initiated as recommended. The cell 
culture was maintained at 37°C and 5% CO2 in complete media for few days to reach the optimum 
confluency. After that, the cells were stored in cryo-vials containing freezing solution (dimethyl 
sulfoxide). The complete media is as recommended by ATCC. 
3.4.9 In vitro cytotoxicity assay 
MTT assay was performed to investigate the cytotoxicity of NPs on DC lines using corresponding 
untreated cells as control. On day 1, the cells were seeded in 96-well plate at a density of 10,000 cells per 
mL. After overnight incubation, cells were exposed to various formulation treatments. On day 3, 10 μL of 
MTT solution was added to each well and further incubated for 4 hours. Finally, 100 μL of MTT solvent 
was added to dissolve the formazan crystals. The absorption intensity of the purple–blue color formed 
was measured at a wavelength of 570 nm by microplate reader.15 Cell viability was calculated using the 
following equation:(20) 
 
 
(1) 
3.4.10 Statistics 
All data are presented as mean ± standard deviation. The significance of the differences between groups 
was analyzed by unpaired Student’s t-test or one-way analysis of variance followed by the Tukey’s post 
hoc test for multiple comparisons. P-value of <0.05 was considered as statistically significant. All the 
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statistical analyses were performed with GraphPad Prism 5.03 software (GraphPad Software, Inc., La 
Jolla, CA, USA). 
3.5 Results 
3.5.1 Effect of polymers’ end groups and viscosities 
The influence of polymer composition (functional end group and inherent viscosity) on physicochemical 
properties of NPs was investigated. Particle size is an important parameter that can affect the 
biopharmaceutical and biodistribution properties of formulations. The smaller particle size will lead to a 
higher total surface area relating to faster release of its payload.(21) PDI is an index for size distribution 
where an enhanced PDI value indicates that the particles do not have a uniform distribution.(22) 
In method 1, the average particle size and PDI for plain NPs prepared with COOH and ester end groups 
were found to range from 202 to 237 nm and 231 to 281 nm, respectively as shown in Figure 3.4A. 
Polymer viscosity (0.15 and 0.55 inherent viscosity) was indicated as a limiting factor for particle size in 
both COOH and ester terminated NPs. With an increase in polymer viscosity the particle size also 
increased as shown in Figure 3.4A and B.(23) After statistical evaluation, there was no significant effect 
observed for the variable end groups of PLGA on plain NPs’ particle size, PDI, and ZP (Figure 3.4C) 
values (Table 3.4 and Figure 3.5). However, the effect of variable end groups and viscosities of the 
polymer on particle size was found significant for ligand modified NPs (Table 3.4) although these two 
variables had no effect on their PDI values. 
In method 2, both particle size and PDI values were in a fairly desirable range for all NPs before freeze-
drying (Figure 3.5A). A proportional relation between polymer viscosity and particle size was observed 
for plain (Figure 3.4A, B and Figure 3.5A, B) and modified (Table 3.4) NPs. In contrary, no significant 
correlation could be made between the variable polymer end groups and physicochemical properties. 
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3.5.2 Effect of ligand-NP bonding types 
In method 1, low viscosity COOH terminated NP had a significantly higher (P<0.05) amount of antibody 
adsorbed compared to other groups and the particles were in an appropriate size range below 350 nm. The 
high viscosity COOH terminated NPs had relatively larger size with wide PDI values. In addition, ZP 
values showed a significant drop toward positive value upon attachment of ligand with NPs as shown 
in Table 3.4 (P<0.05). NPs obtained after covalent attachment of antibody, had the same particle size 
trend as observed in the adsorbed groups. While larger aggregates were formed with antibody-adsorbed 
NPs for ester terminated NPs, which was further minimized using cryoprotectant. The original particle 
size was above the nanometer range, indicating the presence of aggregates (PDI value >0.99). 
In method 2, there was a significant decrease in particle size for the covalently modified NPs compared to 
antibody-adsorbed formulations. But no concrete correlation could be drawn to compare the antibody 
loading through adsorption and covalent attachment of ligand with NPs. In addition, the inclusion of 
antibody to NPs shifted the ZP toward positive values, which indirectly confirms the presence of antibody 
on the NP surface, as summarized in Table 3.4 and Figure 3.5C. This could be ascribed to the amphiphilic 
properties of antibody or shielding the negative charges on the surface by positively charged 
antibody.(24), (25) Table 3.4 represents the overall data for particle size, PDI, ZP, and antibody 
quantification for modified NPs. Furthermore, the SEM photographs confirmed that NPs form spherical 
shaped particles within the desired size range. SEM images of NPs were taken at a voltage of 20–25 kV at 
various magnifications as shown in Figure 3.6. 
3.5.3 Effect of cryoprotectants 
The NPs were in a well-dispersed suspension form before freeze-drying; however they formed aggregates 
upon reconstitution after freeze-drying, which could not be re-dispersed even after sonication. The reason 
behind this irreversible aggregation could be attributed to freeze-drying stress on the particles rendering a 
wide range of PDI value before ligand attachment.(26) Use of cryoprotectants could overcome this stress 
to obtain aggregation-free fine suspension after ligand attachment. However, all the formulations had 
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significant difference in particle size before and after freeze-drying (P<0.05) irrespective of the presence 
of cryoprotectant. 
Notably, the use of trehalose (10%) could not fully minimize the aggregation produced between the 
prepared NPs following method 1 before ligand attachment compared to sucrose (10%). As a 
consequence, the rest of the formulations were continued with sucrose (10%). However, 10% sucrose was 
preferably chosen after comparative optimization based on the different percentages (1%, 5%, and 10%) 
of sucrose used as cryoprotectant (data not shown). Sucrose was found to be a better cryoprotectant to 
retain particle size when compared with trehalose used for plain NP formulations prepared following 
method 1. Thus, the effect of cryoprotectants was partially or not pronounced in formulations under 
method 1 as represented in Figure 3.4B. The ZP value for plain NPs without cryoprotectants was found to 
be more negative compared to formulations with sucrose. Even though the presence of sucrose should 
cause a higher negative charge on particles, the opposite was found.(27) 
For method 2, there was significant change in ZP after addition of cryoprotectant (P<0.05). Also, the 
presence of cryoprotectant showed significant difference in particle size for antibody-adsorbed groups 
(P<0.05). However, the change in particle size was not significant when cryoprotectant was used in 
covalently modified formulations. Table 3.4 demonstrates the effect of sucrose after antibody attachment, 
where PDI was found to be below or equal to 0.43. Whereas formulations that were freeze-dried without 
cryoprotectant showed higher PDIs (highest PDI =0.95). There was significant reduction in particle size 
for all modified NPs after use of cryoprotectant, except the covalently modified formulations of method 2. 
3.5.4 Effect of cross-linkers 
EDC/sulfo-NHS cross-linker was considered to conjugate antibody ligand with prepared NPs following 
method 1.(28), (29) The presence of cross-linkers could be attributed to larger particles after antibody 
attachment. In method 2, the BS3 (spacer) pre-activated NP formulations showed fairly considerable 
physicochemical properties after antibody modification. In both methods, successful attachment of 
antibody was obtained which was confirmed by BCA assay (Table 3.4). 
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3.5.5 Confirmation of structural modification by FTIR 
The peak around 1,750 cm−1 is a marked peak that elicits the presence of a carbonyl bond (C=O stretching 
vibration), which is characteristic of PLGA.(30) An amide stretching is present between 3,310 and 3,250 
cm−1 in anti-CD205 antibody modified PLGA NP spectra, which corresponds to C=O stretching bond. 
Theoretically, amide-I vibrations result from C=O stretching vibration near 1,610 cm−1 as observed in the 
spectra for antibody modified NP.(31) Amide-I bond is the most sensitive to prove the structural change 
in any compound containing proteins. Some contribution in the spectrum from the C=O groups in both 
BS3 free and BS3 containing NP formulations could also be observed.(32), (33) To confirm the presence 
of antibody on the NPs, the spectra for only high viscosity COOH ended PLGA NPs and their 
modification are represented here (Figure 3.7). Spectra for other polymer types and their subtypes are not 
shown here. 
 
3.5.6 Comparison of safety profiles for method 1 and 2 
All NP formulations prepared by method 1 (both ester and COOH terminated NPs) retained DC viability 
(≥80%). The findings indicate that both plain and modified NPs were not toxic to the DCs confirming the 
safety profile of the NPs as shown in Figures 3.8 and 3.9. Similarly, method 2 based NP formulations 
demonstrate a viability of >90%.(11) There was no significant difference in viability among different 
groups (plain and modified) for both methods. However, 0.15E-NP+S showed significant difference 
(P<0.05) compared to other formulations like 0.18C-NP+BS3, 0.55C-NP+BS3, 0.15E-NP+BS3, 0.15E-
NP+BS3+S, and 0.55E-NP+BS3+S prepared following method 2. 
3.6 Discussion 
The choice of a suitable NP formulation technique is dependent on the desired physicochemical 
properties. NP size is an important determinant of the formulation efficacy in vivo. Very large particles 
(around 1 μm) can cause irritant effects after injection.(34) On the other hand, particles smaller than 5 nm 
are likely to be cleared by non-phagocytic cells.(35) Alternatively, particles larger than 100 nm have the 
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chance to be taken up by phagocytic cells (for example, DCs).(34), (36) The formulations prepared by the 
methods mentioned here, aim to target DC receptors in vivo. Thus the particle size range (309±36 to 
544±45 nm) obtained by method 2 could be suitable for DC uptake via subcutaneous delivery.(37), 
(38) However, toxicity issue is a concern for emulsification solvent evaporation technique. Chlorinated 
solvents like chloroform and dichloromethane have issues regarding environmental challenges and human 
use. Considering these issues, ethyl acetate offers a better solubility and safety profile compared to 
chloroform. As a polar solvent ethyl acetate with a solubility of 8.1 volume/volume in water is 
comparatively safer.(39) It has lower interfacial tension (1.7 dyne/cm) compared to chloroform (32.8 
dyne/cm), which forms more stable emulsions and smaller NPs in PVA solutions.(40) A considerable 
decrease in particle size was observed when ethyl acetate was used as solvent in method 2. In addition, all 
the formulations had improved PDI indicating mono-disperse NP suspension. Furthermore, method 2 
showed a batch-to-batch reproducibility for all the formulations of interest that will be required for in vivo 
experiments. The represented SEM images confirmed the formation of spherical NPs within the desired 
size range (Figure 4). The images confirm the homogenous nature of particles with a uniform and 
aggregation-free distribution.(41) 
There are different emulsion stabilizers available such as PVA, carbopol and polaxamer. Among these, 
PVA is found to provide homogenous particles with uniform size distribution.(42) It acts on the boundary 
of aqueous and organic phase to modify the particle size as well as surface charge.(43) PVA is able to 
maintain the interfacial tension at oil-water interface to obtain small sized particles.(44) In addition, it 
prevents the aggregation and preserves the hydrophilicity of particles when used above a concentration of 
2%.(45) A high concentration of PVA is expected to produce particles with narrow granulometric 
distribution. Failure to maintain that would lead to the aggregated particles.(46) Between method 1 (5% 
PVA) and method 2 (2.2% PVA), the difference in particle size could be attributed to not only the 
difference of PVA concentration but also the effect of solvents. Decrease in PVA concentration from 
method 1 to method 2 could lead to larger particles. But, PVA concentration of 5% did not play a better 
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role to reduce particle size due to PVA’s optimum packing.(47) In addition, PVA also renders slightly 
negative charges on the particles.(48) 
ZP value is an important parameter that reflects stability of a colloidal suspension.(49) ZP values for 
COOH terminated NPs were found to be more negative (−25 to −24 mV) compared to ester terminated 
(−19 to −16 mV) NPs. This could be attributed to the presence of carboxyl group on the COOH 
terminated NPs. When the viscosity of the polymers increased, ZP value showed slightly more negative 
charge for uncapped NPs than the capped formulations.(50) When the polymer of higher viscosity is used 
it increases the concentration of the media resulting in semi-folded particles.(51) Increase in concentration 
of the organic phase also resulted in viscosity resistance against the net shear stress. Ultimately 
coalescence of particles occurs to provide increase in NP size.(52), (53) Particles with more positive 
(above +30 mV) or more negative (below −30 mV) ZP are considered colloidally stable but not 
pharmaceutically stable.(16), (54) This indicates that ZP beyond this range needs to be kept in solid and 
dry form rather than colloidal state. Our results show that ZP of antibody modified NPs was about neutral 
or slightly positive or negative. The prepared NPs were therefore lyophilized for pharmaceutical stability 
and should be reconstituted immediately before the administration.(16), (55) 
Freeze-drying is an essential part in retaining the stability of formulations after preparation. This process 
could be stressful leading to colloidal preparations having large aggregates, although there are several 
cryoprotectants available to increase the physical stability of NPs.(56) Cryoprotectants could be water-
soluble sugars such as glucose, trehalose, which are added to prevent NPs from aggregating during drying 
process. Hence, it is advantageous to prepare NPs with addition of cryoprotectants. There are two types of 
cryoprotectants: intracellular that prevents crystal formation and cell membrane rupture; and extracellular 
that minimizes hyperosmotic effect during freeze-drying process. Sucrose and trehalose are extracellular 
cryoprotectants that minimize freeze-drying stress of the formulations.(57) For method 1, antibody 
modified NPs had higher particle size compared to the plain NPs which was predictable. The PDI value 
remained fairly high even after using cryoprotectants. No significant differences in the effect of sucrose 
and trehalose could be identified for these formulations. Addition of cryoprotectant might have formed 
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hydrogen bond between their hydroxyl group and NP surface resulting in masking of the negative charges 
of the particles. 
It has been reported that presence of stabilizers could also play a major role in NP aggregation in the 
drying process.(58) The percentage of stabilizer is critical to maintain its influence on both particle size 
and ZP.(59) In the NP formulations (following method 2), the PVA percentage was 2.2% below the 
optimum range (2.5%–5%) which necessities the use of cryoprotectant. A minimum of 5% cryoprotectant 
is necessary to ensure stability of formulations.(60) In another study, aggregation-free PLGA NP 
suspension was obtained with 1%–2% PVA where 10% of different cryoprotectants (sucrose, trehalose, 
glucose) were used.(61) Therefore, studies were continued with method 2 formulations using 10% 
sucrose as cryoprotectant due to its better cryopreservation. 
The highest antibody incorporation was obtained with low viscosity ester terminated PLGA NPs 
(formulations with cryoprotectants for either conjugation method), whereas low viscosity COOH 
terminated PLGA NPs provided the lowest antibody incorporation (except antibody-adsorbed 
formulations of method 1). The low viscosity ester terminated PLGA had higher antibody attachment due 
to higher surface area (smaller size) of NPs. Besides, with the same amount of initial antibody, the COOH 
terminated PLGA had lower antibody incorporation which could be attributed to the rapid erosion of the 
polymer.(62) For method 2 based formulations, covalently attached NPs were found to be smaller than 
physically adsorbed NPs although the antibody attachment between these groups was not significantly 
different. In addition, ZP did not show any rational correlation between antibody loading and conjugation 
method for both COOH and ester terminated NPs. It was observed that covalently attached low viscosity 
COOH and ester terminated polymers resulted in smaller particle size compared to high viscosity 
polymers, which is expected. Moreover, all the formulations had particle size within desired range for DC 
uptake.(11), (37) It was found that, the 4 hours stirring time during antibody-NP attachment should be 
enough to break down the aggregates and to form a fine suspension leaving the surface available for 
antibody attachment. This is observed from the smaller particle size with acceptable PDI obtained for the 
low viscosity ester terminated NPs after 4 hours incubation with continuous stirring. However, the 
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particle size was above the target range with poor PDI values for the high viscosity ester terminated NPs 
prepared following method 1. On the contrary, ligand modified NP formulations prepared by method 2 
showed equally acceptable range for PDI values with the highest of 0.43±0.05 and lowest of 0.22±0.07. 
The antibody attachment on NP surface was calculated to be in a desired range (2 μg/mg of NP). 
However, no significant correlation could be made between antibody-NP conjugation methods 
(adsorption and covalent attachment) and polymers’ viscosities. Considering the viability, it was slightly 
higher with high viscosity grade PLGA for most of the formulations; and conjugation method could not 
affect DC viability. 
The structural modification of BS3 activated formulations was well confirmed by infrared study. In the 
case of the anti-CD205 conjugated NPs spectrum, presence of N-H stretching of high intensity confirmed 
the conjugation. Second derivative of all spectra (Figure 5B) clearly shows the presence of an amide bond 
between BS3 and antibody. This characteristic peak stands out, reflecting the establishment of the 
antibody conjugation on the NPs. 
The results from method 2 were more reproducible and consistent, whereas the formulations prepared by 
method 1 showed higher deviation from the average in the DC viability tests. Based on the confirmed 
safety profile of the NP formulations, we can further use them for DC uptake and targeting efficiency 
study. 
3.7 Conclusion 
In this research, the effects of various processing parameters were investigated. The formulation variables 
evaluated here could be manipulated to enhance the efficiency of the PLGA NPs. Based on the optimum 
potential parameters it is concluded that formulations prepared using ethyl acetate as solvent (method 2) 
are shown to be promising for NP preparation and will be further utilized in our in vitro experiments. 
Further in vitro investigations such as targeting efficiency, maturation of DCs, cytokine secretion profile, 
and activation of immune response leading to in vivo studies are being conducted in ongoing studies. 
Therefore, the structural characterizations reflected in those formulations will direct us to obtain optimum 
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in vivo effects. This optimization would help other researchers to select the optimal parameters in their 
study. In conclusion, this systematic investigation could promote the development of PLGA NPs for 
further application to design a cancer vaccine. 
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3.10 TABLES 
 
Table 3.3 Variable parameters considered to prepare the NPs 
Polymer end group 
▪ Carboxylic acid terminated 
▪ Ester terminated 
Polymer viscosities  
▪ 0.18 iv COOH  
▪ 0.55 iv COOH 
▪ 0.15 iv ester 
▪ 0.55 iv ester 
Organic solvents 
▪ Chloroform  
▪ Ethyl acetate 
Cross-linkers 
▪ EDC-NHS 
▪ BS3 
PVA 
▪ 5 %  
▪ 2.2 % 
Cryoprotectants 
▪ Sucrose (10%) 
▪ Trehalose (10 %) 
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 Table 3.4 Particle size, PDI, and ZP, and antibody loading for anti-CD205 modified NPs (n=4) 
Notes: C = COOH ended PLGA; E = ester ended PLGA; S = sucrose (10%). Data are presented as 
mean ± standard deviation. 
 
 Formulatio
n 
 Method-1  Method-2 
   Size ± SD 
(nm) 
PDI± SD ZP± SD 
(mV) 
Ab* loading 
(µg/mg of NP) 
 size ± SD 
(nm) 
PDI ± SD ZP± SD 
(mV) 
Ab loading 
(µg/mg of 
NP) 
A
d
so
rp
ti
o
n
 
0.18C-NP  336±19 0.28±0.0
4 
-12.9±0.6 3.62±0.43  556±41 0.29±0.04 -1.9±0.3 2.73±0.17 
0.18C-
NP+S  
 567±36 0.47±0.0
6 
-2.5±0.2 2.64±0.21  311±15 0.32±0.04 -2.9±0.2 2.11±0.67 
0.55C-NP  978±424 0.69±0.1
2 
-9.1±0.6 2.42±0.86  1266±19
3 
0.63±0.04 -3.4±0.2 2.62±0.67 
0.55C-
NP+S 
 733±52 0.58±0.2
6 
-1.2±0.1 1.90±0.31  399±143 0.31±0.07 -0.4±0.1 2.44±0.27 
0.15E-NP  5270±96
5 
0.79±0.2
5 
0.3±0.3 1.91±0.09  3681±45
3 
0.75±0.01 0.1±0.1 2.41±0.30 
0.15E-
NP+S 
 468±14 0.69±0.0
2 
-2.3±0.7 3.45±0.38  417±51 0.43±0.05 0.2±0.1 3.18±0.48 
0.55E-NP  5507±92
7 
1.00±0.0
0 
-1.9±0.2 2.82±0.83  1999±40
4 
0.95±0.05 -0.4±0.3 2.54±0.33 
0.55E-  1946±41 0.97±0.0 0.7±0.4 2.94±0.46  544±45 0.39±0.07 -1.9±0.2 2.31±0.57 
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NP+S 4 
            
C
o
v
a
le
n
t 
0.18C-NP  426±6 0.41±0.0
2 
-2.5±0.7 2.51±0.22  349±24 0.34±0.04 -9.4±0.4 2.70±0.61 
0.18C-
NP+S 
 774±8 0.57±0.0
1 
2.6±0.1 2.25±0.01  421±12 0.37±0.05 2.1±0.4 2.16±0.43 
0.55C-NP  1033±20 0.73±0.0
7 
-1.6±0.5 3.53±0.47  346±15 0.41±0.02 -2.6±0.3 2.13±1.02 
0.55C-
NP+S 
 828±10 0.66±0.0
3 
-2.2±0.1 3.22±0.08  461±10 0.27±0.09 1.7±0.5 2.31±0.63 
0.15E-NP  NA* NA NA NA  305±156 0.65±0.08 -1.1±0.2 1.96±0.16 
0.15E-
NP+S 
 NA NA NA NA  309±36 0.22±0.07 1.5±0.1 2.79±0.24 
0.55E-NP   NA NA NA NA  327±22 0.38±0.05 -4.1±0.2 2.62±0.35 
0.55E-
NP+S 
 NA NA NA NA  314±31 0.32±0.02 2.2±0.5 2.71±0.32 
            
Abbreviations: NP, nanoparticle; PDI, polydispersity index; ZP, zeta potential; SD, standard deviation; NA, not 
applicable; Ab, anti-CD205 antibody; COOH, carboxylic acid; PLGA, poly(D, L-lactide co-glycolide). 
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Abbreviations: NPs, nanoparticles; PVA, polyvinyl alcohol; iv, 
inherent viscosity; EDC-NHS, carbodiimide hydrochloride-N-
hydroxysuccinimide; BS3, bis(sulfo-succinimidyl) suberate. 
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3.11 FIGURES 
 
 Figure 3.3 Reaction schemes to prepare targeted PLGA NP. 
Notes: (A) Carbodiimide method, where EDC/sulfo-NHS was used as the cross-linker. COOH 
terminated PLGA reacts with EDC/sulfo-NHS to form NHS-ester that reacts with antibody to obtain a 
stable amide bond. (B) Using BS3 spacer, where covalent amide bond is formed between ligand and 
BS3 molecules embedded on pre-activated NPs’ surface. This method is applicable for both ester and 
COOH terminated PLGA NPs. 
Abbreviations: PLGA, poly (D, L-lactide co-glycolide); NP, nanoparticle; EDC, carbodiimide 
hydrochloride; NHS, N-hydroxysuccinimide; COOH, carboxylic acid; BS3, bis(sulfo-succinimidyl) 
suberate. 
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 Figure 3.4 Particle size, PDI, and ZP of NPs prepared with different PLGA polymer end groups and 
viscosities following method 1. 
Notes: The bar diagram and line plots represent particle size and PDI value, respectively. (A) 
Represents the NP formulations prepared without cryoprotectant. (B) Represents the same formulations 
preserved with two different cryoprotectants namely sucrose and trehalose. (C) Represents the 
comparative ZP of all NP formulations with or without cryoprotectant. The level of significance was set 
to P<0.05 (one-way ANOVA followed by Tukey’s multiple comparison test method). Each bar and line 
represents mean ± SD (n=12). C = COOH ended PLGA; E = ester ended PLGA, S = sucrose (10%); T = 
trehalose (10%). 
Abbreviations: PDI, polydispersity index; ZP, zeta potential; NP, nanoparticle; PLGA, poly(D, L-
lactide co-glycolide); ANOVA, analysis of variance; SD, standard deviation; COOH, carboxylic acid; 
FD, freeze-drying. 
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 Figure 3.5 Particle size, PDI, and ZP of NPs prepared with different PLGA polymer end groups and 
viscosities following method 2. 
Notes: The bar diagram and line plots represent particle size and PDI value, respectively. (A) 
Represents all the NP formulations with or without BS3 prepared without cryoprotectant. (B) 
Represents the same formulations preserved with sucrose (10%) as cryoprotectant. (C) Represents the 
comparative ZP of all NP formulations with or without cryoprotectant. The level of significance was set 
to P<0.05 (one-way ANOVA followed by Tukey’s multiple comparison test method). Each bar and line 
represents mean ± SD (n=12). C = COOH ended PLGA; E = ester ended PLGA; S = sucrose (10%). 
Abbreviations: PDI, polydispersity index; ZP, zeta potential; NP, nanoparticle; PLGA, poly(D, L-
lactide co-glycolide); ANOVA, analysis of variance; SD, standard deviation; COOH, carboxylic acid; 
FD, freeze-drying; BS3, bis(sulfo-succinimidyl) suberate. 
 
 Figure 3.6 SEM images. 
Notes: SEM images of NPs (A) 0.15 iv ester terminated PLGA NPs at magnification of 30.84 KX at 
EHT (extra high tension) 25 kV; (B) antibody modified 0.15 iv ester terminated PLGA NPs at 
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magnification of 78.75 KX at EHT 25 kV. 
Abbreviations: SEM, scanning electron microscopy; NPs, nanoparticles; PLGA, poly(D, L-lactide co-
glycolide); iv, inherent viscosity; Mag, magnification. 
 
 
 Figure 3.7 Infrared spectrum of NPs. 
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Notes: Primary (A) and secondary derivative (B) of IR spectrum for 0.55C-NP (0.55 iv COOH 
terminated plain PLGA NPs) (blue), 0.55C-NP+BS3 (BS3 containing 0.55 iv COOH terminated PLGA 
NPs) (red), and 0.55C-NP+BS3+anti-CD205 antibody (BS3 containing 0.55 iv COOH terminated Ab 
modified PLGA NPs) (black). Data are represented in absorbance unit versus wavelength (cm−1). 
Abbreviations: IR, infrared; NP, nanoparticle; COOH, carboxylic acid; PLGA, poly(D, L-lactide co-
glycolide); BS3, bis(sulfo-succinimidyl) suberate; iv, inherent viscosity; Ab, anti-CD205 antibody. 
 
 
 Figure 3.8 DC viability (MTT assay) after 24 hours of exposure to plain and antibody modified NPs 
(method 1). 
Notes: The treated NP concentration was 1 mg/mL for cell density of 10,000. Result was calculated 
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based on the absorbance of treated cells in comparison with untreated cells, where blank values were 
subtracted from each group (n=3). C = COOH ended PLGA, E = ester ended PLGA, S = sucrose (10%), 
and T = trehalose (10%). 
Abbreviations: DC, dendritic cell; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide; NPs, nanoparticles; COOH, carboxylic acid; PLGA, poly(D, L-lactide co-glycolide). 
 
 
 Figure 3.9 DC viability (MTT assay) after 24 hours of exposure to plain and modified NPs (method 2). 
Notes: The treated NP concentration was 1 mg/mL for cell density of 10,000. Result was calculated 
based on the absorbance of treated cells in comparison with untreated cells, where blank values were 
subtracted from each group (n=3). C = COOH ended PLGA, E = ester ended PLGA, and S = sucrose 
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(10%). 
Abbreviations: DC, dendritic cell; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide; NPs, nanoparticles; COOH, carboxylic acid; PLGA, poly (D, L-lactide co-glycolide). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
3.12 References 
 
 
 1. Bandyopadhyay A, Fine RL, Demento S, Bockenstedt LK, Fahmy TM. The impact of 
nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials. Apr 2011;32(11):3094-
3105. 
2. Reuter A, Panozza SE, Macri C, et al. Criteria for dendritic cell receptor selection for efficient 
antibody-targeted vaccination. Journal of immunology. Mar 15 2015;194(6):2696-2705. 
3. Butler M, Morel AS, Jordan WJ, et al. Altered expression and endocytic function of CD205 in 
human dendritic cells, and detection of a CD205-DCL-1 fusion protein upon dendritic cell maturation. 
Immunology. Mar 2007;120(3):362-371. 
4. Platzer B, Stout M, Fiebiger E. Antigen cross-presentation of immune complexes. Frontiers in 
immunology. 2014;5:140. 
5. Barbuto S, Idoyaga J, Vila-Perello M, et al. Induction of innate and adaptive immunity by 
delivery of poly dA:dT to dendritic cells. Nature chemical biology. Apr 2013;9(4):250-256. 
6. Cooper DL, Harirforoosh S. Design and optimization of PLGA-based diclofenac loaded 
nanoparticles. PloS one. 2014;9(1):e87326. 
7. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: 
an overview of biomedical applications. Journal of controlled release : official journal of the 
Controlled Release Society. Jul 20 2012;161(2):505-522. 
8. Lewis JS, Zaveri TD, Crooks CP, 2nd, Keselowsky BG. Microparticle surface modifications 
targeting dendritic cells for non-activating applications. Biomaterials. Oct 2012;33(29):7221-7232. 
9. Haddadi A, Hamdy S, Ghotbi Z, Samuel J, Lavasanifar A. Immunoadjuvant activity of the 
nanoparticles' surface modified with mannan. Nanotechnology. Sep 5 2014;25(35):355101. 
10. Sah H, Thoma LA, Desu HR, Sah E, Wood GC. Concepts and practices used to develop 
functional PLGA-based nanoparticulate systems. International journal of nanomedicine. 2013;8:747-
765. 
81 
 
11. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, Lavasanifar A. Active targeting of 
dendritic cells with mannan-decorated PLGA nanoparticles. Journal of drug targeting. May 
2011;19(4):281-292. 
12. Keum CG, Noh YW, Baek JS, et al. Practical preparation procedures for docetaxel-loaded 
nanoparticles using polylactic acid-co-glycolic acid. International journal of nanomedicine. 
2011;6:2225-2234. 
13. Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK. Surface functionalization of 
PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in 
cancer therapy. Nanotechnology. Jan 21 2011;22(3):035101. 
14. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA 
nanoparticles surface modified with monoclonal antibody. Journal of controlled release : official 
journal of the Controlled Release Society. Jul 16 2007;120(1-2):18-26. 
15. Zou W, Liu C, Chen Z, Zhang N. Studies on bioadhesive PLGA nanoparticles: A promising 
gene delivery system for efficient gene therapy to lung cancer. International journal of pharmaceutics. 
Mar 31 2009;370(1-2):187-195. 
16. Mukherjee B, Santra K, Pattnaik G, Ghosh S. Preparation, characterization and in-vitro 
evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. 
International journal of nanomedicine. 2008;3(4):487-496. 
17. Al-Nemrawi NK, Dave RH. Formulation and characterization of acetaminophen nanoparticles 
in orally disintegrating films. Drug delivery. Jul 11 2014:1-10. 
18. Kaur R, Chitanda JM, Michel D, et al. Lysine-functionalized nanodiamonds: synthesis, 
physiochemical characterization, and nucleic acid binding studies. International journal of 
nanomedicine. 2012;7:3851-3866. 
19. Valencia PM, Hanewich-Hollatz MH, Gao W, et al. Effects of ligands with different water 
solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials. Sep 
82 
 
2011;32(26):6226-6233. 
20. Li F, Sun J, Zhu H, Wen X, Lin C, Shi D. Preparation and characterization novel polymer-
coated magnetic nanoparticles as carriers for doxorubicin. Colloids Surf B Biointerfaces. Nov 1 
2011;88(1):58-62. 
21. Dillen K, Vandervoort J, Van den Mooter G, Verheyden L, Ludwig A. Factorial design, 
physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. International 
journal of pharmaceutics. May 4 2004;275(1-2):171-187. 
22. Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano-formulation: the kinetics of 
tissue distribution and blood-brain barrier penetration. International journal of pharmaceutics. Sep 15 
2011;416(1):331-338. 
23. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies 
for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. 
Journal of controlled release : official journal of the Controlled Release Society. Feb 11 
2008;125(3):193-209. 
24. Copp JA, Fang RH, Luk BT, et al. Clearance of pathological antibodies using biomimetic 
nanoparticles. Proceedings of the National Academy of Sciences of the United States of America. Sep 
16 2014;111(37):13481-13486. 
25. Sperling RA, Parak WJ. Surface modification, functionalization and bioconjugation of colloidal 
inorganic nanoparticles. Philosophical transactions. Series A, Mathematical, physical, and engineering 
sciences. Mar 28 2010;368(1915):1333-1383. 
26. Hermans K, Van den Plas D, Everaert A, Weyenberg W, Ludwig A. Full factorial design, 
physicochemical characterisation and biological assessment of cyclosporine A loaded cationic 
nanoparticles. Eur J Pharm Biopharm. Sep 2012;82(1):27-35. 
27. Fonte P, Soares S, Costa A, et al. Effect of cryoprotectants on the porosity and stability of 
insulin-loaded PLGA nanoparticles after freeze-drying. Biomatter. Oct-Dec 2012;2(4):329-339. 
83 
 
28. Ikeda J, Sun YL, An KN, Amadio PC, Zhao C. Application of carbodiimide derivatized 
synovial fluid to enhance extrasynovial tendon gliding ability. J Hand Surg Am. Mar 2011;36(3):456-
463. 
29. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems 
in cancer therapeutics. Advanced drug delivery reviews. Dec 14 2008;60(15):1615-1626. 
30. Sampath M, Lakra R, Korrapati P, Sengottuvelan B. Curcumin loaded poly (lactic-co-glycolic) 
acid nanofiber for the treatment of carcinoma. Colloids Surf B Biointerfaces. May 1 2014;117:128-134. 
31. Kountz SL. The effect of bioscience and technological momentum on the surgical treatment of 
chronic illness. Surgery. Jun 1975;77(6):735-740. 
32. Barth A. Infrared spectroscopy of proteins. Biochimica et biophysica acta. Sep 
2007;1767(9):1073-1101. 
33. Glassford SE, Byrne B, Kazarian SG. Recent applications of ATR FTIR spectroscopy and 
imaging to proteins. Biochimica et biophysica acta. Dec 2013;1834(12):2849-2858. 
34. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. A new double emulsion 
solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. Journal of 
controlled release : official journal of the Controlled Release Society. Jan 19 2009;133(2):90-95. 
35. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nature biotechnology. Oct 
2007;25(10):1165-1170. 
36. Kettiger H, Schipanski A, Wick P, Huwyler J. Engineered nanomaterial uptake and tissue 
distribution: from cell to organism. International journal of nanomedicine. 2013;8:3255-3269. 
37. Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar A. Activation of antigen-
specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharmaceutical research. Sep 
2011;28(9):2288-2301. 
38. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent immune 
response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine. 
84 
 
Nov 22 2002;21(1-2):67-77. 
39. Soppimath KS, Aminabhavi TM. Ethyl acetate as a dispersing solvent in the production of 
poly(DL-lactide-co-glycolide) microspheres: effect of process parameters and polymer type. Journal of 
microencapsulation. May-Jun 2002;19(3):281-292. 
40. Sahana DK, Mittal G, Bhardwaj V, Kumar MN. PLGA nanoparticles for oral delivery of 
hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in 
vitro and in vivo using estradiol as a model drug. Journal of pharmaceutical sciences. Apr 
2008;97(4):1530-1542. 
41. Jose S, Sowmya S, Cinu TA, Aleykutty NA, Thomas S, Souto EB. Surface modified PLGA 
nanoparticles for brain targeting of Bacoside-A. European journal of pharmaceutical sciences : official 
journal of the European Federation for Pharmaceutical Sciences. Oct 15 2014;63:29-35. 
42. Yoncheva K, Vandervoort J, Ludwig A. Influence of process parameters of high-pressure 
emulsification method on the properties of pilocarpine-loaded nanoparticles. Journal of 
microencapsulation. Jul-Aug 2003;20(4):449-458. 
43. Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: 
a factorial design study. International journal of pharmaceutics. May 15 2002;238(1-2):77-92. 
44. Wang H, Jia Y, Hu W, Jiang H, Zhang J, Zhang L. Effect of preparation conditions on the size 
and encapsulation properties of mPEG-PLGA nanoparticles simultaneously loaded with vincristine 
sulfate and curcumin. Pharm Dev Technol. May-Jun 2013;18(3):694-700. 
45. Mobarak DH, Salah S, Elkheshen SA. Formulation of ciprofloxacin hydrochloride loaded 
biodegradable nanoparticles: optimization of technique and process variables. Pharm Dev Technol. 
Nov 2014;19(7):891-900. 
46. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled 
Drug Delivery Carrier. Polymers (Basel). Sep 1 2011;3(3):1377-1397. 
47. Sanad RA, Abdel Malak NS, El-Bayoomy TS, Badawi AA. Preparation and characterization of 
85 
 
oxybenzone-loaded solid lipid nanoparticles (SLNs) with enhanced safety and sunscreening efficacy: 
SPF and UVA-PF. Drug discoveries & therapeutics. Dec 2010;4(6):472-483. 
48. Vandervoort J, Yoncheva K, Ludwig A. Influence of the homogenisation procedure on the 
physicochemical properties of PLGA nanoparticles. Chemical & pharmaceutical bulletin. Nov 
2004;52(11):1273-1279. 
49. Nabi-Meibodi M, Vatanara A, Najafabadi AR, et al. The effective encapsulation of a 
hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent 
evaporation method. Colloids Surf B Biointerfaces. Dec 1 2013;112:408-414. 
50. Gomez-Gaete C, Bustos GL, Godoy RR, et al. Successful factorial design for the optimization 
of methylprednisolone encapsulation in biodegradable nanoparticles. Drug development and industrial 
pharmacy. Feb 2013;39(2):310-320. 
51. Premaletha K, Licy CD, Jose S, Saraladevi A, Shirwaikar A, Shirwaikar A. Formulation, 
characterization and optimization of hepatitis B surface antigen (HBsAg)-loaded chitosan microspheres 
for oral delivery. Pharm Dev Technol. Mar-Apr 2012;17(2):251-258. 
52. Awotwe-Otoo D, Zidan AS, Rahman Z, Habib MJ. Evaluation of anticancer drug-loaded 
nanoparticle characteristics by nondestructive methodologies. AAPS PharmSciTech. Jun 
2012;13(2):611-622. 
53. Li X, Xu Y, Chen G, Wei P, Ping Q. PLGA nanoparticles for the oral delivery of 5-Fluorouracil 
using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo 
studies. Drug development and industrial pharmacy. Jan 2008;34(1):107-115. 
54. Westesen K. Novel lipid-based colloidal dispersions as potential drug administration systems – 
expectations and reality. Colloid Polym Sci. 2000/07/01 2000;278(7):608-618. 
55. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation 
of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine. 3// 
2006;2(1):8-21. 
86 
 
56. Rizkalla N, Range C, Lacasse FX, Hildgen P. Effect of various formulation parameters on the 
properties of polymeric nanoparticles prepared by multiple emulsion method. Journal of 
microencapsulation. Feb 2006;23(1):39-57. 
57. Janz Fde L, Debes Ade A, Cavaglieri Rde C, et al. Evaluation of distinct freezing methods and 
cryoprotectants for human amniotic fluid stem cells cryopreservation. J Biomed Biotechnol. 
2012;2012:649353. 
58. Zhang X, Guan J, Ni R, Li LC, Mao S. Preparation and solidification of redispersible 
nanosuspensions. Journal of pharmaceutical sciences. Jul 2014;103(7):2166-2176. 
59. Mura S, Hillaireau H, Nicolas J, et al. Influence of surface charge on the potential toxicity of 
PLGA nanoparticles towards Calu-3 cells. International journal of nanomedicine. 2011;6:2591-2605. 
60. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: 
formulation, process and storage considerations. Advanced drug delivery reviews. Dec 30 
2006;58(15):1688-1713. 
61. Jeong YI, Shim YH, Kim C, Lim GT, Choi KC, Yoon C. Effect of cryoprotectants on the 
reconstitution of surfactant-free nanoparticles of poly(DL-lactide-co-glycolide). Journal of 
microencapsulation. Sep 2005;22(6):593-601. 
62. Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL. Sustained release of recombinant 
human insulin-like growth factor-I for treatment of diabetes. Journal of controlled release : official 
journal of the Controlled Release Society. Jul 3 2000;67(2-3):281-292. 
87 
 
CHAPTER 4 
4. Design and immunological evaluation of anti-CD205 tailored PLGA based nanoparticulate 
cancer vaccine   
 
 
Sheikh Tasnim Jahan, Sams M. A. Sadat, and Azita Haddadi2 
 
 
Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK 
S7N 5E5, Canada 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
2 Corresponding Author: Azita Haddadi 
3D01.01, D Wing Health Sciences, 107 Wiggins Road, College of Pharmacy and Nutrition, University of 
Saskatchewan, Saskatoon SK, S7N 5E5; Phone: (306) 966-6495; Fax: (306) 966-6377; e-mail: 
azita.haddadi@usask.ca 
88 
 
4.1 Brief introduction to chapter 4 
The main goal of the present study is to establish the development of OVA and/or MPLA loaded NPs 
targeted with antibody, their physicochemical characterization, DC uptake study, safety profile of OVA 
NPs on DCs, release pattern of OVA, DC maturation study and cytokine secretion profiles.  
The rationale behind these experiments is to achieve robust immune response from dual combination of 
MPLA-OVA loaded targeted NPs. It is more likely that MPLA-OVA combination in NPs can 
simultaneously induce T helper (Th) cells and cytotoxic T lymphocytes (CTL). However, it is necessary 
to deliver this antigen-adjuvant combination within a carrier system to avoid degradation and early release 
of antigenic material. In addition, the carrier will demonstrate a controlled release of therapeutics for a 
prolonged period of time to subsequently overcome the administration of booster doses. Moreover, the 
surface decorated carrier will deliver the antigen-adjuvant cargo to the target cell (professional antigen 
presenting DC) to obtain enhanced immune response.  
The method to formulate nanoparticles was double-emulsification solvent evaporation technique. 
Dynamic light scattering was used to gauge particle size, polydispersity index and zeta potential. MTS [3-
(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay was 
performed to determine the viability of DCs. Circular dichroism was used to confirm the structural 
integrity of particles. Bicinchoninic acid assay (BCA) was performed to quantify the OVA after loading 
and release study. Flow cytometry was used for evaluation of DC maturation markers (CD40, CD86 and 
MHCII). Enzyme linked immunosorbent assay (ELISA) was used to quantify the cytokines. 
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4.2 Abstract  
The aim of this research was to develop a targeted antigen-adjuvant assembled delivery system that will 
enable dendritic cells (DCs) to efficiently mature to recognize antigens released from tumor cells. In brief, 
model antigen, ovalbumin (OVA) and monophosphoryl lipid A (MPLA) adjuvant were encapsulated 
within the nanoparticle (NP) by double emulsification solvent evaporation method. Targeted NPs were 
obtained through ligand incorporation via physical adsorption or chemical conjugation process. 
Intracellular uptake of the NPs was assessed using Coumarin-6 dye. Evaluation of physicochemical 
characterization of NPs was performed based on the polymer end groups, their viscosities and ligand-NP 
bonding type. Remarkably, the developed delivery system had suitable physicochemical properties such 
as particle size, surface charge, OVA encapsulation efficiency, bi-phasic OVA release pattern, and safety 
profile. The ligand modified formulations had higher targeting efficiency than the non-tailored NPs. This 
was also evidenced when the targeted formulations expressed comparatively higher fold increase in 
surface activation markers such as CD40, CD86, and MHCII molecules. The maturation of DCs was 
further confirmed through secretion of extracellular cytokines compared to control cells in the DC 
microenvironment. In conclusion, the DC stimulatory response was integrated to develop a relationship 
between the NP structure and desired immune response. Therefore, the present study narrates comparative 
evaluation of some selected parameters to choose the suitable formulation for in-vivo cancer 
immunotherapy.  
 
 
 
 
 
 
 
Keywords: Nanoparticle, Ovalbumin, MPLA, anti-CD205, PLGA, dendritic cells 
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4.3 Introduction 
Cancer is the most detrimental disease in first world nations as well as developing countries. The goal of 
cancer therapy is to eradicate tumor cells without effecting normal healthy cells.(1) Moreover, therapeutic 
approaches are smartly chosen based on their selective targeting of malignant cells. Nowadays, novel 
treatment option like immunotherapy has excelled with favorable outcomes and limited side-effects. It is 
well-accepted complementary intervention for patients with weakened immune system resulted from 
long-term cancer treatments. It has the potential to augment the therapeutic response with synergistic 
efficacy when combined other treatment modalities.(2) The immunotherapeutic approach can appear as 
an ideal treatment option due to its unique mechanism of action.(3)  
A cancer patient receives immunotherapy through therapeutic vaccine that induces antigen specific T 
cells, tumor relevant chemokine receptors but avoids interaction with suppressor cells and their 
expansion.(4) This type of vaccine aims in clonal expansion of cytotoxic T cells that identifies cancer 
cells and kills them by sequential events of perforin and granzyme release, thereby activating the caspase 
cascade and finally leading to apoptosis.(5), (6) In contrary, clinical trials were found to be ineffective 
initially. Failure in clinical trials is due to lack of optimal immune stimulation (either for mature DC or 
suppressive DC), inadequate antigen loading, incorrect route of administration and dose, prior analysis of 
DC transcriptosome.(7), (8) Therefore, to fight the limitation of the immune system to detect cancer 
inspired the researchers to manipulate DCs with target specific tools.  
The in-vivo therapeutic vaccination involves the targeted delivery of antigen to DCs which will fuse 
tumor antigen to antibody (Ab) specific for a DC receptor. This strategy is cost-effective and less 
laborious compared to ex-vivo DC vaccines.(9) For example, when anti-CD205 Ab is conjugated with 
OVA, the receptor mediated antigen presentation increases significantly for major histocompatibility 
complex (MHC) class I and MHC class II (MHCII). The target CD205 receptor could continually delete 
peripheral T cells at steady state to establish tolerance and solely provide immunity when DCs are 
matured.(10) Whereas, in case of ex-vivo vaccination, when DCs are injected, problems such as failure to 
reach lymph node, insufficient amount of injected DCs, and disorder of immuno-function due to 
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immunosuppressive environment occur. The molecules in that environment (CTLA-4, PD-1, CD200, IL-
10, TGF-β) are capable to inhibit the T cell function by formation of regulatory T (Tregs) cells.(11)  
Nanoparticle based delivery systems are popular carrier for delivery of antigenic material to antigen 
presenting cells (APCs).(12) To become an ideal delivery system, the combination with antigen and 
adjuvant is very important. This cargo system will be able to deliver specific antigen to the APCs to 
manipulate their response.(13), (14) The present study aims to deliver surface modified NP to obtain 
immunological responses as mentioned in Figure 4.1. Surface modified NPs possess a hydrophilic layer 
that tends to escape reticuloendothelial system to reach receptors on target APCs, specifically the 
DCs.(15) 
Immunostimulatory particulate delivery systems with biodegradable polymers have gained popularity due 
to their size, controlled release properties, and biocompatibility with tissues. Poly-lactic-co-glycolide 
(PLGA) based delivery system has become an interesting strategy for antigen based cancer 
immunotherapy.(16) Biodegradable PLGA is approved by the US FDA and European Medicine Agency 
(EMA) for use in humans.(17) The encapsulation of protein antigen in the PLGA particle protects the 
protein from degradation in-vivo. The antigen loaded particles release antigen in a controlled manner to 
prolong the availability of antigen in-vivo. However, the extended release of antigen as well as induction 
of innate and adaptive immune response  are concerns.(18), (19)  
For this study, we have chosen anti-CD205 monoclonal Ab to target CD205 receptor on DC because it is 
the extensively studied receptor for antigen delivery.(20) The formulations were designed using capped 
and uncapped PLGA; both offering low and high viscosity grades. Results are discussed based on a 
relative evaluation of the physicochemical properties, in-vitro studies and immunological responses. The 
purpose of this study is to assess the desired formulations that would be safe to deliver in-vivo to release 
its content in a controlled release manner to obtain necessary immunotherapeutic response.  
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4.4 Materials and methods 
4.4.1 Materials 
MPLA (molecular weight 1763.469 Da) was obtained from Avanti Polar Lipids Inc. (Alabama, USA). 
Ester terminated PLGA 50:50 (inherent viscosity or iv 0.15-0.25 dl/g and 0.55-0.75 dl/g) and COOH 
terminated PLGA 50:50 (iv 0.18 dl/g and 0.55-0.75 dl/g) were purchased from Lactel, Absorbable 
Polymers (Birmingham, AL, USA). Polyvinyl alcohol (PVA), bis (sulfo-succinimidyl) suberate (BS3), 
ovalbumin from chicken egg white (grade V), Coumarin-6, alpha minimum essential medium, fetal 
bovine serum (FBS) and bicinchoninic acid (BCA) assay kit was purchased from Sigma-Aldrich Co. (St 
Louis, MO, USA). Cell titre non-radioactive cell proliferation assay MTS [3-(4, 5-dimethylthiazol-2-yl)-
5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium was purchased from Promega (Madison, 
WI, USA). Biotin anti-mouse CD205 monoclonal Ab (MAb) was purchased from Biolegend (San Diego, 
CA, USA). JAWSII dendritic cell line was obtained from American Type Culture Collection (ATCC), 
Manassas, VA, USA. Granulocyte-macrophage colony stimulating factor (GM-CSF) and slow fade gold 
Antifade mountant with DAPI (4′,6-diamidino-2-phenylindole) were purchased from Thermo Fischer 
Scientific, Waltham, MA, USA. Anti-mouse CD16/CD32 MAb (Fc blocker), CD40, CD86, MHCII Abs, 
and their respective isotype controls were purchased from BD Biosciences (San Jose, CA, USA). Murine 
IFNγ, IL12p70, IL-6, and TNF-α ELISA kits were purchased from eBioscience (San Diego, CA, USA). 
All other reagents such as ethyl acetate, methanol, sodium hydroxide (NaOH), sodium dodecyl sulfate 
(SDS) were of analytical grade. 
4.4.2 Preparation, surface modification and quantification of coumarin-6 loaded NPs 
PLGA NPs were prepared using the oil/water (O/W) emulsification solvent evaporation technique as 
mentioned elsewhere.(21) Briefly, 6.5% (w/v) PLGA was dissolved in ethyl acetate solvent. 
Subsequently, 100 µg of coumarin-6 was added to this organic phase. The organic phase was transferred 
in drops into the aqueous phase comprised of 2.2 % polyvinyl alcohol (PVA). To obtain pre-activated 
NPs, BS3 was present in the aqueous PVA solution. The resulting primary emulsion was stirred, washed 
and resuspended in water. Cryoprotectant (10% sucrose) was added to obtain aggregation free lyophilized 
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NPs.(22) The freeze-dried NPs were surface modified with anti-CD205 Ab via adsorption and covalently 
attachment process as mentioned previously.(23) Briefly, 20 mg of NPs was taken and dispersed in 
phosphate buffer solution, PBS (pH 7.2) followed by stirring (40C, 4 hours) and washing of unattached 
anti-CD205 Ab. The amount of Ab was quantified by BCA assay.(24) 
Amount of coumarin-6 was quantified using fluorimetry using microplate reader with an excitation 
wavelength at 430 nm and an emission wavelength at 485 nm. First, coumarin-6 loaded NPs were 
dispersed in methanol for 24 hours.(25) The supernatant was collected after washing the NPs twice by 
centrifugation. A standard curve of coumarin-6 was prepared in the concentration ranged from 0.78-
100 μg/ml.(22) The encapsulation efficiency and loading of coumarin-6 was calculated based on the 
following equations: (26) 
𝐶𝑜𝑢𝑚𝑎𝑟𝑖𝑛 − 6 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑙𝑎𝑜𝑑𝑒𝑑 𝑐𝑜𝑢𝑚𝑎𝑟𝑖𝑛 − 6 (µ𝑔)
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 (𝑚𝑔)
 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑐𝑜𝑢𝑚𝑎𝑟𝑖𝑛 − 6  (𝑚𝑔)
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑐𝑜𝑢𝑚𝑎𝑟𝑖𝑛 − 6 𝑎𝑑𝑑𝑒𝑑 (𝑚𝑔)
×100 
4.4.3 Surface modification and quantification of OVA loaded NPs 
OVA loaded NPs were prepared by water/oil/water double emulsification solvent evaporation method as 
mentioned elsewhere.(27) In brief, 10 mg OVA of was dissolved in100 μl PBS and transferred to PLGA-
ethyl acetate solution. 200 µg of MPLA dissolved in 1:4 methanol-chloroform mixture was added to the 
PLGA mixture for the formulations with MPLA.  The sonicated primary emulsion was added to 2.2% of 
PVA to form a secondary emulsion. Once the organic solvent was evaporated; suspension was washed 
twice, freeze-dried, and stored at -200C. All the formulations were cryopreserved with 10% sucrose 
solution.(14) 
Surface modification of OVA loaded NPs was obtained using physical adsorption and covalent 
attachment method as mentioned in the previous section. The amount of OVA in NPs was quantified 
using BCA assay.(28) Briefly, 5 mg of NPs were re-dispersed in 3ml of 0.05M NaOH containing 1% of 
SDS. The suspension was incubated overnight in an orbital shaker. Next day, the supernatant was 
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collected after centrifugation. Samples were placed in a 96-well plate (Corning Costar, USA) and 
absorbance was measured at 565 nm using a microplate reader. The result was compared with a standard 
curve prepared by OVA in the concentration range of 15.6 μg/ml to 1000 μg/ml. (29), (30) 
4.4.4 Cell viability assay 
DCs were seeded at a density of 10,000 cells per well in 96-well plates with complete media containing 
alpha minimum essential medium (MEM) media, 20% FBS, 5 ng/ml of GM-CSF, and 1% penicillin-
streptomycin-amphotericin B cocktail.(31) For the assay, MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reagent was used per manufacturer’s 
directions. Briefly, NP suspension was diluted in complete medium and 20 µl of each dilution containing 
1 mg/ml OVA was added in triplicate wells. The samples were incubated for 72 hours. After that, 10 µl of 
MTS reagent was added to each well and the plate was incubated again for 2 hours at 370C. The 
absorbance was measured at 490 nm with a microplate reader.(32)  
4.4.5 OVA release study 
In-vitro release studies of OVA from PLGA NPs were carried out by incubating specific amount of NPs 
in 2 ml of PBS at 370C with agitation. At predetermined times (for 20 days), the suspension was 
centrifuged. OVA containing supernatants were collected and stored at -200C. Later, the protein present in 
samples were determined by BCA assay kit and read with a microplate reader at 565 nm.(33)  
4.4.6 DC uptake study 
DCs were treated with different formulations of coumarin-6 loaded NPs. DCs were harvested after 24 
hours of incubation with the formulations. The cells were washed with ice-cold FACS buffer to remove 
non-internalized NPs. About 2 x 105 cells were incubated with anti-mouse Fc blocker for 15 minutes. The 
suspension was then washed with FACS buffer. Test groups were surface modified NPs and non-
modified NPs. Untreated cells were used as negative control. Fold-increase in DC uptake was calculated 
dividing the mean fluorescence intensity (MFI) of coumarin-6 positive cells (test groups) by untreated 
cells. All samples were acquired on BD FACS Calibur machine and analyzed using Kaluza flow 
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software.(27) For analysis by flow cytometry, a total of 10,000 gated events were used. The detector was 
adjusted in a way so that the negative population appears in the first logarithmic decade. 
4.4.7 Intracellular localization of NPs analyzed by confocal laser scanning microscopy (CLSM) 
About 5 x 106 DCs were seeded in a six-well plate. After stabilization for 2 hours, the DCs were treated 
with coumarin-6 loaded NPs. After overnight incubation, the cells were washed with PBS and fixed with 
4% paraformaldehyde solution for 20 minutes. The cell nuclei were then counterstained for 20 minutes 
with DAPI (1 mg/ml). The cells were examined under fluorescence microscopy (IX71-F22FL/PH, 
OLYMPUS). Finally, the uptake was visualized in a glass bottom petridish with a confocal laser scanning 
microscope (LSM 510 Meta, Carl Zeiss, Germany).(34) 
4.4.8 Characterization of surface phenotype by flow cytometry 
Different NP formulations were incubated overnight with about 5 x 105 DCs in six-well plates. After 
overnight incubation, about 2 x 105 of DCs were collected. Then, cells were washed thoroughly and 
incubated with Fc blocker to block any non-specific binding. Next, the cells were stained with 
phycoerythrin (PE) conjugated specific Abs for CD40, anti-CD86 or MHCII for 30 minutes at 40C. The 
isotype standard for each maturation marker was also used to measure background fluorescence 
intensity.(35) Lipopolysaccharide (LPS) 1µg/ml was used as positive control. And an unstimulated cell 
was used as negative control. NP-DC samples were acquired on FACS Calibur machine and analyzed 
using Cell Quest Pro software. 
4.4.9 Detection of cytokine secretion  
The supernatants from the DC culture was stored at -20˚C for analysis of the level of IL-12, IL-6, IFNγ 
and TNF-α using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The 
samples were then placed in 96-well microplate using a microplate reader at 450 nm (background 570 
nm) according to manufacturer’s directions.(35) The minimum detection levels of the cytokines were 15, 
4, 15, and 15 pg/ml for IL-12, IL-6, IFNγ, and TNF-α, respectively.  
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4.4.10 Statistical analysis 
The data are given as mean ± SD and statistical significance was determined by Student’s t-test. Values of 
p < 0.05 were considered statistically significant unless specifically mentioned. Data were analyzed using 
GraphPad Prism 5.03 software (GraphPad Software, Inc., La Jolla, CA, USA). 
4.5 Results 
4.5.1 Characterization of coumarin-6 loaded plain and Ab modified NPs 
Table 4.1 summarizes the NP size, polydispersity index (PDI), zeta potential (ZP), encapsulation 
efficiency (EE), and coumarin-6 loading (per mg of NPs). The particle size of plain NPs ranged from 
121±5 to 162±5 nm. All the formulations were cryopreserved with 10% sucrose. Following Ab 
attachment (both adsorbed and covalent), the particle size was 201±10 to 562±5 nm. The increase in 
polymer viscosity increased both particle size and PDI although they were not significantly different. The 
EE of coumarin-6 ranged from 73.91±2.87 to 88.13±2.01% for plain NPs and 64.13±2.98 to 73.75±0.99% 
for Ab modified formulations. The presence of BS3 did not show any effect on the formulations. 
Moreover, particle size showed significant relationship with PDI, ZP, EE, and loading of coumarin-6 
(***p<0.05). The formulations (plain and modified) had ZP value of -8.91±0.26 to -1.93±0.18 mV. No 
significant relation within groups was observed as performed by statistical software. 
4.5.2 DC uptake study 
A quantitative uptake of coumarin-6 loaded NPs by DCs is represented in Figure 4.2A and Figure 4.2B. 
Treatment of DCs with Ab modified NPs allowed higher uptake of particles compared to non-modified 
NPs as found in other studies.(27) As shown in Figure 4.2A (a - h), compared to untreated cells (control), 
a clear significant shift for MFI towards right for coumarin-6 loaded NPs was observed in all the 
histograms. Moreover, highest shift was visible when Ab was present in the formulation. 
The bar diagrams in Figure 4.2B represents the comparative fold increase in MFI for all the treatment 
groups. For example, there was a significant increase in MFI for the Ab adsorbed COOH (0.18 iv) 
terminated NPs compared to the plain unmodified formulations (***p<0.05). For these two groups, the 
fold increase in MFI was 30 [Plain NP] and 89 [NP-AD] compared to control (***p<0.05). Similarly, 
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covalently attached 0.18 iv COOH terminated NPs [NP-COV] showed significantly higher fold increase 
in MFI (77) compared to that (18) of plain unmodified formulations [Plain-BS-NP] (***p<0.05). 
However, covalently attached formulation of this PLGA NPs [NP-COV] had lower MFI than its Ab 
adsorbed [NP-AD] formulations (**p<0.05). A similar trend was observed for the high viscosity COOH 
terminated PLGA NPs and fold increase in MFI for [Plain NP], [NP-AD], [Plain-BS-NP], and [NP-COV] 
was 60, 121, 57, and 110, respectively. In addition, when comparing between two viscosity grades, the 
high viscosity formulations showed significantly higher fold increase in MFI compared to the low 
viscosity COOH terminated formulations (***p<0.05). 
For ester terminated NPs, there was significant difference for fold increase in MFI for the plain and Ab 
modified formulations (***p<0.05). The BS3 containing 0.15 iv ester formulations had comparatively 
higher fold increase in MFI when compared with the formulations without BS3 (***p<0.05). The fold 
increase in MFI for [Plain NP], [NP-AD], [Plain-BS-NP], and [NP-COV] of low viscosity ester 
terminated PLGA NPs was 27, 45, 67, and 129, respectively. When comparing between the [Plain NP] 
and [NP-AD] formulations of high viscosity ester PLGA, [NP-AD] formulations showed 179 times 
higher fold increase in MFI (***p<0.05). Similar result was observed for Ab adsorbed ester ended NPs of 
the two viscosity grades. When both viscosities of ester terminated NPs were compared, the high 
viscosity [NP-COV] formulations did not necessarily show higher fold increase in MFI as observed for its 
low viscosity grade. Among the low viscosity PLGA NP formulations, 0.15E-COV had the highest 
targeting efficiency as represented in Figure 4.2B. 
Figure 4.2C represents the intracellular localization of coumarin-6 loaded NPs (green color) that was 
further confirmed by CLSM. The images show that anti-CD205 Ab modified NPs had comparatively 
higher uptake of NPs by DCs than unmodified NPs. 
4.5.3 Characterization of OVA/OVA-MPLA loaded plain and Ab modified NPs 
Table 4.2 represents the NP size, PDI, ZP, EE, and loading (per mg of NPs) of OVA. The size of OVA, 
OVA-MPLA, Ab-OVA, Ab-OVA-MPLA loaded PLGA NPs were within 171 ± 3 nm, 159 ± 4 nm, 379 ± 
2 nm, and 501 ± 9 nm, respectively. The ZP for all Ab free OVA and OVA-MPLA NPs ranged from -
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27.1 ± 0.77 mV to -18.42 ± 0.03 mV. The integration of Ab reduced the overall negative surface charge 
of NPs. For the Ab modified formulations, the zeta values ranged from 1.31 ± 0.17 mV to 4.54 ± 0.21 
mV. Good reproducibility in size and ZP was observed between different batches of NPs. The PDI, ZP, 
EE, and OVA loading had significant relationship with particle size (***p<0.05). The OVA EE for the 
OVA/OVA-MPLA NPs and Ab modified OVA/OVA-MPLA NPs were within 59.15 ± 1.56% and 42.56 
± 2.56%, respectively. There was no significant difference within groups as analyzed by statistical 
software. 
4.5.4 OVA release study 
The in-vitro release study for OVA loaded NPs demonstrated a substantial effect on release percentage 
depending on polymer’s molecular weight and type. After 12 hours, the cumulative release of OVA from 
low and high viscosity COOH terminated NP was 39.88% and 30.87%, respectively (Figure 4.3A). 
Similarly (post 12 hour), OVA release for the low and high viscosity ester terminated NP was 31.49% and 
26%, respectively (Figure 4.3A). The release following 12 hours was significantly higher than the initial 
(1st hour) release (*p<0.05). After day 7, the release of OVA from both COOH and ester terminated NPs 
was increased cumulatively (Figure 4.3B) (*p<0.05). About 2 weeks were required to release about 50% 
of the OVA from the high viscosity PLGA NPs (COOH > ester; *p>0.05). Whereas, low viscosity PLGA 
NPs were found to release 50% of OVA within 24 hours (COOH ended) and 7 days (ester ended). 
However, all OVA loaded PLGA NPs exhibited biphasic behavior over 20 days of release study as 
represented in Figure 4.3.(36) 
4.5.5 Cell viability assay 
The viability percentage was 79 to 93% with OVA concentration of 0.5 mg/ml.(37) Plain NPs (without 
OVA) had 90-100% viability as mentioned previously.(21) Soluble OVA showed reasonable toxicity to 
DCs (79.34%). No significant reduction of viability was observed when MPLA was present in the 
formulations as represented in Figure 4.4. 
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4.5.6 The effect of surface modification with anti-CD205 Ab on DC maturation 
The groups were untreated DCs (negative control), DCs treated with LPS 1µg/ml (positive control), and 
DCs treated with OVA and OVA-MPLA NPs (test groups). Figure 4.5 and Figure 4.6 represents the 
comparative expressions of maturation markers (CD40, CD86, and MHCII). For all treatment groups, 
DCs were incubated with variable amounts of NPs containing constant amount of loaded OVA. It is 
evident that, the presence of anti-CD205 Ab in formulations increases MFI and percentage of positive 
cells compared to untreated DCs (**p<0.05).(28) As represented in Figure 4.5A, Ab adsorbed low 
viscosity COOH terminated NPs showed higher expression of all three markers (*p<0.05). As a result, the 
Ab adsorbed OVA-MPLA low viscosity COOH terminated NPs showed higher upregulation of all the 
markers (CD40 MFI: 68.80, CD86 MFI: 132.75, and MHCII MFI: 279.03) compared to its covalently Ab 
attached groups (CD40 MFI: 58.51, CD86 MFI: 78.64, and MHCII MFI: 131.48) (Figure 4.5A). 
Considering the comparative fold increase in MFI for the same PLGA type, the Ab modified high 
viscosity COOH terminated OVA/MPLA loaded NPs followed similar trend as its low viscosity grade. 
The highest maturation of DCs were obtained with 0.18C-OVMP-AD NPs that showed 5, 7, and 9 fold 
increase in MFI for expression of CD40, CD86, and MHCII molecules compared to the unstimulated 
cells, respectively (Figure 4.6A). Following similar trend as low viscosity, Ab adsorbed formulations of 
high viscosity COOH terminated NPs showed higher expression of all three markers (Figure 4.5B and 
Figure 4.6B).  
For ester terminated NPs, 0.15E-OVMP-COV NPs showed superior expression of activation markers than 
the 0.15E-OVMP-AD NPs. Simultaneously, the percentage of CD40+ cells and MFI was higher for the 
0.15 iv ester terminated OVA/MPLA modified NPs (Figure 4.5C). For example, 0.15E-OVMP-COV NPs 
expressed 4, 5, and 7 fold increase in MFI than the 0.15E-OVMP-AD NPs (Figure 6C). Between the two 
viscosities of ester terminated PLGA NPs, a similar trend as the COOH terminated OVA/MPLA 
formulations were observed. Figure 4.5D and Figure 4.6D represents the histogram and bar diagrams for 
the 0.55 iv ester terminated PLGA NPs.  
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Presence of MPLA in all these formulations showed significant change in MFI and percentage of positive 
cells compared to untreated cells (*p<0.05). It is worth mentioning that, both high viscosity PLGAs NPs 
showed lower expression of three markers in comparison to its low viscosity subtype. When comparing 
the effect of PLGA viscosity on maturation, the low viscosity formulations showed comparatively higher 
shift in MFI. 
4.5.7 Cytokine secretion profile 
In parallel to the phenotypic up-regulation of co-stimulatory molecules, mature DCs also secreted 
immunological playmakers such as IL-12, IL-6, IFNγ, and TNF-α upon exposure to free OVA, OVA-
MPLA, Ab-AD, Ab-COV NP groups.(38) Figure 4.7 shows the secretion of cytokines in the DC 
supernatants upon stimulation with titrated amount of NPs. There was consistently high secretion of 
cytokines by the anti-CD205 Ab modified OVA-MPLA NPs within similar groups (Figure 4.7A – 4.7H). 
Highest amount of IL-12 (2165.22 ± 215 pg/ml) was secreted after DC stimulation with 0.18C-OVMP-
COV NPs. Highest amount of IL-6 (1343.23 ± 87 pg/ml), and IFNγ (2691.45 ± 70 pg/ml) was detected in 
the supernatants of 0.18C-OVMP-AD NPs. This was significantly high compared to the minimal 
secretion of the cytokines by free OVA treated DCs (***p<0.05). TNF-α concentration was significantly 
highest with the 0.55C-OVMP-COV NPs (2434.35 ± pg/ml) when compared with free OVA (***p<0.05).  
4.6 Discussion 
Coumarin-6 is widely used in uptake studies due to its biocompatibility, low leaking rate, and high 
fluorescence activity.(39) In this study, coumarin-6 loaded NPs had suitable physicochemical properties 
to perform in-vitro cellular uptake. All these formulations had acceptable particle size range (121±5 nm to 
562±5 nm) (Table 4.1). Particle size has a proportional relationship with the NP uptake.(34) Particles of 
100-200 nm are usually internalized by receptor mediated endocytosis. Larger particle (>500 nm) are 
taken up by phagocytosis process.(40) This justifies the higher uptake of Ab-modified larger particles that 
occurred by combination of mechanisms. The large surface area of these particles is beneficial for higher 
loading of anti-CD205 Ab by adsorption mechanism.(3) Consequently, anti-CD205 Ab coated NPs had 
greater affinity for DCs than other blood opsonins.(41) This distinct surface modification escapes body’s 
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natural defense systems with improved circulation time and higher chance to reach the target cells.(42) 
Bar diagrams in Figure 4.2B represents the comparative change in MFI when coumarin-6 is present in the 
formulations. There was a substantial increase in MFI for the high viscosity COOH terminated PLGA 
NPs because these formulations encapsulated more coumarin-6 compared to low viscosity PLGA 
formulations (Figure 4.2). On contrary, BS3 embedded low viscosity ester terminated NPs showed higher 
uptake compared to the high viscosity ester formulations. This could be attributed to PLGA erosion and 
exposure of entrapped Abs in low viscosity ester terminated NPs.(43) Relatively lower uptake in high 
viscosity ester formulations (with BS3), could be due to less embedment of BS3 available to link with 
anti-CD205 Ab (Figure 4.2B). Moreover, masking of BS3 with the hydrophobic PLGA chain could also 
contribute to lower uptake of high viscosity ester formulations.(23) Lower encapsulation of coumarin-6 
was also observed in the BS3 containing NPs, which justifies the lower MFI. Accordingly, the targeting 
efficiency of 0.55E-AD NPs was the highest (179 times versus 30) when compared with its unmodified 
NPs.  
Physicochemical properties of NPs are also important to correlate with desired immune response. Table 
4.2 represents the cationic charged NPs after Ab conjugation with desired size range (323 ± 3 nm to 501 ± 
9 nm). For subcutaneous vaccine delivery, particle size ranged from 200-500 nm is immunogenic.(44) 
Furthermore, positively charged particles are favorable for vaccination and ZP values close to zero were 
likely to result in aggregation.(45) Formulations, that possess ZP value greater than +30mV and less than 
-30mV are considered colloidally stable. Beyond this range, cryopreservation is required to maintain 
stability during shelf-life of the vaccine.(46) In the present study, 10% sucrose was suitable as that 
resulted in aggregation free slightly positive freeze-dried NPs. However, the particle size and ZP are not 
the sole determinant of immune response in vivo.(44) For the ester terminated NPs, the highest 
encapsulation efficiency of OVA was with 0.55E-BS-OVMP-NPs (59.15 ± 1.56 %) although there was 
no significant difference between groups. In case of COOH terminated NPs, the highest OVA was loaded 
in 0.55C-BS-OVMP-NP (55.42 ± 0.21 µg/mg of NPs). The ionic interactions between the amine groups 
of OVA and the COOH groups of PLGA are responsible for the overall encapsulation efficiency.(33) 
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PLGA is one of the most popular biodegradable polymers for drug delivery systems.(15) The viscosity 
increase will result in prolonged degradation rate of the polymer.(42) PLGA follows biphasic release 
behavior, where its content is released from the surface to the medium in the initial phase due to its 
solubility and water penetration into the polymer matrix (Figure 4.3A). In the second phase, progressive 
drug release occurred throughout the time frame by diffusion and erosion of the polymer (Figure 4.3B). 
The presence of COOH terminated group results in autocatalysis of the PLGA degradation process.(43). 
The similar pattern of PLGA degradation could have occurred in this study. From the OVA release study, 
it could be confirmed that, the release of a protein from a polymeric matrix in an aqueous media slows 
down due to polymer gelation. This change in polymer suspension is favorable for sustain release of 
protein from the NPs in-vivo.(47) In addition, MTS assay shows that incorporating OVA in the 
formulations did not show any significant effects on DC viability over 72 hours in the culture media 
(Figure 4.4).(48) 
To confirm the maturation of DCs, the expression of maturation markers (CD40, CD86, and MHCII) and 
a cytokine cocktail (IL-12, IL-6, IFNγ, and TNF-α) was investigated to compare various formulations 
(Figure 4.5, Figure 4.6, and Figure 4.7).(49) The maturation of DCs was induced by the OVA and OVA-
MPLA formulations rather than soluble OVA. Within 24 hours period, about 30% of OVA was released 
from all types of PLGA NPs. The expression of stimulatory and costimulatory molecules during 24 hours 
was due to release of OVA in the DC microenvironment. This is a good indication that the formulations 
would release sufficient amount of OVA while subcutaneous injection to mice model over the three 
weeks period of vaccination. The DC maturation was further triggered by MPLA that increased the 
expression of all three markers, preferably in the Ab tailored NPs.(50) MPLA is able to induce antigen-
specific immune response without affecting the systems in the body (cardiovascular, reproductive and 
respiratory). It can boost both cell-mediated and humoral immunity when incorporated in vaccine 
formulations.(33) The superiority of the Ab-AD groups over the Ab-COV was also obvious in the 
formulations (with exception with 0.15 iv ester terminated NP formulations). This could be attributed to 
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fast release of the loosely bound surface linked OVA from the OVA-AD groups in the DC media. 
Although, Ab-adsorbed OVA-MPLA formulations showed better maturation of DCs, both Ab-AD and 
Ab-COV formulations should be administered in mouse model to conclude about their efficacy post 
vaccination.  
DCs are stimulated by secreting cytokines after well recognition of certain patterns of pathogens. 
Secretion of the cytokines indicates the signal required for activation of T cells.(51) The immuno-
stimulatory effect of formulations was evaluated by the levels of various cytokines. The findings of this 
study reveal that Ab modified NPs consistently showed higher cytokine secretion compared to 
unmodified NPs. Moreover, co-delivery of OVA-MPLA resulted in significant secretion of T helper 1 
(Th1) type cytokines including IL-12, IL-6, IFNγ, and TNF-α. It is known that, IL-12 influences T cell 
differentiation, which is further regulated by IL-6. IL-6 is a potent regulator of DC maturation in-vivo.(52) 
In addition, IL-12 also induces the percentages of IFNγ producing cells. Therefore, the release of these 
cytokines can efficiently convert immature DCs into T cell stimulatory mature DCs.(53) The cytokine 
cocktail present in the DC supernatant shows a Th1 biased immune response. These results are consistent 
with earlier studies where MPLA was able to mature DCs with expression of markers as well as secretion 
of cytokines. (35) (38) 
4.7 Conclusion 
In this study, we have developed anti-CD205 targeted NPs for subcutaneous delivery of therapeutic 
vaccines. The PLGA NPs were produced by emulsification solvent-evaporation method with suitable 
physicochemical properties. The low viscosity ester terminated NPs had the smallest size and suitable ZP 
among all the formulations. Compared with the Ab-free NPs, the functionalized PLGA NPs showed 
higher ability to recognize the CD205 receptors on DCs. The targeting efficiency of the antibody 
adsorbed high viscosity ester terminated NPs was the highest. Among all the formulations, the ligand 
attached low viscosity COOH terminated NPs could mature the DCs most with about 50 % of OVA 
released in 24 hours. In addition, ligand attached low viscosity COOH terminated NPs was also able to 
stimulate DCs to secret rational amount of cytokines. This respective formulation can be chosen to 
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conduct in-vivo vaccination experiments due to its ability to maintain all other desired physicochemical 
properties. Taken together, all results support our hypothesis that anti-CD205 Ab modified NPs are 
effective in terms of in-vitro DC stimulation with either type of polymers depending on the aim of 
treatment. However, researchers could also design the in-vivo experiments by choosing any of the PLGA 
types mentioned in this study. In future, we aim to subcutaneously inject the formulations containing 
OVA-MPLA (non-targeted and targeted) to develop the dose-response relationship in animal model. 
Therefore, this model vaccine delivery system could be adapted to design a therapeutic cancer vaccine to 
harness patient’s immune responses.  
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4.10 TABLES 
Table 4.1. Particle size, PDI, ZP, EE of coumarin-6 (%) and coumarin-6 loading (g/mg) of COOH and 
ester terminated NPs before and after Ab attachment (n=3). 
Formulation keys: SD=Standard deviation, ZP=Zeta potential, EE= Encapsulation efficiency, 
NP=Nanoparticle, Ab=Antibody, BS=BS3, C = COOH, E = Ester. 
 
Formulation  
Size ± SD 
(nm) 
 PDI ± SD  
ZP ± SD 
(mV) 
 
EE of Coumarin-
6 ± SD (%) 
 
Coumarin-6 loading 
± SD (g/mg) 
0.18C-NP  132 ± 7  0.12 ± 0.03  -8.01 ± 0.52  73.91 ± 2.87  16.78 ± 0.71 
0.55C-NP  141 ± 7  0.23 ± 0.09  -7.01 ± 0.74  75.37 ± 3.12  22.26 ± 2.20 
0.15E-NP  129 ± 4  0.24 ± 0.05  -6.02 ± 0.34  81.63 ± 0.32  23.18 ± 1.90 
0.55E-NP  137 ± 3  0.26 ± 0.03  -5.87 ± 0.54  83.13 ± 0.67  24.20 ± 3.60 
0.18C-BS-NP  121 ± 5  0.26 ± 0.03  -7.23 ± 0.11  81.90 ± 2.38  11.59 ± 0.99 
0.55C-BS-NP  143 ± 6  0.32 ± 0.03  -8.32 ± 0.19  83.83 ± 4.02  15.91 ± 0.12 
0.15E-BS-NP  144 ± 3  0.25 ± 0.04  -6.32 ± 0.11  79.18 ± 1.98  21.78 ± 0.34 
0.55E-BS-NP  162 ± 5  0.26 ± 0.06  -7.91 ± 0.26  88.13 ± 2.01  25.80 ± 1.21 
Ab-0.18C-NP  263 ± 7  0.30 ± 0.03  -2.22 ± 0.01  67.13±1.19  8.01±0.78 
Ab-0.55C-NP  340 ± 4  0.36 ± 0.05  -1.93 ± 0.18  73.75 ± 0.99  10.14 ± 0.19 
Ab-0.15E-NP  276 ± 6  0.32 ± 0.07  -2.54 ± 0.21  70.15 ± 1.25  11.26 ± 0.54 
Ab-0.55E-NP  402 ± 9  0.33 ± 0.02  -2.34 ± 0.12  71.23 ± 0.91  12.68 ± 0.44 
Ab-0.18C-BS-NP  201 ± 10  0.36 ± 0.04  -7.42 ± 0.21  70.25 ± 1.46  10.77 ± 1.84 
Ab-0.55C-BS-NP  443 ± 6  0.42 ± 0.03  -6.27 ± 0.22  72.79 ± 3.24  12.86 ± 0.54 
Ab-0.15E-BS-NP  474 ± 3  0.35 ± 0.04  -5.31 ± 0.14  64.13 ± 2.98  9.75 ± 0.62 
Ab-0.55E-BS-NP  562 ± 5  0.46 ± 0.06  -5.11 ± 0.68  69.83 ± 2.57  15.82 ± 0.27 
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Table 4.2. Particle size, PDI, ZP, EE of OVA (%) and OVA loading (g/mg) of COOH and ester 
terminated NPs before and after Ab attachment (n=3). 
Formulation 
 Size ± SD 
(nm) 
 
PDI ± SD 
 ZP ± SD 
(mV) 
 EE of OVA 
± SD (%) 
 OVA loading 
± SD (g/mg) 
0.18C-OV-NP  150 ± 5  0.22 ± 0.89  -22.55 ± 0.32  45.68 ± 1.01  63.21 ± 2.11 
0.55C-OV-NP  156 ± 2  0.21 ± 0.11  -24.76 ± 0.42  46.21 ± 3.11  62.56 ± 3.60 
0.15E-OV-NP  170 ± 6  0.32 ± 0.03  -20.11 ± 0.32  41.86 ± 0.98  67.18 ± 3.50 
0.55E-OV-NP  171 ± 3  0.31 ± 0.06  -19.11 ± 0.87  42.13 ± 2.54  70.33 ± 2.80 
0.18C-OVMP-NP  141 ± 2  0.26 ± 0.01  -19.01 ± 0.56  39.01 ± 1.35  53.11 ± 1.44 
0.55C-OVMP-NP  145 ± 5  0.32 ± 0.03  -26.21 ± 0.25  45.73 ± 2.91  59.27 ± 1.21 
0.15E-OVMP-NP  151 ± 3  0.36 ± 0.06  -19.16 ± 0.15  41.45 ± 1.46  57.16 ± 2.98 
0.55E-OVMP-NP  152 ± 6  0.21 ± 0.07  -20.01 ± 0.61  52.62 ± 5.22  62.64 ± 1.64 
0.18C-BS-OV-NP  141 ± 6  0.45 ± 0.91  -27.1 ± 0.77  38.03 ± 2.38  65.42 ± 2.90 
0.55C-BS-OV-NP  143 ± 2  0.31 ± 0.04  -24.02 ± 0.07  40.55 ± 1.25  65.91 ± 0.52 
0.15E-BS-OV-NP  144 ± 9  0.21 ± 0.07  -21.03 ± 0.55  51.12 ± 0.74  62.09 ± 0.24 
0.55E-BS-OV-NP  163 ± 8  0.31 ± 0.09  -19.1 ± 0.48  48.13 ± 0.91  68.48 ± 2.27 
0.18C-BS -OVMP-NP  156 ± 7  0.24 ± 1.20  -25.11 ± 0.44  49.10 ± 0.43  51.65 ± 0.56 
0.5C-BS -OVMP-NP  159 ± 4  0.21 ± 0.98  -24.11 ± 0.35  55.42 ± 0.21  54.11 ± 4.15 
0.15E-BS -OVMP-NP  144 ± 9  0.23 ± 0.34  -18.42 ± 0.03  56.11 ± 0.55  49.01 ± 1.33 
0.55E-BS -OVMP-NP  151 ± 2  0.36 ± 0.14  -19.45 ± 0.56  59.15 ± 1.56  51.35 ± 0.46 
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Formulation keys: SD=Standard deviation, ZP=Zeta potential, PDI=Polydispersity index, EE= 
Encapsulation efficiency, NP=Nanoparticle, Ab=Antibody, BS=BS3, C = COOH, E = Ester, 
OV=Ovalbumin, MP=Monophosphoryl lipid A. 
 
 
Ab-0.18C-OV-NP  323 ± 3  0.31 ± 0.09  1.31 ± 0.17  31.13 ± 1.10  39.91 ± 1.21 
Ab-0.55C-OV-NP  330 ± 1  0.36 ± 0.02  2.95 ± 0.18  33.75 ± 0.91  40.14 ± 0.19 
Ab-0.15E-OV-NP  376 ± 5  0.30 ± 0.17  4.54 ± 0.21  30.15 ± 1.01  32.57 ± 0.74 
Ab-0.55E-OV-NP  379 ± 2  0.30 ± 0.03  3.32 ± 0.43  30.23 ± 2.90  49.58 ± 0.47 
Ab-0.18C-OVMP-NP  413 ± 6  0.31 ± 0.9  3.13 ± 0.11  39..04 ± 1.25  42.15 ± 1.52 
Ab-0.55C-OVMP-NP  461 ± 3  0.31 ± 0.05  2.91 ± 0.34  35.53 ± 2.21  44.11 ± 1.46 
Ab-0.15E-OVMP-NP  421 ± 1  0.28 ± 0.41  2.97 ± 0.34  35.21 ± 1.15  39.16 ± 2.21 
Ab-0.55E-OVMP-NP  486 ± 4  0.34 ± 0.25  4.25 ± 0.52  42.56 ± 2.56  40.15 ± 3.11 
Ab-0.18C-BS-OV-NP  401 ± 1  0.21 ± 0.31  1.92 ± 0.01  41.46 ± 0.61  39.01 ± 0.56 
Ab-0.55C-BS-OV-NP  501 ± 9  0.23 ± 0.21  1.45 ± 0.15  40.42 ± 0.36  40.15 ± 0.62 
Ab-0.15E-BS-OV-NP  337 ± 5  0.31 ± 0.52  1.67 ± 0.01  40.46 ± 0.11  37.90 ± 0.42 
Ab-0.55E-BS-OV-NP  487 ± 3  0.21 ± 0.62  3.51 ± 0.03  45.24 ± 0.09  42.15 ± 0.55 
Ab-0.18C-BS-OVMP-NP  380 ± 1  0.31 ± 0.09  1.42 ± 0.04  29.01 ± 2.01  40.15 ± 0.91 
Ab-0.55C-BS-OVMP-NP  419 ± 4  0.29 ± 0.05  1.99 ± 0.13  34.11 ± 0.23  42.43 ± 0.55 
Ab-0.15E-BS-OVMP-NP  324 ± 3  0.31 ± 0.04  3.22 ± 0.11  36.21 ± 0.93  40.11 ± 0.21 
Ab-0.55E-BS-OVMP-NP  407 ± 9  0.39 ± 0.06  1.87 ± 0.02  39.01 ± 0.14  41.45 ± 0.91 
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4.11 FIGURES 
Figure 4.1. Graphical representation of NPs uptake by the immature DC and subsequent activation as 
well as maturation of DC followed by various cytokine production, antigen presentation, and expression 
of co-stimulatory markers.  
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Figure 4.2: Maturation study with OVA loaded NPs. A) The effect of antibody decorated PLGA NPs on 
DC uptake assessed by flow cytometry. Column (a-d): Overlay of the histograms of untreated cells (red), 
cells treated with plain NPs (green), and cells treated with Ab-modified NPs (purple) for 0.18 iv COOH 
and 0.55 iv COOH groups with and without BS3. Column (e-h): Overlay of the histograms representing 
DC uptake of 0.15 iv ester and 0.55 iv ester terminated NPs being formulated with and without BS3. 
Histograms are representative of three individual experiments. B) The bar diagram showing comparative 
fold increase in MFI of plain NPs and DCs treated with Ab-modified formulations for 0.18 iv COOH, 
0.55 iv COOH, 0.15 iv ester, and 0.55 iv ester terminated NPs respectively. MFI for different NPs has 
been compared considering untreated cells (coumarin-6 only) as 1. All the studies were done in triplicates 
(p<0.05). Formulation key: C = COOH, E = Ester, BS = BS3, AD = Adsorption, COV = Covalent. C) 
Representative overlapped CLSM images for coumarin-6 loaded NPs (0.18 iv COOH only) in DCs. Blue 
color represents the DAPI stained nuclei which are encompassed by green fluorescence for the groups 
treated with coumarin-6 loaded NPs.  
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C)  
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Figure 4.3. Cumulative percentage release of OVA from different PLGA graded NPs over time period of 
20 days. The line diagram represents the release profile of 0.18 iv COOH terminated, 0.55 iv COOH 
terminated, 0.15 iv ester terminated, and 0.55 iv ester terminated PLGA-OVA NPs in a PBS (pH 7.4) at 
37˚C. Diagrams A and B represent the initial burst release and sustained release of OVA, respectively. 
Here, n = 3, d = day, hr = hour. 
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Figure 4.4. Cell viability (MTS assay) of DCs treated for 72 hours with OVA containing PLGA NP 
formulations (n = 3). The treated NP concentration was 1 mg/ml for cell density of 10,000.  
Formulation keys: C = COOH ended PLGA, E = Ester ended PLGA, OV = OVA, MP = MPLA, AD = 
adsorption, COV = covalent. 
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Figure 4.5. Effect of CD205 antibody modified PLGA NPs on the up-regulation of CD40, CD86, and 
MHCII molecule upon DC maturation. Untreated DC was used as negative control. LPS treated DCs were 
positive control. After 24 hours incubation, non-adherent cells were harvested, stained with the antibodies 
and analyzed by flow cytometry as described in the methods section. Expression of maturation markers 
by 0.18 iv COOH (A), 0.55 COOH (B), 0.15 ester (C), and 0.55 ester (D) terminated PLGA NPs. The top 
and bottom numeric values on the histograms represent percentages of positive cells and MFI for CD40, 
CD86, and MHCII markers. Representative histograms from one of three individual experiments are 
shown here.  
Formulation keys: NP=Nanoparticle, AD=Adsorption, COV=Covalent binding, C = COOH, E=Ester, 
OV=Ovalbumin, MP=Monophosphoryl lipid A. 
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Figure 4.6. Bar diagrams representing the fold increase in MFI for DC maturation markers after treatment 
with 0.18 iv COOH (A), 0.55 COOH (B), 0.15 ester (C), and 0.55 ester (D) terminated PLGA NPs. 
Results are representative of at least three experiments.  
Formulation keys: NP=Nanoparticle, AD=Adsorption, COV=Covalent binding, C = COOH, E=Ester, 
OV=Ovalbumin, MP=Monophosphoryl lipid A. 
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Figure 4.7. Effect of OVA/OVA-MPLA NPs for cytokines secretion from mature DCs. Untreated DC 
was used as negative control. LPS treated DCs were positive control. After 24 hours incubation, DC 
culture supernatants were analyzed for IFNγ (A, B), IL-12, (C, D), IL-6 (E, F), and TNF-α (G, H) 
secretion. This figure is representative for 0.18 iv COOH, 0.55 iv COOH, 0.15 ester, and 0.55 ester 
terminated plain and anti-CD205 tailored NPs (n=3) (p<0.05).  
Formulation keys: NP=Nanoparticle, AD=Adsorption, COV=Covalent binding, C = COOH, E=Ester, 
OV=Ovalbumin, MP=Monophosphoryl lipid A, LPS=Lipopolysaccharide. 
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5.1 Brief introduction to chapter 5 
This chapter is mainly focused on evaluation of immune stimulatory response of the developed model 
vaccine. The experiments included are assessment of structural integrity of OVA for 20 days, vaccination 
of WT balb/c mice, isolation of T cells, in-vitro co-culture experiments, flow cytometry experiments to 
assess T cell proliferation, estimation of cytokines, determination of IgG levels, vaccination of OT1 mice, 
CTL (CD8) proliferation study and estimation of cytokine secretions. 
Formulations were developed by emulsification solvent evaporation method. The polymer that was 
selected for animal experiments was 0.18iv COOH terminated PLGA. Several formulations were 
developed and characterized in terms of their particle size, zeta potential, PDI, loading of OVA and EE.   
Several groups were included in the mice vaccination study. The dose-response relationship was 
established based on the results obtained from chapter 4. The animal experiments were conducted with 
OT1 mice to assess their ability to produce CTLs necessary to destroy antigens. 
In conclusion, the presence of MPLA is necessary to augment dynamic response to produce CTLs to 
destroy the cancer antigens and produce memory T cells prevent further relapse. The MPLA-OVA 
encapsulated targeted PLGA nanoparticles stands out as a promising model delivery system to provide 
clinical benefits.  
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5.2 Abstract  
 
Targeted delivery of therapeutics has the potential to localize the therapeutic agent to a target tissue with 
no side-effects. This article aims in developing a model targeted immunotherapeutic approach that will 
harness effective T cell response. Here, we investigated how ovalbumin (OVA) loaded targeted PLGA 
nanoparticle (NP) formulation impacted antigen-adjuvant exposure to the immune system. The NPs were 
prepared by double emulsification solvent evaporation technique. The anti-CD-205 targeted formulations 
were obtained either through physical adsorption or covalent conjugation method. The structural integrity 
of OVA was confirmed by circular dichroism spectroscopy. Our results indicated that the combined 
formulation induced more powerful responses than each single component formulation. Wild type (WT) 
balb/c mice immunized with the targeted PLGA NPs encapsulated with OVA-MPLA induced antigen-
specific IgG antibodies with high avidity, increased secretion of cytokines and generation of memory T 
cells. OVA specific T cell receptor (TCR) transgenic OT1 mice showed highest production of cytotoxic T 
cells (CTLs) and increased secretion of cytokines upon immunization with the targeted OVA-MPLA 
formulations. This enhanced response might be attributed to OVA depot effect at the subcutaneous site of 
injection and effective induction of dendritic cells (DCs) activation and helper T (Th) cell differentiation 
in the lymph nodes. Therefore, the PLGA based vaccine delivery system would have significant 
implications for rational vaccine design.  
 
 
 
 
Keywords: Nanoparticle, Ovalbumin, MPLA, vaccine, anti-CD205, PLGA 
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5.3 Introduction 
The idea of using patient’s immune system has advanced in clinical field only in the last decade. These 
recent advances highlight the role of immunosuppressive microenvironment in tumor progression. This 
active immunotherapy depend on patient’s immune system to recognize and destroy intended target.(1)  
The ability to show an immune response upon reinfection is the foundation of vaccination. The immune 
response is mediated by antigen specific memory T cells that can generate faster than naïve T cells.(2) 
The evolution of DC-based vaccine is promising in terms of restoring the capability of DCs to recognize 
non-self antigens. Since now, Provenge (Dendreon Corp.) is the FDA approved only cancer vaccine in 
market.(3) However, intricacies are not limited to DC subset, tumor antigens, antigen loading and route of 
administration. The ex-vivo generated DC vaccines have some pitfalls which guides towards in-vivo 
manipulated vaccines. Though, there is question regarding the targeting specificity and efficiency of these 
strategies, there are several advantages that approves the logistics of vaccine preparation for future.(4)  
Nowadays, targeted cancer vaccine utilizing an unique antigen shared by various cancer can be a strategy 
to elicit maximum coverage.(5) The strategy to load DCs with antigens and adjuvants using particulate 
delivery system is gaining tremendous popularity due to several advantages. It maintains the controlled 
arrival of antigen-adjuvant to the antigen presenting cells (APCs) to be presented on the major 
histocompatibility complex (MHC) molecules. Lastly, the extensive groundwork essential for tailor-made 
vaccine can be minimized using cost-effective, large scale production of in-vivo vaccines for large 
number of patients.(6)  
Adjuvant is a key component of ideal particulate vaccines. Modern vaccines can produce optimum 
immune response in presence of adjuvant through their combined diversity.(7) Among all the adjuvants, 
TLRs agonists have gained attention as it can be displayed on DCs. In addition, a ligand binding to this 
receptor can efficiently facilitate antigen processing, presentation as well as DC maturation.(8) Among 
the TLR agonists, MPLA have gained popularity due to its less toxicity than lipopolysaccharide (LPS). 
MPLA, a modified synthetic derivative of LPS has been shown to promote T helper (Th) cell-1 
influenced antigen specific response and used in therapeutic vaccines for several types of diseases. 
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Codelivery of OVA and MPLA will trigger the TLR pathway to generate mature DCs for inducing 
primary T cell response. The induction of T cell responses is an important aim of vaccination.(9)  
FDA approved poly (D, L-lactic-co-glycolic-acid) (PLGA) are tested delivery vehicles that can increase 
the immunogenicity of the incorporated vaccine antigens/adjuvants.(10) The present research highlights 
the use of OVA-MPLA loaded in PLGA NPs used as a delivery system.(11) The formulations were 
modified using CD-205 targeting ligand for the CD-205 receptors on DCs. This active targeting strategy 
can induce higher humoral and cellular immune responses. The activation of T cells by PLGA NPs is 
represented in figure 5.1. Consistent with other studies, these targeted NPs were able to produce strong 
immune responses upon immunization to mice model.(12), (13)  In particular, the CD8+ T cell activation 
will be monitored. Activated CD8+T cells can kill the malignant cells and acquire long-lasting memory 
preventing relapses.(14) 
The purpose of this research was to investigate the use of PLGA NPs as a vaccine delivery system to 
codeliver antigen along with MPLA for induction of potent T cell responses. The physicochemical 
properties will be linked with the biological effects to formulate the cancer vaccine.(15) First, 
physicochemical properties of 0.18 i.v. (or iv) COOH terminated PLGA NPs will be discussed. Based on 
previous in-vitro experiments on various types of PLGA viscosities (low and high) and end groups 
(ester/COOH), the most optimized delivery vehicle was selected. Subsequently, the antigen specific 
immune response was evaluated in WT balb/c mice. Assessment of T cell proliferation, serum IgG level 
and cytokine secretion profile was performed following vaccination of WT mice. Finally, immune 
response of TCR transgenic OT-1 mice derived CD8 T cell upon nano-vaccine delivery system was 
evaluated. All these experimental approaches allow us to establish a NP-dose response relationship which 
could be mimicked to explore novel cancer vaccines in future. 
5.4 Materials and methods 
5.4.1 Materials 
MPLA (molecular weight 1763.469 Da) was purchased from Avanti Polar Lipids Inc. (Alabama, USA). 
COOH terminated PLGA 50:50 (iv 0.18 dl/g and 0.55-0.75 dl/g) were purchased from Lactel, Absorbable 
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Polymers (Birmingham, AL, USA). Polyvinyl alcohol (PVA), bis (sulfo-succinimidyl) suberate (BS3), 
ovalbumin from chicken egg white (grade V), alpha minimum essential medium, fetal bovine serum 
(FBS) and bicinchoninic acid (BCA) assay kit was purchased from Sigma-Aldrich Co. (St Louis, MO, 
USA). Biotin anti-mouse CD205 monoclonal Ab (MAb) was purchased from Biolegend (San Diego, CA, 
USA). JAWSII dendritic cell line was obtained from American Type Culture Collection (ATCC), 
Manassas, VA, USA. Granulocyte-macrophage colony stimulating factor (GM-CSF) was purchased from 
Thermo Fischer Scientific (Waltham, MA, USA). CellTrace Carboxyfluorescein succinimidyl 
ester (CFSE) cell proliferation kit was purchased from molecular probes (Eugene, OR, United States). 
Anti-mouse CD16/CD32 MAb (Fc blocker), TNF-α ELISA kits and PEcy5 CD3 molecular complex were 
purchased from BD Biosciences (San Jose, CA, USA). Easysep CD3 and CD8 cell isolation kit was 
purchased from Stemcell technologies (Vancouver, BC, Canada). Endofit ovalbumin and SIINFEKL 
peptide was from InvivoGen (San Diego, CA, USA). Keyhole limpet hemocyanin (KLH) was purchased 
from EMD Millipore (ON, Canada). Murine IFNγ, IL-2 and IL-6 ELISA kits were purchased from 
eBioscience (San Diego, CA, USA). Reserve-AP Anti-Mouse IgG (H+L) Antibody, Human Serum 
Adsorbed and Phosphatase labeled was purchased from KPL Inc. (Gaithersburg, MD, USA). All other 
reagents such as ethyl acetate, methanol, sodium hydroxide (NaOH), sodium dodecyl sulfate (SDS) were 
of analytical grade. 
5.4.2 Preparation, surface modification and quantification of OVA loaded NPs 
PLGA NPs encapsulated with OVA and/or MPLA were prepared by water/oil/water double 
emulsification solvent evaporation method as mentioned elsewhere.(16) Briefly, 10 mg OVA of was 
dissolved in100 μl PBS and added to the polymer-solvent solution. For the formulations with MPLA, 200 
µg of MPLA was dissolved in 1:4 methanol-chloroform mixture was added to the polymer-solvent 
mixture. The resulting mixture was then emulsified in 2.2% of PVA to form a secondary emulsion. The 
NPs were collected after 2 hours of stirring followed by centrifugation. Finally, the NPs were freeze-dried 
and stored for further use. (17) Surface modification of NPs was performed through physical adsorption 
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and covalent binding process as mentioned previously.(18) The amount of OVA in NP formulations was 
quantified using BCA assay.(19)  
5.4.3 Assessment of structural integrity of OVA in the NP by circular dichroism (CD) 
CD spectra were recorded using Chirascan Plus CD Spectrometer (Applied Photophysics, Leatherhead, 
Surrey, UK) to assess the structural integrity of OVA in NPs. CD data were collected from 197 to 280 nm 
at a scan time of 0.5 second per point (total time per sample is 4 minutes) at 20°C using a 1mm quartz 
cuvette. Data were averaged over 3 scans and expressed as millidegrees.  Baseline was corrected for every 
sample before acquiring data. OVA solution in phosphate buffered saline (PBS) was used as the 
reference. OVA samples were collected after 20 days of incubation in PBS. The percentage of alpha-
helix, anti-parallel and parallel beta sheet, beta-turn and random coil of the secondary structure of OVA 
was estimated by CDNN software. The recorded CD spectra and the deconvolution results of the samples 
were compared to those of the standard to evaluate changes in the secondary structure of the OVA 
samples.(20) 
5.4.4 Animal experiments 
5.4.1.1 Mouse model 
WT mice (balb/c) were purchased from the Charles River International (St-onstant, Quebec, Canada). 
TCR transgenic OT1 mice (background C57bl/6) were purchased from Charles River International 
(Domain des Oncins, Germain Nuelles, France). All experiments were performed in accordance to the 
University of Saskatcheewan guidelines for the care and use of laboratory animals (protocol # 20140073). 
All experiments were performed using 8–16 week old female mice.  
5.4.1.2 Isolation and culture of murine bone marrow-derived DCs (BM-DCs) 
Primary DC were generated from murine BM-precursors from femur of mice. Briefly, femurs  of mice 
(balb/c for WT and C57BL/6 for OT1) were removed and cleaned from surrounding tissues. For 
disinfection, intact bones were put in 70 % ethanol for 2 minutes and washed with Hank’s balanced salt 
142 
 
solution (HBSS).  Later, both ends of the bone was cut with a sterile scissor and the BM was flushed from 
intact bones with PBS using an syringe. Cells were triturated, filtered (by 40 μm cell strainer) and 
collected in a 15-ml centrifuge tube. The single-cell suspension was obtained after subsequent washes 
with DC complete media (RPMI-1640 with L-glutamine and Gentamycin) supplemented with 20 ng/mL 
of GM-CSF and 10 % heat-inactivated FBS. On day 3, 10 mL of fresh DC media containing 20 ng/mL 
GM-CSF was added. At day 6, culture media was replaced by fresh media containing 20 ng of GM-CSF. 
At day 7, BM-DCs were ready for co-culture with T cells. The purity of the DCs were about 85 % based 
on the expression of CD11c. The viabilty of the cells were about 90-95 % on day 7.(21) 
 5.4.1.3 Mouse vaccination experiment 
WT balb/c mice (5 mice/group) were subcutaneously vaccinated in the right flank region with specific 
amount of NPs. Fourteen days later all mice received similar booster dose of immunization. Seven days 
after the second immunization, draining lymph nodes and spleens were isolated to perform the co-culture 
experiment for ELISA and flow cytometry. CD3+T cells were isolated as suggested by the manufacturer. 
Blood was collected by cardio-puncture after 21 days after priming. Sera isolated by centrifuge were 
stored at -200C for analysis. OVA-specific total IgG was measured by ELISA.(22) The animal groups for 
the experiments were unimmunized mice (collected T cells served as APC), free OVA, free OVMP, OV-
NP, OV-MP NP, Ab-modified OVA-NP and Ab-modified OVA-MPLA treated mice for 0.18 COOH 
terminated NP, respectively.  
 OT1 mice (4 mice/group) were also vaccinated in the comparable manner. Spleens and lymph nodes 
were collected and processed as required. CD8+T cells were isolated as described in the manufacturer’s 
protocol. The groups were control group-no treatment, free OVA, free OVMP, OV-BS-NP, OV-AD NP, 
OV-COV-NP, OVMP-BS NP, OVMP-AD NP and OVMP-COV NP.  
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5.4.1.4  Preparation of single cell suspension of the mouse splenocytes 
T cells were isolated from mice spleen after following several steps. Briefly, mouse was sacrified to 
collect the spleen in sterile condition. The washed spleen was minced through 70 µm pore size strainer. 
The collected cell suspension was washed with RPMI, 1% antibiotic, 2% glutamine and 10 % FBS 
containing complete RPMI media. The red blood cells were lysed with lysis buffer for 5 minutes. After 
that, the cell suspension washed twice and counted. Isolation of CD3+ and CD8+ positive cells were 
performed by negative selection method using the Easysep cell isolation kit as per manufacturer’s 
protocol.(23) 
5.4.1.5 T cell proliferation assay using CFSE method 
The T cells were stained with CFSE to assess the proliferation through dye-dilution. In brief,  the T cells 
were isolated from splenocytes and labeled with CFSE at a concentration of 2.5 µM. The reaction was 
quenched by adding FBS to the cell suspension. Followed by two washes, the cell count was set to 
1X106/ml. 100 µl of T cells (responders) and 100 µl irradiated (700 rad) DCs stimulators were co-cultured 
in 96-well plates. The number of T cells per well was kept constant (1X105 T cells); DC:T cell ratio was 
thus either 1:4 and 1:10. For WT mice, several other ratios (data not shown) were evaluated, although 1:4 
ratio showed the best fit. For OT1 mice, results with 1:4 ratio is mentioned in the result section. For each 
groups, DCs were plated in two different numbers (25 X103 and 10 X103).(24) FOr WT mouse, different  
DC:T cell co-culture were then pulsed with either 20 μM Ovaendofit (CD3 test protein) and 20 μM of 
KLH (irrelevant antigen). For OT1 mouse, DC:T coculture was restimulated with 1 μM of OVA257–264 
epitope (SIINFEKL, CD8 test peptide) or 1 μM of KLH (irrelevant antigen). Five days after co-culture in 
96-well plates, the cells were harvested, stained with respective antibody (CD3 or CD8) to determine the 
CFSE labeled T cell divisions by flow cytometry. Data were further analysed using Flowjo software, 
version 7.6.5  (Ashland, OR, USA).(25)  
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5.4.1.6 Determination of total IgG 
OVA-specific IgG in the serum were quantitatively determined by enzyme-linked immunosorbent assay 
(ELISA) as mentioned elsewhere.(26) Briefly, U-bottom 96 well plates were coated with 10 µg/ml of 
OVA followed by incubation at 40C overnight. The next day, plates were washed with PBST (PBS 
containing 0.05% of Tween 20) and blocked by incubating with 1 % (m/ v) BSA for 1 hour at 370C. After 
washing with PBST, 100 µl of appropriate sera dilutions were added to each well and incubated overnight 
at 40C. Next day, plates were washed and incubated with goat anti-mouse IgG (H+L)-alkaline 
phosphatase at 100 µl/well for 2 hours at 370C. Thereafter, the plates were washed again with PBST, and 
100 µl of PNPP substrate was added to each well and incubated for 20 minutes at room temperature. The 
optical density was measured at 405nm (background 490nm) by microplate reader linked with UV 
spectrophotometer (Biotek, VT, USA). 
5.4.1.7 Determination of cytokine levels by ELISA  
The supernatants from the co-culture was collected and stored at -20˚C for analysis of the level of IL-2, 
IL-6, IFNγ and TNF-α using commercially available enzyme-linked immunosorbent assay (ELISA) kits 
in a 96-well microplate using a microplate reader at 405 nm (background 490 nm) according to 
manufacturer’s directions.(27) The minimum detection levels of the cytokines were 3, 4, 15, and 15 pg/ml 
for IL-2, IL-6, IFNγ, and TNF-α, respectively.  
5.4.1.8 Statistical analysis 
The data are given as mean ± SD and statistical significance was determined by Student’s t-test. Values of 
p < 0.05 were considered statistically significant unless specifically mentioned. All data were analyzed 
using GraphPad Prism 5.03 software (GraphPad Software, Inc., La Jolla, CA, USA). Flow cytometry 
experiments were analyzed using Flowjo 7.6.5 software. 
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5.5 Results 
5.5.1 Characterization of NPs 
The 0.18 iv PLGA NPs prepared by the double emulsification solvent evaporation technique, had a 
narrow size distribution as represented in figure 5.2 (A-D). The mean size of plain OV-NP and OVMP-
NP was within 141 ± 2 nm and 156 ± 7 nm, respectively. Modified NPs were larger, due to the presence 
of encapsulated anti-CD-205 antibody. The size for OV-Ab-NP and OVMP-Ab-NPs was within 401 ± 1 
nm and 413 ± 6 nm, respectively. The incorporation of Ab in the NPs leads to a reduced surface charge of 
3.13 ± 0.11 mV compared to plain NPs with -27.1 ± 0.77 mV. The antigen loading of plain and modified 
OV-NPs and OVMP-NPs was ranged from 39.01 ± 0.56 to 65.42 ± 2.90 μg/mg of NPs.(27) 
5.5.2 Confirmation of structural integrity of OVA in NPs 
Secondary structural stability was analyzed by CD spectra of 0.18 COOH terminated PLGA NPs as 
represented in figure 5.3A and 5.3B. Figure 5.3B represents the percentages of α-helix, β-anti-parallel, β-
parallel, β-turn and random coil of the secondary structure present in free OVA, OV-NP, OV-COV-NP 
and OVMP-COV-NP samples. The results demonstrate that the release process within 20 days had no 
significant effect (p-value > 0.05) on the structural integrity of OVA when compared with the standard 
solution. 
5.5.3 In-vitro CD3+ T cell proliferation post-vaccination   
To examine the effect of NPs on T cell proliferation, CFSE dilution in OVA-specific T cells was analyzed 
after co-incubation with DCs for four days. Cell division and the percentage of cells having diluted 
fluorescent intensity was analyzed using Flowjo software as mentioned in figure 5.4A.(28) When 
restimulated with relevant Ovaendofit protein, 0.18C-OVMP-AD NPs led to a substantially high increase 
in the number of T cells undergoing division (96 %). In contrast, non-targeted 0.18C-OVMP NPs could 
induce only 87.5 % of T cell division. We observed only 41.7 % and 38 % of T cell divisions for plain 
0.18C-OV NPs and 0.18C-OV-AD NPs, respectively. Besides, T cells obtained from unimmunized mice 
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showed 0.54 % of proliferated T cells. In contrast, presence of KLH or absence of restimulation showed 
low percentages of cell divisions. Figure 5.4B (a-c) represents the bar diagrams for 0.18C-OVMP-AD 
NPs demonstrating the generations of cell divisions in presence of Ovaendofit, KLH and no restimulation.  
5.5.4 In-vitro secretion of cytokines from WT balb/c mice derived CD3 T cells and DCs  
Cytokines that are mostly produced by responder T cells in presence of irradiated DCs are IFNγ, IL-2, IL-
6 and TNF-α (figure 5.5A-5L).(28) Among seven groups (unimmunized mice, free OVA, free OVMP, 
0.18C-OV NP, 0.18C-OV-AD NP, 0.18C-OVMP NP, O.18C-OVMP-AD NP), there was significantly 
high (p<0.05) amount of cytokines secreted by 0.18C-OVMP-AD NPs upon restimulation with OVA-
relevant protein when compared with the unimmunized mice group. The amount secreted by this 
formulation was such as, IFNγ (12943.31 ± 325 pg/ml), IL-2 (1294.22 ± 16.78 pg/ml), IL-6 (1299.66 ± 
137.77 pg/ml) and TNF-α (4566.21 ± 341.11 pg/ml). Presence of MPLA in the formulation had 
significant impact on secretion of all four cytokines. 
5.5.5 Estimation of total IgG  
After 21 days of vaccination, the serum total IgG was observed as mentioned in figure 5.6. Compared to 
free OVA, all the groups produced significantly high amount of anti-OVA IgG titers (p<0.05). There was 
significant difference in IgG titer among the groups: free OVMP, 0.18C-OV NP, 0.18C-OV-AD NP, 
0.18C-OVMP NP, O.18C-OVMP-AD NP. Mice treated with 0.18C-OVMP-AD NP serum had highest 
OVA-specific IgG antibodies. This confirms that the increase in humoral immune response by this group 
could be due to presence of both OVA and MPLA in the targeted PLGA NPs.(29) 
5.5.6 In-vitro CD8+ T cell proliferation post-vaccination  
Figure 5.7 (A-C) represents the CTL cell proliferation assay from mice in the vaccination study.(30) 
Compared to unimmunized, free OVA and free OVMP vaccinated mice groups, there is significantly 
higher percentage of CFSE+CD8+ T cells in the NP groups (plain and modified) (p<0.05) (figure 5.7A).  
In presence of recall peptide SIINFEKL, the CD-205 targeted 0.18C-OVMP-AD NPs showed 98 % of  
divided CTLs in contrast to 0.18C-OVMP-COV NPs (88.9 %) (figure 5A). This is higher than the non-
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targeted formulations (61 %), but there is no significant difference between the AD-NP and COV-NP 
groups (p<0.05).  Both of these targted NPs showed antigen specific proliferation of CD8+ T cells, 
whereas restimulation with KLH showed most of the divisions limited upto generation 2 (figure 5.7B and 
5.7C). Similar trend was observed when there was no restimulation.   
5.5.7 In-vitro secretion of cytokines from OT1 mice derived CD8 T cells and DCs  
After 5 days of restimulation, cytokines were quantified by ELISA as represented in figure 5.8 (A-L). 
Upon restimulation with relevant peptide SIINFEKL, 0.18C-OVMP-COV NP induced the highest amount 
of Th1 cytokine IL-2 (1898.94 ± 111.11 pg/ml) which is significantly different from other groups except 
0.18C-OVMP-COV NPs (figure 5.8D) (p<0.05). Similar trend was observed for IFNγ and IL-6 secretion 
by 0.18C-OVMP-AD NPs upon SIINFEKL restimulation (p<0.05). Moreover, the highest level of TNF-α 
was induced by 0.18C-OVMP-AD NPs. There was significant difference in TNF-α secretion between 
0.18C-OVMP-COV NP and 0.18C-OVMP-AD NP (3862.19 ± 48.12 pg/ml vs. 2795.19 pg/ml) (p<0.05).  
In contrast, in presence of restimulation with KLH and absence of restimulation, the level of all four 
cytokine secretions was significantly low (p<0.05). The levels of targeted formulation conjugated with 
TLR ligand was significantly higher than that of non-targeted or targeted formulations (p<0.05).  (31) 
5.6 Discussion 
In this study, we analyzed the functionality of T cells by immunization with PLGA NP encapsulated with 
model antigen OVA, immune stimulatory MPLA and targeting moiety (anti-CD205 Ab). This trio-
combined PLGA NPs showed enhanced antigen presentation (mentioned in previous paper) by DCs, 
proliferation of OVA-specific CD8+ T cells and high production of type 1 cytokines. This PLGA based 
vaccine delivery sytem is promising due to its own properties.(32) 
The physicochemical properties of the model vaccine ensured batch to batch reproducibility. The small 
differences in size between different formulations demonstrated consistency of the method of preparation. 
The narrow size distribution (PDI: 0.22 ± 0.89 to 0.39 ± 0.06) along with particle size below 500 nm is 
indicative of immunogenicity of particles. Several sttudies on NPs have relvealed that size factor is not 
the only reason for the immunogenicity.(33) 
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A series of CD spectra measurements were performed to examine the secondary structure of OVA in the 
plain and modified OVA loaded PLGA NP samples. All samples indicate a high content of α-helix 
structure in proteins found in far-UV region between 208 to 222 nm.(34) The spectrum for Ab-modified 
groups showed that even after 20 days there was minimal change in the secondary structure of protein. 
The differences in the height of the spectral valleys are due to differences in concentrations of the OVA 
formulations. Therefore, the relative proportions of the secondary structures of the OVA in NP samples 
were comparable to standard (free) OVA. This indirectly confirms the application of OVA-NPs for 
biological models.(20) 
T cells were labelled with CFSE to track its offspring that are divided with half the number of 
carboxyfluorescein labelled molecules. Each cell division can be then tracked by subsequent decrease in 
fluorescence by flow cytometry.(35) The proliferation of overall T cells showed OVA specific increase in 
cell divisions which is pronounced with targeted formulation containing both antigen and adjuvant. In 
addition, T cells obtained after vaccination of WT mice with targeted PLGA NP loaded with OVA-MPLA 
when exposed to DCs produced significantly high quantity of cytokines. The effect of restimulation was 
pronounced in presence of Ovaendo, not KLH, which confirms the antigen specific response in-vitro. 
Besides, the targeted formulation (0.18C-OVMP-AD NP) effectively induced significantly highest level 
of humoral response compared to other groups. Therefore, subcutaneous application of NP vaccination 
dose induced proliferation of T cells accompanied by elevated levels of OVA-specific cytokine secretion 
as well as total IgG antibodies.(36) 
It is speculated that the antigen loaded particles possess an inherent capacity to drive CTL 
proliferation.(37, 38) We immunized OT1 mice twice to induce the activation of endogenous SIINFEKL-
specific T cells. Thus, the proliferation of antigen specific T cells was increased post vaccination. 
Compared with the PBS group, vaccination with targeted OVMP-NPs significantly increased the 
percentages of OVA specific CD8+ T cells as measured due to the restimulation with OVA257–
264 (SIINFEKL) in the context of MHCI.(25) There was a trend for increased OVA-specific CD8+ T cell 
responses in the OVMP-NP group, compared to free OVA and free OVMP. It is expected that OVA alone 
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in the absence of MPLA, does not elicit adequate T cell activation and formation of cytotoxic T cells as 
found with OV-NPs. The evaluation of cytokines produced in the co-culture indicated a strong bias 
towards Th1 phenotype, characterized by high level of IFNγ production in both WT and OT1 mice.(39) 
Most tumor associated antigens are intracellular proteins, which bind with newly synthesized MHCI 
molecules and shuttled to the cell surface for recognition by T cells. Thus, to be an effective vaccine, cell 
mediated immunity, particularly production of CTLs are most important. These CTLs can show 
cytotoxicity, secrete effector cytokines; such as IFNγ and TNF-α, which can mediate local 
inflammation.(40) The DC targeting vaccines utilizes this unique ability to stimulate CTLs to response to 
kill cancerous cells. However, a balance should be maintained between proper maturation signal and 
activating CTLs with adequate production of IL-2.(41)  
The outcomes confirm the validity of all in-vitro results as well as the usefulness of PLGA as the vaccine 
carrier. The overall formulation process is a guideline to reduce the number of components used in 
traditional vaccines. However, the efficiency of the vaccination depends on effective antigen presentation 
to T cells. Inclusion of adjuvants together with antigen in the NPs leads to increased stimulation of APCs 
as it matures to process the antigen for T cell activation.(42) Largely, the vaccination with targeted NPs 
containing adjuvant enhanced both B and T cell immune responses.(43)  
5.7 Conclusion 
We successfully generated OVA-MPLA loaded PLGA NPs as a new vaccine carrier system and 
characterized them in-vitro. Using WT balb/c and OT1 mice models for antigen-specific T cell activation, 
we showed that OVA-loaded PLGA-based NPs activated T cell and increases antigen specific T cell 
proliferation. Furthermore we observed the generation of CD8 T cells in-vitro specifically for targeted 
OVA-MPLA formulations. Covalently modified formulations showed higher percentages of 
proliferations compared to the Ab-adsorbed formulations. The results attributed that PLGA NPs protected 
the NPs in-vivo and showed both cellular and humoral response. In total, targeted formulations loaded 
with adjuvant-antigen is a suitable model for future vaccine formulations. Specifically, these NPs may 
serve as carrier for cancer-derived antigens in order to improve tumor-specific immunity. Further 
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experiments need to address when disease specific antigens will be incorporated in the PLGA NPs to 
achieve the success of vaccination in a therapeutic setting. In designing a vaccine, several facts should be 
taken in consideration to break the chance of irreversible autoimmunity. Nevertheless, the DC 
immunobiology and formulation parameters that influence the immune response will evolve; it is 
understandable that particulate based delivery systems will become a reality in future. 
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5.10 FIGURES 
 
 
 
Figure 5.1. Activation of T cells by PLGA NP based cancer vaccine. 
Abbreviations: DC, dendritic cell, PLGA, poly (D, L-lactide co-glycolide), TCR, T cell receptor, MHC, 
Major histocompatibility complex, CTL, cytotoxic T lymphocyte, NP=Nanoparticle. 
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Figure 5.2. Representative size distribution curve for particle size. (A) and (B) are size distribution curve 
by intensity and number, respectively for plain OVMP-NP. (C) and (D) are size distribution curve by 
intensity and number, respectively for modified (COV)-OVMP-NP.  
Notes: Particle size is measured by Malvern zetasizer nanoseries by DLS technique. Size is represented as 
d.nm (d=diameter). 
Abbreviations: NP=Nanoparticle, AD=Adsorption, COV=Covalent binding, OV=Ovalbumin, 
MP=Monophosphoryl lipid A. 
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Figure 5.3. CD spectra of NPs. A) Representative CD spectra of 0.18 COOH terminated PLGA NPs. B) 
Percentages of α-helix, β-anti-parallel, β-parallel, β-turn and random coil of the secondary structure for 
free OVA, 0.18C-OV-NP, 0.18C-OV-COV-NP and 0.18C-OVMP-COV-NP after 20 days in PBS media. 
(n=3) 
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Figure 5.4. T cell proliferation assay from WT mice in the vaccination study. (A) Data is represented as 
histograms and Flowjo-analyzed cell-divisions for each group. In-vitro CFSE-labelled T cells obtained 
from a specific mice group was co-cultured with irradiated primary DCs. After four days, the cells were 
harvested, washed and stained with respective antibodies to determine the number of divisions by flow 
cytometry. (B) Bar diagram representing the percentages of generations present during cell divisions 
when restimulated with 20 µM Ovaendofit (a), 20 µM KLH (b) and in presence of no stimulation (c) for 
0.18C-OVMP-AD NPs. 
Abbreviations: NP=Nanoparticle, AD=Adsorption, C=COOH terminated PLGA NP, OV=Ovalbumin, 
MP=Monophosphoryl lipid A (MPLA).  
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Figure 5.5 (A-L): Cytokine levels in the supernatants of cultured T cells from WT balb/c mice in the 
vaccination study. Notes: DCs and CD3+T cells were in a ratio of 1:4, where T cells were 100, 000 
cells/well and DCs were 25, 000 cells/well in the co-culture. After four days of incubation, the culture 
supernatants were analyzed for IFNγ (A, B, C), IL-2, (D, E, F), IL-6 (G, H, I), and TNF-α (J, K, L) 
secretion. Figure A, D, G and J are cytokine secretion in co-culture after restimulation with 20 µM of 
Ovaendo relevant protein in-vitro. B, E, H and K are cytokine secretion in co-culture after restimulation 
with 20 µM of KLH irrelevant protein in-vitro. Figure C, F, I and L are cytokine secretion in co-culture 
after no restimulation in-vitro. (n=3) (p<0.05) 
Abbreviations: NP=Nanoparticle, AD=Adsorption, C=COOH terminated PLGA NP, OV=Ovalbumin, 
MP=Monophosphoryl lipid A (MPLA).  
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Figure 5.6. OVA-specific serum IgG titer estimation SC vaccination of WT balb/c mice. Notes: After SC 
vaccination, the mice were cardio-punctured to collect blood. Blood was centrifuged to collect the serum 
from supernatant. Total IgG was measured using ELISA technique.  (n=3) (p<0.05) 
Abbreviations: NP=Nanoparticle, AD=Adsorption, C=COOH terminated PLGA NP, OV=Ovalbumin, 
MP=Monophosphoryl lipid A (MPLA).  
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Figure 5.7. T cell proliferation assay from OT1 mice in the vaccination study. (A) Data is represented as 
histograms and Flowjo-analyzed cell-divisions for each group. In-vitro CFSE-labelled T cells obtained 
from a specific mice group was co-cultured with irradiated primary DCs. After five days, the cells were 
harvested, washed and stained with respective antibodies to determine the number of divisions by flow 
cytometry. (B) Bar diagram representing the percentages of generations present during cell divisions 
when restimulated with 1 µM SIINFEKL (a), 1 µM KLH (b) and in presence of no stimulation (c) for 
0.18C-OVMP-AD NPs. (C) Bar diagram representing the percentages of generations present during cell 
divisions when restimulated with 1 µM SIINFEKL (a), 1 µM KLH (b) and in presence of no stimulation 
(c) for 0.18C-OVMP-COV NPs. 
Abbreviations: NP=Nanoparticle, AD=Adsorption, COV=Covalent binding, C=COOH, E=Ester, 
OV=Ovalbumin, MP=Monophosphoryl lipid A (MPLA).  
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Figure 5.8. Cytokine levels in the supernatants of cultured T cells from OT1 mice in the vaccination 
study. Notes: DCs and CD8+T cells were in a ratio of 1:4, where T cells were 100, 000 cells/well and 
DCs were 25, 000 cells/well in the co-culture. After five days of incubation, the culture supernatants were 
analyzed for IFNγ (A, B, C), IL-2, (D, E, F), IL-6 (G, H, I), and TNF-α (J, K, L) secretion. Figure A, D, G 
and J are cytokine secretion in co-culture after restimulation with 1 µM of SIINFEKL peptide in-vitro. B, 
E, H and K are cytokine secretion in co-culture after restimulation with 1 µM of KLH (irrelevant protein) 
in-vitro. Figure C, F, I and L are cytokine secretion in co-culture after no restimulation in-vitro. (n=3) 
(p<0.05) 
Abbreviations: NP=Nanoparticle, AD=Adsorption, C=COOH terminated PLGA NP, OV=Ovalbumin, 
MP=Monophosphoryl lipid A (MPLA).  
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Chapter 6 
6. General discussion, future directions and conclusions 
6.1. General discussion 
Although the discussions specific for Chapters 3-5 have been made, the intent of this chapter is to provide 
an overall discussion of the thesis work. The overall goal of the project was to understand the relationship 
between NP structure and activity, and address the key questions. This will in term direct to determine the 
best featured criteria for a targeted cancer vaccine.  
Chapter 3 was about developing the best suitable method to prepare PLGA NPs. Emulsification solvent 
evaporation method was used to prepare NPs. Several modifications such as change in PVA 
concentration, switching between solvent types, modification in sonication time and amplitude, 
modification in centrifugation time and speed were performed based on trial and error method. Two 
solvents were employed to prepare NPs, from which ethyl acetate was chosen as the best one for further 
experiments. The next step was to select a suitable cryoprotectant from sucrose and trehalose. Sucrose 
was most suitable when the reconstitution of the nano-suspension was done. Formulations having 
cryoprotectant provided aggregation free colloidal dispersion. Several parameters were evaluated to 
obtain NPs with physicochemical properties. The major challenge of designing PLGA based targeted 
system was the ability to conjugate the anti-CD-205 Ab to the NPs. The non-covalent adsorption method 
was a simple process.(1) But the covalent bonding between the ligand and the BS3-NPs necessitate 
confirming by IR spectroscopy.(2) A proportional relationship between NP size and viscosity was 
observed for both plain and modified NPs. However, no significant relationship was observed between 
terminal group of PLGA and physicochemical properties. In addition, no significant correlation could be 
featured to compare the antibody loading through either of the methods (adsorption and covalent 
attachment). In conclusion, formulations prepared with ethyl acetate were promising for NP preparation 
and was further utilized in ex-vivo experiments. 
179 
 
Chapter 4 was based on the targeting efficiency assessment and expression of maturation markers on 
DCs. Formulations were developed with coumarin-6 fluorescent dye to assess the uptake of NPs by DCs. 
The mechanisms involved here was either phagocytosis or receptor mediated endocytosis.(3) Flow 
cytometry experiment with fluorescent dye loaded NPs showed that the ligand modified formulations 
were better uptaken by DCs when compared with the non-modified ones. High viscosity ester and COOH 
terminated coumarin-6 loaded NPs had higher uptake (AD>COV) which could be attributed due to higher 
amount of ligand loading on the NPs, though there was no significant difference in ligand loading on NPs. 
Another reason could be higher level of coumarin-6 loading in high viscosity grades contributed to 
greater MFI by those NPs. Maturation study of DCs demonstrates that ligand modified OVA-adjuvant 
loaded NPs performed higher upregulation of maturation markers.  Though, the loading of OVA was 
higher in high viscosity grade polymers (ester or COOH terminated), the expression of markers were 
comparatively lower compared to low viscosity formulations. This could be attributed to less OVA 
release from the PLGA network. When evaluating the release pattern of OVA in the media for 20 days, a 
biphasic pattern was observed.  The low viscosity PLGA NPs were found to release 50% of OVA within 
24 hours (COOH ended) and 7 days (ester ended). About 14 days were required to release 50 % of OVA 
from the high viscosity PLGA NPs (both COOH and ester, where COOH>ester). Formulations had 
suitable physicochemical properties with 79-93% of cell viability after 3 days. In addition, sufficient 
secretion of T helper cell 1 (Th1) and Th2 cytokines was observed. This confirmed the maturation of 
DCs. Treatment of DCs with MPLA containing NPs released higher amount of Th1 cytokines (IFN-γ, IL-
12, IL-2) than control groups.  All the above results justify the successful delivery of targeted NP vaccine 
system in-vitro to assess their targeting efficiency and DC stimulatory immune response.  
Chapter 5 describes the potentiating of antigen-specific immune response by targeted NPs during the 
vaccination study. The formulations developed (chapter 4) were assessed to observe their capability to 
stimulate T cells in-vivo. Three weeks’ vaccination regimen was designed where WT mice were 
vaccinated twice. At the end of three weeks, spleens and lymph nodes were collected to co-culture T cells 
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with DCs. The co-culture was exposed to recall antigen, irrelevant antigen and no stimulation. It was seen 
that in presence of recall (relevant) antigen, the T cells had higher proliferation. In addition, sufficient 
quantity of cytokines was secreted in the DC: T cell microenvironment. All the four polymeric groups 
(low viscosity ester, high viscosity ester, low viscosity COOH and high viscosity COOH NPs) were 
evaluated for the T cell proliferation experiment. However, among all low viscosity COOH terminated 
OVA-PLGA NPs were most promising. The level of IgG secreted by several groups of low viscosity 
COOH terminated OVA loaded PLGA NPs was also high. The results obtained so far were indicative for 
further experiments to be carried out in OT1 mice. With 20 times lower dose of recall antigenic peptide 
SIINFEKL, the proliferation was higher than the WT mice. The proliferation of CD8+ T cells was most 
prominent when both OVA and MPLA are present in the formulations. The percent of CD8+ T cell 
proliferation and cytokine secretion by the targeted NPs confirmed the antigen-specific immune 
responses.  
A systematic conclusion was drawn based on the observations. The following results could be concluded:  
A. Effect of polymer viscosity  
• A proportional relation was observed between polymer viscosity and the particle size. This was 
observed for both ester- and COOH- terminated polymers. 
• Zeta potential value did not show any significant relation with polymer viscosity. 
• High viscosity grade PLGA NPs showed slightly higher viability percentage. However, there was 
no significant difference in viability percentage for the OVA loaded NPs ester and COOH 
terminated NPs. 
• A proportional relation between coumarin-6 loading and polymer viscosity of PLGA was 
observed, but it was not statistically significant. 
• With increase in polymer viscosity the DC uptake also increased. Uptake was highest with the 
high viscosity ester terminated NPs. 
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• An inversely proportional relation was observed between polymer viscosity and the release of 
OVA over the specified time. 
• With increase in viscosity the OVA loading increased, but it was not significant. 
• Low viscosity formulations showed comparatively higher DC maturation than the high viscosity 
PLGA NPs. 
• Low viscosity 0.18C-PLGA NPs showed higher secretion of IL-12, IL-6 and IFN-γ. And, 0.55C-
PLGA NPs showed higher secretion of TNF-α in in-vitro stimulated DC media. 
• Low viscosity COOH terminated NPs showed higher proliferation of CD3+T cells and cytokine 
secretion in-vitro compared to other groups 
B. Effect of polymer type  
• When comparing polymer type, the COOH-terminated polymers (low and high viscosity) 
provided smaller particles compared to ester-terminated polymers.  
This was not the case for OVA/OVA-MPLA loaded NPs. There was no correlation between 
particle size and polymer type.  
• Zeta potential value did not show significant relationship with the polymer type (ester/COOH), 
though COOH terminated NPs had slightly higher negative charge. 
• There was no significant change in viability percentage of DCs for different type of polymers.  
• Coumarin-6 loading was not affected by polymer type. 
• OVA loading was not affected by polymer type. 
• Ester terminated targeted NPs had the highest uptake compared to targeted COOH terminated 
NPs. 
• COOH terminated OVA loaded NPs showed comparatively higher OVA release than ester 
terminated NPs. 
• DC maturation and polymer type did not show any correlation. 
• There was no correlation between cytokine secretion in-vitro from stimulated DCs. 
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• COOH terminated NPs showed comparatively higher proliferation of CD3+ T cells than the ester 
terminated NPs. 
C. Effect of antibody attachment method 
• Covalently attached low viscosity COOH and ester terminated PLGA NPs resulted in smaller 
particle size compared to high viscosity polymers. Though the antibody loading between these 
groups was not significantly different. For the OVA-MPLA NPs same trend was observed. 
Whereas, for OVA-NPs the Ab-AD groups had smaller size than the Ab-COV groups. 
• Zeta potential and antibody loading was not correlated. 
• Zeta potential did not show any significant relation with bonding type. 
• Bonding type has no significant effect on DC viability. 
• Coumarin-6 loading had no significant relationship with bonding type. 
• OVA loading had no significant relationship with bonding type. 
• DC uptake of NPs increased when they were modified with anti-CD-205 antibody. 
• Ab-adsorbed groups showed higher uptake than the covalently attached Ab-NP except 0.15E-
NPs. 
• Ab-adsorbed groups showed better maturation than the covalently attached Ab-NP. 
• Ab-modified groups had higher secretion of cytokines compared to the non-modified groups. 
• Ab-modified groups showed higher proliferation of both CD3+ and CD8+ T cells in in-vitro. 
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6.2 Future directions 
Based on the mentioned outcomes, the objectives of this research were successful. The physicochemical 
properties of the NPs were suitable for subcutaneous delivery of this model vaccine. Simulation of 
formulation parameters can be performed by other researchers in future. In future, some extension of this 
experiment can be continued as follows: 
i) Assessment of CD4 and CD8 T cell proliferation in WT mice  
ii) Estimation and comparison of Th1 and Th2 CD4 cytokines  
iii) Use of TLR4 knockout mice to observe the role of adjuvant in the PLGA carrier-OVA-MPLA tri-
combination 
iv) Granzyme and perforin expression in OT1 mice can be determined by flow cytometry using anti-
human perforin and anti-human granzyme B antibodies 
v) Assessment of CD4 effect in OT2 mice 
vi) Experiments can be designed to load cancer antigens in the NPs with subsequent vaccination of mice 
followed by tumor challenge. Tumor growth can be monitored after booster dose of vaccine. Tumor 
size can be measured several times in a week using a slide caliper. Tumor volume can be estimated 
according to the formula: Tumor volume=0.5 X length X width2 
vii) Intracellular cytokines (IFNγ, IL-4) can be determined by flow cytometry staining  
Therefore, critical factors like particle size, polymer degradability, adjuvant effect needs to be optimized 
during every step of development of nanocarriers capable of delivering the antigen. In general, it can be 
said that for effective antigen delivery to the DCs, detailed understanding of the three components 
(antigen, adjuvant and targeting moiety) of the delivery system is necessary to ensure batch to batch 
reproducibility. 
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6.3 Conclusion 
Overall, a comprehensive evaluation of effect of formulation parameters was performed in this project. 
PLGA was evaluated in terms of its terminal group and viscosity to select the best suitable formulations 
to determine the dose-response relationship. Low viscosity COOH terminated PLGA NP was found to 
produce competitive immune response both in-vitro and in-vivo. These findings would be insightful when 
designing a vaccine for a specific type of cancer. In conclusion, the findings confirm that PLGA NPs 
carrying cancer antigens will be able to produce antigen specific immune responses. This response could 
be generalized to any type of cancer depending on the antigen loaded in NPs, which could be considered a 
vaccine for a wide range of cancer types. Yet, the understanding of DC immunobiology and formulation 
parameters that influences the immune response will evolve; it is obvious that particulate based delivery 
systems will become a reality in near future. 
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Appendix A 
A.1 Development and characterization of TMRD loaded NPs 
TMRD loaded NPs were prepared by double-emulsification solvent evaporation method. TMRD is 
soluble in PBS and dissolved in the first aqueous phase. Sonication of the primary W/O phase provided a 
better nano-emulsion formation. Second sonication enhanced mixing the secondary aqueous phase (PVA) 
with the primary emulsion. The NPs were collected following washing the free PVA, which provided a 
white to light pink color. The NP preparation scheme is given in figure A.1. 
 
 
 
 
 
 
 
Figure A.1. Preparation scheme of TMRD loaded NPs 
Tables A.1 summarize the characterization of TMRD loaded NPs in terms of their particle size, PDI and 
ZP. Plain NPs were prepared for all the PLGA categories (low and high viscosity) as the control groups. 
NPs containing cryoprotectants were prepared for only low viscosity (0.18 i.v. COOH and 0.15 i.v. ester) 
PLGA groups. Particle aggregation after freeze-drying was minimized using sucrose as a cryoprotectant. 
All the formulations as prepared for coumarin-6 loaded NPs were not formulated due to poor loading of 
Dissolve TMRD in PBS(aqueous phase), 
Dissolve PLGA in ethyl acetate (oil phase)
Now add aqueous phase to oil phase to get O/W 
emulsion 
Then add 2.2 % PVA to this phase to obtain 
W/O/W double-emulsion
Wash the PVA by centrifugating twice
Then freeze-dry the obtained NPs (add sucrose 
before freeze-drying if necessary) 
Store at -20 degree celcius after drying
Sonication 
Sonication 
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water-soluble TMRD. Some selected formulations were prepared with numbers of replicates before 
changing the fluorescent tag for preparing NPs for the uptake studies. 
Table A.1: TMRD loaded COOH-terminated NPs prepared using method 2 (n=3) 
Formulation Recovery Particle size (nm) PDI ZP (mV) 
% BFD AFD BFD AFD BFD AFD 
0.18C-NP 46 % 132±2 208±6 0.23±0.01 0.20±0.01 -17.78±0.43 -3.16±0.20 
0.18C-NP+S 54 % 136±7 187±9 0.27±0.05 0.17±0.02 -10.32±0.52 -2.72±0.34 
0.55C-NP 49 % 149±3 894±33 0.11±0.02 0.65±0.03 -12.78±0.42 -0.93±1.49 
0.55C-NP+BS3 51 % 135±1 523±3 0.23±0.01 0.35±0.01 -5.06±0.32 -1.42±0.03 
0.15E-NP 55% 150±3 759±23 0.19±0.02 0.54±0.05 -5.66±0.32 -4.01±0.04 
0.15E-NP+BS3 54 % 163±4 432±4 0.19±0.01 0.43±0.02 -9.88±0.34 -5.53±0.29 
0.15E-NP+S 52% 167±5 322±21 0.17±0.01 0.23±0.08 -5.9±0.25 -3.42±0.04 
0.55E-NP 56% 148±3 553±6 0.14±0.01 0.32±0.09 -10.9±0.43 -3.48±0.83 
Notes: Data are represented as mean±SD 
Abbreviations: BFD= before freeze-drying, AFD=after freeze-drying, PDI=polydispersity index, 
C=COOH terminated PLGA, NP= Nanoparticle, ZP= Zeta potential, E=Ester terminated PLGA, 
S=Sucrose 10 % 
 
A.2 Characterization of antibody modified TMRD NPs 
Table A.2 contains BCA assay data for antibody modified NPs. COOH terminated and ester terminated 
NPs showed 3.12±0.23 and 3.31±0.43 μg of antibody per mg of NPs, respectively. These are the primary 
formulations selected to prepare antibody modified NPs.  Antibody loading in the NPs were in reasonable 
range (2-3 μg/per of NP). The next step was to load TMRD in the NPs and determine the percentage of 
loading and EE. 
187 
 
Table A.2: Antibody attachment on TMRD loaded NPs prepared using method 2 (n=3) 
Formulation Particle size 
(nm) 
PDI ZP 
(mV) 
EE of Ab 
(%) 
Ab loading 
(g/mg of NP) 
0.18C-NP 476±78 0.430±0.06 -4.02±0.10 72.12 % 2.89±0.87 
0.18C-NP+S 421±13 0.255±0.02 -2.08±0.16 65.29% 3.12±0.23 
0.55C-NP 511± 12 0.229±0.09 -3.01±0.11 73.23 % 3.11±0.34 
0.55C-NP+BS3 145±1 0.157±0 -2.89±0.24 69.92 % 3.01±0.25 
0.15E-NP 667±12 0.487±0.08 -5.79±0.21 68.45 % 3.31±0.43 
0.15E-NP+BS3 452±11 0.279±0.03 -11.28±0.54 70.45 % 3.16±0.15 
0.15E-NP+S 324±14 0.238±0.07 -0.60±0.11 68.13 % 2.75±0.47 
0.55E-NP 529±21 1.45±0.06 -2.90±0.64 63.22 % 2.91±0.45 
Notes: Data are represented as mean±SD 
Abbreviations: S= Sucrose (10%), PDI=polydispersity index, C=COOH terminated PLGA, E=Ester 
terminated PLGA, NP= Nanoparticle, ZP= Zeta potential, EE= Encapsulation efficiency, Ab=anti-CD205 
antibody 
 
A.3 TMRD loading and encapsulation efficiency 
2 mg of TMRD-loaded NPs was dispersed in 5.0 ml of 0.1 M NaOH solution containing 5% (w/v) 
sodium dodecyl sulphate (SDS). This mixture was stirred for 24 hours in dark at room temperature until a 
completely clear solution was obtained. The fluorescence intensity was measured at emission wavelength 
of 582 nm using a fluorescent spectrophotometer with a microplate reader. Analyses were performed by 
comparing the fluorescence intensity of each sample to a calibration curve obtained from standard 
solutions of TMRD in 0.1M NaOH containing 5% (w/v) SDS. (1) 
Table A.3 represents the loading and encapsulation efficiency of TMRD in plain and antibody-modified 
NPs. It was observed that only 1.78±0.22 to 3.01±0.29 μg of TMRD was loaded per mg of plain NPs. 
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Besides, for antibody-modified NPs it was 1.22±0.85 to 2.29±0.87 μg of TMRD loaded per mg of 
modified NPs. This low amount of TMRD loading was further confirmed by fluorescence microscopy 
images of NPs. Figure A.2 shows presence of low amount of TMRD in the formulations when observed 
under fluorescence microscope. 
Table A.3: TMRD loading and encapsulation efficiency in NPs (n=3) 
Notes: Data are represented as mean±SD 
Abbreviations: S= Sucrose (10%), PDI=polydispersity index, C=COOH terminated PLGA, E=Ester 
terminated PLGA, NP= Nanoparticle, ZP= Zeta potential, EE= Encapsulation efficiency 
 
Without antibody With antibody 
Formulation EE of TMRD 
(%) 
TMRD loading 
(g/mg of NP) 
EE of TMRD 
(%) 
TMRD loading 
(g/mg of NP) 
0.18C-NP 40.2 % 2.45±0.21 31.22 % 1.49±0.09 
0.18C-NP+S 31.23 % 2.23±0.18 28.40 % 1.22±0.85 
0.55C-NP 45.72 % 3.01±0.29 30.10 % 2.29±0.87 
0.55C-NP+BS3 21.48% 1.78±0.22 23.56 % 1.67±0.60 
0.15E-NP 32.57 % 2.46±0.69 29.21 % 2.01±0.22 
0.15E-NP+BS3 23.11 % 1.99±0.51 33.59 % 1.56±0.17 
0.15E-NP+S 33.14 % 2.23±0.18 27.22 % 1.55±0.42 
0.55E-NP 25.99 % 2.32±0.09 22.11 % 1.34±0.04 
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Figure A.2. Fluorescence microscopy images of TMRD loaded 0.18 COOH terminated PLGA NPs at 
magnification of 10,000 X 
A.4 DC uptake study with TMRD loaded NPs 
For this study, TMRD loaded NPs were used to evaluate their uptake by JAWSII (DC) cell lines. TMRD 
loaded NPs did not show any significant change in fluorescence which indicated poor uptake by DCs. 
This might be due to the low TMRD in NPs, which was previously confirmed by percentage of TMRD 
loading in NPs and fluorescent microscopy images.  
Figure A.3 shows the fluorescence intensity changes between untreated and treated cells. The 
fluorescence intensity was measured for a standard number (10,000) of live cells. The MFI between 
treated and untreated groups was not significant.  
10 µm 20 µm 10 µm 
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Figure A.3. DC uptake study with TMRD loaded PLGA NPs. 
Notes: Dot plots and histograms in left panel represent untreated DCs, middle panel for 0.18C-TMRD-
NPs and right panel for 0.18C-TMRD-AD NPs. Histograms show single color analysis of fluorescence. 
Numbers at the corner of histogram shows the percentage of positive cells for TMRD NPs and MFI. This 
is representative from triplicate. 
 
A.5. Discussion on Appendix A 
The preparation of NPs loaded with TMRD was successful. The issue was lower loading of TMRD below 
the detection level in flow cytometry. This could be attributed to various reasons as mentioned below: 
• TMRD leaking  
• Weak support by the secondary aqueous phase (W1/O/W2) 
• Use of ethyl acetate (polar solvent) 
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Despite of all these shortcomings, the ultimate solution was using a different fluorescent dye, strong 
support by the secondary aqueous phase or increasing PVA concentration and using of non-polar solvent, 
e.g. chloroform, dichloromethane.  
Use of ethyl acetate, which is a polar solvent was continued for experiments with coumarin-6 dye. 
Coumarin-6 is soluble in ethyl acetate, so there is no need to change the concentration of the PVA (outer 
aqueous phase). Therefore, the chance of dye leaking was minimized. A dye which is soluble in organic 
phase will preferably remain in that phase along with PLGA. Evaporation of organic solvent will keep the 
coumarin-6 loaded in PLGA matrix, which is independent of the concentration of PVA. Therefore, an 
alternate fluorescent dye was used which could easily solubilise in ethyl acetate. Thus, NPs encapsulating 
coumarin-6 were further formulated to investigate the DC uptake.  
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Appendix B 
B.1 Fluorescence microscopy images with coumarin-6 loaded PLGA NPs 
Coumarin-loaded NP suspension observed under fluorescence microscope confirmed the presence of dye 
(figure B.1). This is a qualitative confirmation of presence of higher amount of coumarin-6 compared to 
TMRD.
 
Figure B.1. Fluorescence microscopy images of TMRD loaded 0.18 COOH terminated PLGA NPs at 
magnification of 10,000 X and 40, 000 X 
B.2. Intracellular localization of coumarin-6 loaded PLGA NPs visualized by fluorescence 
microscopy 
Fluorescence microscopy images were performed with coumarin-6 loaded PLGA NPs. This experiment is 
a complementary experiment that provides a qualitative assessment of the uptake of the NPs by DCs. On 
the day of sample preparation, cover slips of adhered cells were washed twice with ice-cold PBS and 
fixed with 4% paraformaldehyde. After that, the fixed cells were washed twice again with ice-cold PBS 
and the nuclei of the cells were counterstained with gold anti-fade reagent with DAPI prior to subject in 
the microscope. Figure B.2 represents the images for untreated and treated groups. 
 
1 µm 1 µm 
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Figure B.2. Representative single stained (CD11c FITC) and double-stained (CD11c FITC and DAPI) 
fluorescence microscopy images for 0.18C-Cou-NPs. Notes: A) Untreated DCs, B) 0.18C-Cou-NPs, C) 
Green channel                              Merge 
20µm 20µm 
20µm 20µm 
20µm 
20µm 20µm 
20µm 
Cells only 
Plain NPs 
 NP-COV 
NP-AD 
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0.18C-Cou-AD NPs, and D) 0.18C-Cou-COV NPs.  Blue color represents the DAPI stained nuclei which 
are encompassed by green fluorescence for the groups treated with coumarin-6 loaded NPs. 
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Appendix C 
C.1 Maturation study of DCs with CpG as adjuvant 
To do the maturation study, the formulations contain the ovalbumin as a model antigen. The presence of 
foreign antigen will initiate the immature DCs to mature and trigger the upregulation of DC maturation 
markers. In order to potentiate and modulate the immune response an adjuvant, cytosine triphosphate 
guanine (CpG), was also added to the formulation loaded with OVA to compare with OVA-NPs. These 
NPs were prepared by W/O/W double emulsification solvent evaporation method. The formulations had 
high loading and encapsulation of OVA. Table C.1 contains the particle size, PDI, ZP, OVA EE and 
loading of OVA for low viscosity (0.18 iv) COOH terminated NPs. Standard curve equation in figure C.1 
was used to determine the OVA content in NPs. 
Table C.1. Particle size, PDI, ZP, EE of OVA (%) and OVA loading (g/mg) of 0.18 iv COOH 
terminated PLGA NPs before and after Ab attachment (n=3) 
Notes: Data are represented as mean±SD 
Abbreviations: S= Sucrose (10%), PDI=polydispersity index, C=COOH terminated PLGA, NP= 
Nanoparticle, ZP= Zeta potential, EE= Encapsulation efficiency, AD=Adsorption, OV=Ovalbumin 
 
Formulation 
 Size ± SD 
(nm) 
 
PDI ± SD 
 ZP ± SD 
(mV) 
 EE of OVA 
± SD (%) 
 OVA loading 
± SD (g/mg) 
0.18C-OV-NP  170±35  0.31±0.12  -22.45±0.13  50.64±1.67  75.2±2.98 
0.18C-OV+S NP  153±7.56  0.30±0.26  -20.75±0.31  51±1.22  42.1±1.24 
0.18C-OV- AD NP  543±23  0.48±0.23  -15.01±0.24  44.65±0.43  46.4±4.44 
0.18C-OV- AD+S NP  327±11  0.31±0.71  -10±0.33  45.23±0.61  40.54±2.67 
0.18C-OV-CpG+S NP  155±21  0.29±0.34  -21.38±0.61  40.34±1.43  35.22±2.56 
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Figure C.1. Standard curve of Ovalbumin in 0.1 M NaOH containing 5% (w/v) SDS. The absorbance of 
samples and standards were measured at 562 nm in a 96 well plate with microplate reader. 
In order to observe the maturation of DCs following the treatment with NP-antigen-adjuvant combination, 
this study was conducted. Flow cytometry analysis was conducted to investigate the upregulation of 
CD40, CD86 and MHCII molecules.  After 24-hour incubation of cells treated with the formulations, cell 
suspension of specific number (2X105 cells/ml) was incubated with titrated amount of anti CD40, CD86 
and MHCII with PE conjugated second antibodies. The isotype control of each antibody was used to 
measure the background fluorescence intensity for the relevant antibody. The gate for FACS analysis was 
set in such a way to represent the live cells. Figure C.2 represents the upregulation of maturation markers 
on DCs after 24 hours. 
In figure C.2, the upregulation of CD40 marker for sucrose containing plain and modified NPs show 1.2 
and 1.7 times increase in expression of CD40 compared to untreated cells, respectively. Figure C.2 shows 
2.2 and 2.4 times increase in expression of CD86 on DC surface following the treatment with plain and 
antibody modified formulation, respectively. For CpG containing NPs the expression of CD86 and CD40 
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was not very significant. This could be attributed to the low loading of CpG in the NPs. Similarly, for 
MHCII molecules, the upregulation was 2.7 times for plain OVA containing NPs. In contrast, it was only 
two times for antibody-modified and CpG containing NPs. Thus, the NPs had poor ability to mature DCs 
when water-soluble CpG adjuvant was loaded. These results helped us to use an organic solvent soluble 
adjuvant (MPLA) to be used in the formulations. 
 
Figure C.2. Bar diagrams representing the fold increase in MFI for DC maturation markers after treatment 
with 0.18 iv COOH terminated PLGA NPs. Results are representative of at least three experiments. 
Figure C.3 is a representation of expression of CD86 marker for untreated as well as treated DCs. The 
percentage of positive cells increased for plain NPs when compared with untreated cells. Moreover, when 
plain NPs were compared with antibody modified NPs, the percentage of positive cells did not increase 
but the MFI increased to 50.86 from 26.25. Similar dot plot and histograms were also obtained for CD40 
and MHCII molecules (data not shown). 
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Figure C.3. Representative dot plot and histograms for 0.18C-OV-NPs. Notes: Effect of CD205 antibody 
modified PLGA NPs on the up-regulation of CD86 upon DC maturation. Untreated DC was used as 
negative control. After 24 hours of incubation, non-adherent cells were harvested, stained with the 
antibodies and analyzed by flow cytometry as described in the methods section. The top and bottom 
numeric values on the histograms represent percentages of positive cells and MFI for CD86 markers.  
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Appendix D 
D.1 Maturation study with adjuvant MPLA loaded OVA NPs in presence of BS3 
Chapter 4 contains flow cytometry data for formulations with no BS3. The formulations with BS3 are 
represented here. 
According to figure D.1 (A-D), the upregulation of maturation markers in different treatment groups 
indicate DC maturation. Specifically, CD86 and MHCII molecules were showing consistent upregulation 
in all the formulations. However, the higher expression of CD40 was found to vary between targeted and 
non-targeted NP groups. Therefore, it can be concluded that the presence of TLR4 ligand MPLA 
triggered the expression of the markers. This synthetic lipid induces strong protective Th1 based 
immunity with secretion of pro-inflammatory and inflammatory mediators.  
Figure D.2 represents the cytokine secretion profile by four PLGA NP groups that contains BS3. There is 
significant difference in the cytokine secretion level by anti-CD205 Ab modified formulations compared 
to the control (Cells only and free OVA) (p<0.05).  
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Figure D.1. Bar diagrams representing the fold increase in MFI for DC maturation markers after treatment 
with 0.18 iv COOH (A), 0.55 COOH (B), 0.15 ester (C), and 0.55 ester (D) terminated PLGA NPs 
containing BS3. Results are representative of at least three experiments. 
Notes: Results are representative of at least three experiments. Fold increase in both cell types was 
calculated considering MFI of untreated cells (CD40 stained) as control. Each bar represents the mean % 
± SD (n=3). 
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Figure D.2: Effect of OVA/OVA-MPLA NPs for cytokines secretion from mature DCs. After 24 hours of 
incubation, DC culture supernatants were analyzed for IFNγ (A, B), IL-12, (C, D), IL-6 (E, F), and TNF-α 
(G, H) secretion. This figure is representative for BS3 containing 0.18 iv COOH, 0.55 iv COOH, 0.15 
ester, and 0.55 ester terminated plain and anti-CD205 tailored NPs (n=3) (p<0.05). 
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Appendix E 
E.1 CD spectra of OVA loaded 0.15 iv ester terminated PLGA NPs  
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Figure E.1 A) Representative CD spectra of 0.15 ester terminated PLGA NPs. B) Percentages of α-helix, 
β-anti-parallel, β-parallel, β-turn and random coil of the secondary structure for free OVA, 0.15E-OV-NP, 
0.15E-OV-COV NP and 0.15E-OVMP-COV NP after 20 days in PBS media. (n=3) 
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Appendix F 
F.1 T cell proliferation study  
F.1.1 Assessment of proliferation with WT balb/c mice by CFSE method 
 
DC and T cell co-culture was assessed with a starting cell number of T cells (1X106) and DCs (2X105) for 
96 hours. CFSE method was employed to analyze the proliferation of overall T cells.  T cells were stained 
with fluorescent dye CFSE to observe for 4 days. The formulations mentioned here are 0.18 COOH 
terminated, 0.55 COOH terminated, 0.15 ester terminated and 0.55 ester terminated NPs with OVA and 
MPLA. The restimulation of the WT mice isolated CD3+T cells with relevant protein (OVAendofit, 
20µM) and irrelevant protein (KLH, 20µM) was performed during co-culture (day1). 
Figure F.1 (A) represents the histogram for free OVA and free OVMP treated groups. The unimmunized 
mice show no (0 %) proliferation after 96 hours. IL-2 re-stimulated mice showed 57.1 % cells to be 
divided with generations (seven) distributed in all stages. Free OVA treated mice T cells showed most of 
its population in generation ‘zero’ even after re-stimulation. This was also reflected in cytokine secretion 
profile. Free OVMP treated mice showed about 51 % divided population within 4 days. There was 
significant increase in CFSE+CD3+ (96.5 %) in Ovaendo re-stimulated population compared to its non-
stimulated group (50.6%). Besides, free OVA (Ovaendo), free OVA (KLH), free OVA (No Ag), and free 
OVMP (Ovaendo), free OVMP (KLH), free OVMP (No Ag) showed 14.9 %. 8.77 %, 1.56 %, 50.9 %, 
15.5 % and 6.54 % proliferating cells, respectively. 
The percent divided by 0.18C-OV NP (KLH), 0.18C-OV NP (No Ag), 0.18C-OVMP NP (KLH), 0.18C-
OVMP NP (No Ag), 0.18C-OV-AD NP (KLH), 0.18C-OV-AD NP (No Ag), 0.18C-OVMP-AD NP 
(KLH), 0.18C-OVMP-AD NP (No Ag) was 46.4 %, 55 %, 1.93 %, 3.22 %, 39.1 %, 43.4 %, 5.18 % and 
2.95 %, respectively. 
The percent divided by 0.55C-OV NP (Ovaendo), 0.55C-OV NP (KLH), 0.55C-OV NP (No Ag), 0.55C-
OVMP NP (Ovaendo), 0.55C-OVMP NP (KLH), 0.55C-OVMP NP (No Ag), 0.55C-OV-AD NP 
(Ovaendo), 0.55C-OV-AD NP (KLH), 0.55C-OV-AD NP (No Ag), 0.55C-OVMP-AD NP (Ovaendo), 
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0.55C-OVMP-AD NP (KLH), 0.55C-OVMP-AD NP (No Ag) was 12.8 %, 6.54 %, 6.81 %, 15.3 %, 8.87 
%, 8.74 %, 13.9 %, 10.7 %, 10.8 %, 15.2 %, 5.39 % and 4.76 %, respectively. Similarly, histograms in 
figure 59 (I-IV) follows the same trend. This represents histograms for 0.55C-OV-BS-NP, 0.55C-OVMP-
BS-NP, 0.55C-OV-COV-NP AND 0.55C-OVMP-COV-NP treated groups. 
Figure F.1 (E) represents the histograms for 0.15 ester OVA and OVA-MPLA NPs. 0.15E-OVMP-NP 
shows higher distribution of cells in different generations in presence of relevant antigen. Whereas, in 
presence of KLH or no stimulation in-vitro the % of positive cells (CFSE-CD3) is limited up to 
generation 2. The percent divided by 0.15E-OV NP (Ovaendo), 0.15E-OV NP (KLH), 0.15E-OV NP (No 
Ag), 0.15E-OVMP NP (Ovaendo), 0.15E-OVMP NP (KLH), 0.15E-OVMP NP (No Ag), was 33.2 %, 
15.6 %, 67.6 %, 22.4 %, 7.02 % and 46.3 %, respectively.  
Figure F.1 (F, G) represents the histograms for 0.55E-OV-NP, 0.55E-OV-MP-NP, 0.55E-OV-AD-NP and 
0.55E-OVMP-AD-NP treated groups. There was no consistency in % of fluorescence shift before and 
after re-stimulation.  
The percent divided by 0.55E-BS-OV NP (Ovaendo), 0.55E-BS-OV NP (KLH), 0.55E-BS-OV NP (No 
Ag), 0.55E-BS-OVMP NP (Ovaendo), 0.55E-BS-OVMP NP (KLH), 0.55E-BS-OVMP NP (No Ag), 
0.55E-BS-OV-COV NP (Ovaendo), 0.55E-BS-OV-COV NP (KLH), 0.55E-BS-OV-COV NP (No Ag), 
0.55E-BS-OVMP-COV NP (Ovaendo), 0.55E-BS-OVMP-COV NP (KLH), 0.55E-BS-OVMP-COV NP 
(No Ag) was 13.6 %, 21.1 %, 20.7 %, 10.3 %, 8.56 %, 11.7 %, 85.4 %, 83.4 %, 15.5 %, 17.8 %, 36.7 % 
and 15 %, respectively.  
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Figure F.1. Overall T cell proliferation assay with WT mice in the vaccination study. Data is represented 
as histograms and flowjo-analyzed cell-divisions for each group. The groups are controls (A), 0.18C-
OV/OVMP NPs (A), 0.55C-OV/OVMP NPs (C, D), 0.15E-OV/OVMP NPs (E) and 0.55E-OV/OVMP 
NPs (F,G). Briefly, in-vitro CFSE-labelled T cells obtained from a specific mice group was co-cultured 
with irradiated primary DCs. After four days, the cells were harvested, washed and stained with 
respective antibodies to determine the number of divisions by flow cytometry. In the co-culture there was 
several groups each restimulated with 20 µM Ovaendofit, or 20 µM KLH or non-stimulated. 
Abbreviations: NP=Nanoparticle, OV=OVA, MP=MPLA, C=COOH, E=Ester, AD=Adsorption, 
COV=Covalent binding.  
 
F.1.2 Assessment of cytokine secretion in WT balb/c T cell and DC co-culture 
Figure F.2 to F.5 represents the cytokine secretion pattern for WT mice after treatment with 0.18 COOH 
terminated OVA/MPLA NPs. Chapter 5 contains the summary data for the cytokines, whereas, this 
section contains details of cytokines secreted by each treatment under different conditions. Unimmunized 
mice were used as negative control and OVMP treated mice were used as positive control in the 
experiment. Supernatants of the co-culture (DC:T=1:4) were collected after day 4 and kept frozen until 
use. The cytokines observed were, IFNγ, IL-2, IL-6 and TNF-α. The manufacturer’s instructions was 
followed to perform ELISA for the cytokines.   
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Figure F.2. IFNγ secretion profile of in-vitro activated CD3+ T cells after 96 hrs for 0.18 COOH 
terminated NPs. (n=3) (p<0.05) 
Notes: CD3 T cells were isolated from WT balb/c mice and co-cultured with primary DCs. Supernatants 
obtained at the end of 96 hours were collected and analyzed for IFNγ secretion. Treatment groups were 
unimmunized mice, free OVA, free OVMP, 0.18C-OV-NP, 0.18C-OV-AD-NP, 0.18C-OVMP-NP, and 
0.18C-OVMP-AD-NP. Easysep T cell negative isolation kit was used as per manufacturer’s suggestion to 
isolate CD3 positive overall T cells (purity>80 %). T cells were collected, stained with CFSE and co-
cultured with pretreated DCs, where T cells were fixed (1X105) with graded dose of irradiated DCs at a 
ratio of 1:4. The co-culture was then stimulated with T cell test Ovaendo or irrelevant antigen (KLH). The 
unstimulated T cells were used as negative control.  
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Figure F.3. IL-2 secretion profile of in-vitro activated CD3+ T cells after 96 hrs for 0.18 COOH 
terminated NPs. (n=3) (p<0.05) 
Notes: CD3 T cells were isolated from WT balb/c mice and co-cultured with primary DCs. Supernatants 
obtained at the end of 96 hours were collected and analyzed for IL-2 secretion. Treatment groups were 
unimmunized mice, OVA free, OVMP free, 0.18C-OV-NP, 0.18C-OV-AD-NP, 0.18C-OVMP-NP, and 
0.18C-OVMP-AD-NP. Easysep T cell negative isolation kit was used as per manufacturer’s suggestion to 
isolate CD3 positive overall T cells (purity>80 %). T cells were collected, stained with CFSE and co-
cultured with pretreated DCs, where T cells were fixed (1X105) with graded dose of irradiated DCs at a 
ratio of 1:4. The co-culture was then stimulated with T cell test Ovaendo or irrelevant antigen (KLH). The 
unstimulated T cells were used as negative control.  
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Figure F.4. IL-6 secretion profile of in-vitro activated CD3+ T cells after 96 hrs for 0.18COOH 
terminated NPs. (n=3) (p<0.05) 
Notes: CD3 T cells were isolated from WT balb/c mice and co-cultured with primary DCs. Supernatants 
obtained at the end of 96 hours were collected and analyzed for IL-6 secretion. Treatment groups were 
unimmunized mice, free OVA, free OVMP, 0.18C-OV-NP, 0.18C-OV-AD-NP, 0.18C-OVMP-NP, and 
0.18C-OVMP-AD-NP. Easysep T cell negative isolation kit was used as per manufacturer’s suggestion to 
isolate CD3 positive overall T cells (purity>80 %). T cells were collected, stained with CFSE and co-
cultured with pretreated DCs, where T cells were fixed (1X105) with graded dose of irradiated DCs at a 
ratio of 1:4. The co-culture was then stimulated with T cell test OVAendo or irrelevant antigen (KLH). 
The unstimulated T cells were used as negative control.  
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Figure F.5. TNF-α secretion profile of in-vitro activated CD3+ T cells after 96 hrs for 0.18 COOH 
terminated NPs. (n=3) (p<0.05) 
Notes: CD3 T cells were isolated from WT balb/c mice and co-cultured with primary DCs. Supernatants 
obtained at the end of 96 hours were collected and analyzed for TNF-α secretion. Treatment groups were 
unimmunized mice, free OVA, free OVMP, 0.18C-OV-NP, 0.18C-OV-AD-NP, 0.18C-OVMP-NP, and 
0.18C-OVMP-AD-NP. Easysep T cell negative isolation kit was used as per manufacturer’s suggestion to 
isolate CD3 positive overall T cells (purity>80 %). T cells were collected, stained with CFSE and co-
cultured with pretreated DCs, where T cells were fixed (1X105) with graded dose of irradiated DCs at a 
ratio of 1:4. The co-culture was then stimulated with T cell test Ovaendo or irrelevant antigen (KLH). The 
unstimulated T cells were used as negative control. 
 
F.1.3 Assessment of T cell proliferation with OT1 mice by CFSE method   
CFSE method was employed to analyze the proliferation of CD8+ T cells in OT1 mice. The main 
objective of this experiment was to confirm the antigen OVA specific response in OT1 mouse. The 
experiment was optimized based on the results obtained from WT balb/c mice. 0.18 COOH terminated 
nanoparticles showed the most promising results for both T cell proliferation study as well as cytokines. 
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The dose of antigen re-stimulation was cut-down in OT1 mice from 20 µM to 1 µM based on some pilot 
studies performed on them.  
DC and T cell co-culture was assessed with a starting cell number of T cells (1X105). CD8T cells were at 
a ratio of 1:4 and 1:10. Primary DCs were at 2.5X104 and 1X104 for the corresponding ratios. T cells were 
stained with fluorescent dye CFSE to observe for 5 days with OVA and MPLA. The restimulation of 
isolated CD8+T cells was performed with relevant peptide (1 µM) and irrelevant protein (KLH, 1 µM) 
during co-culture (day1). 
OT1 mice were vaccinated twice (week 1 and week 3), spleens and lymph nodes were collected for 
purification of CD8 T cells. Primary DCs isolated from mouse bone marrow was irradiated before co-
culture. DCs were co-cultured with CD8 T cells and re-stimulated with either CD8 peptide or KLH 
irrelevant antigen. Figure E.6 shows the proliferation study of CFSE labelled T cells after 5 days of co-
culture. Unimmunized mice were used as negative control. Free OVA-MPLA treated mice were used as 
positive control.  
The percent divided by DC: TCFSE (KLH), DC: TCFSE (No Ag), free OVA (KLH). free OVA (No Ag), free 
OVMP (KLH), free OVMP (No Ag), 0.18C-BS-OV NP (KLH), 0.18C-BS-OV NP (No Ag), 0.18C-BS-
OVMP NP (KLH), 0.18C-BS-OVMP NP (No Ag), 0.18C-OV-AD NP (KLH), 0.18C-OV-AD NP (No 
Ag), 0.18C-OV-COV NP (KLH), 0.18C-OV-COV NP (No Ag), 0.18C-OVMP-AD NP (KLH), 0.18C-
OVMP-AD NP (No Ag), 0.18C-OVMP-COV NP (KLH), 0.18C-OVMP-COV NP (No Ag) was 2.29 %, 
0.085 %, 19.1 %, 13.2 %, 19.7 %, 66.2 %, 22 %, 24.7 %, 8.61, 11.6 %, 14.7 %, 33.6 %, 15.9 %, 6.8 %, 
71.4 %, 43.5 %, 23.4 % and 20.5 % respectively. 
 
232 
 
 
 
233 
 
 
Figure F.6. Representative histogram for CD8 T cells proliferation after 96 hours of co-culture by flow 
cytometry for 0.18 COOH terminated nanoparticles (1-9). In brief, OT-1 mouse (3-4/group) was 
vaccinated twice, sacrificed to collect spleens and lymph nodes after 21 days. DC (irradiated) was co-
cultured with CD8 T cells after purification using isolation kit. Several groups were included in the study 
that was either re-stimulated with relevant SIINFEKL peptide or KLH (irrelevant) or kept unstimulated. 
After five days, T cells were harvested, washed, stained with CD8 antibody and data was acquired in flow 
cytometer.   
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Notes: 1. Unimmunized cells, 2. Free OVA, 3. Free OVMP, 4. 0.18C-OV-BS3-NP, 5. 0.18C-OVMP-
BS3-NP, 6. 0.18C-OV-AD-NP, 7. 0.18C-OV-COV-NP, 8. 0.18C-OVMP-AD-NP AND 9. 0.18C-OVMP-
COV-NP. Left side histogram shows different proliferative generations represented in percentage. All 
histogram shows up to seven generations. Left side histogram represents the proliferative generations in 
graded color of pink.  Data is analyzed using flowjo software version 7.6.5.  
 
F.1.4 Assessment of cytokine secretions in OT-1 mice T cell and DC co-culture 
Figure F.7 to F.10 (1-9) represents the cytokine secretion pattern in the co-colture supernatant of OT-1 
mouse and primary DCs. Supernatants were collected after day 5 and kept frozen until use. The cytokines 
observed were IFNγ, IL-2, IL-6 and TNF-α. The manufacturer’s instructions was followed to perform 
ELISA for the cytokines.The cytokine secretion is assessed per 500, 000 cells. Two ratios of DC:T cells 
are represented here for cytokine secretion. DC:T at 1:4 and 1:10 was evaluated. Individual results of LN 
derived CD8 T cells and Dc co-culture are also mentioned for some of the formulaitons. The amount of 
cytokine secretion is comparatively higher than the WT mice. 
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Figure F.7 (1-9): Effect of OVA/OVA-MPLA NPs for IFNγ secretion in DC: T co-culture supernatant on 
day 5. The ratio of DC: T was 1:4 and 1:10 where T cells was 1X105 and DCs were 2.5X104 and 1X104. 
These T cells were isolated from splenocytes. Lymph node (LN) derived CD8 T cells were plated with 
DCs at 1:4 ratio (DC: T). After five days’ incubation, culture supernatants were collected, stored and 
analyzed for IFNγ secretion. This figure is representative for nine groups as numbered above. (n=3) 
(p<0.05)  
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Figure F.8 (1-9): Effect of OVA/OVA-MPLA NPs for IL-2 secretion in DC: T co-culture supernatant on 
day 5. The ratio of DC: T was 1:4 and 1:10 where T cells was 1X105 and DCs were 2.5X104 and 1X104. 
These T cells were isolated from splenocytes. Lymph node (LN) derived CD8 T cells were plated with 
DCs at 1:4 ratio (DC: T). After five days’ incubation, culture supernatants were collected, stored and 
analyzed for IL-2 secretion. This figure is representative for nine groups as numbered above. (n=3) 
(p<0.05) 
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Figure F.9 (1-9): Effect of OVA/OVA-MPLA NPs for IL-6 secretion in DC: T co-culture supernatant on 
day 5. The ratio of DC: T was 1:4 and 1:10 where T cells was 1X105 and DCs were 2.5X104 and 1X104. 
These T cells were isolated from splenocytes. Lymph node (LN) derived CD8 T cells were plated with 
DCs at 1:4 ratio (DC: T). After five days’ incubation, culture supernatants were collected, stored and 
analyzed for IL-6 secretion. This figure is representative for nine groups as numbered above. (n=3) 
(p<0.05) 
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Figure F.10 (1-9): Effect of OVA/OVA-MPLA NPs for cytokines secretion in DC: T co-culture 
supernatant on day 5. Notes: The ratio of DC: T was 1:4 and 1:10 where T cells was 1X105 and DCs were 
2.5X104 and 1X104. These T cells were isolated from splenocytes. Lymph node (LN) derived CD8 T cells 
were plated with DCs at 1:4 ratio (DC: T). After five days’ incubation, culture supernatants were 
collected, stored and analyzed for TNF-α secretion. This figure is representative for nine groups as 
numbered above. (n=3) (p<0.05) 
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